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Increasing evidence suggests that the oral microbiome is highly relevant to cardiometabolic 
outcomes. Associations between the oral microbiome and extra-oral outcomes are most 
commonly hypothesized to result from a chronic inflammatory response to a dysbiotic oral 
microbiome. However, an alternative mechanism hypothesized to link the oral microbiome to 
cardiometabolic risk is via the production of nitric oxide, a physiologically important gaseous 
transmitter. The enterosalivary nitrate-nitrite-nitric oxide pathway of nitric oxide generation is 
dependent on the presence of nitrate-reducing oral bacteria in the mouth to reduce salivary nitrates 
to nitrite, which are then swallowed and made systemically bioavailable for further reduction into 
nitric oxide in the blood vessels and tissues. Thus, this pathway presents a mechanism for oral 
bacteria to exert a beneficial influence on cardiometabolic health. The overall objective of this 
dissertation is to advance the understanding of the role of nitrate-reducing oral bacteria in 
cardiometabolic outcomes in a population setting. This objective was met using three aims. First, 
a systematic literature review was conducted to identify and assess the associations between 
nitrate-reducing oral bacteria and insulin resistance, plasma glucose, diabetes, blood pressure and 
hypertension found in the existing literature. The literature review found no study that explicitly 
tested the hypothesis of an association between nitrate-reducing oral bacteria and the 
cardiometabolic outcomes of interest. In addition, there were very few observed associations 
between nitrate-reducing oral bacteria and these cardiometabolic outcomes, and the findings were 
  
inconsistent across studies. Secondly, the associations between nitrate-reducing oral bacteria and 
insulin resistance, plasma glucose, blood pressure, prediabetes and hypertension were assessed 
using baseline data from a cohort of diabetes-free participants. Increased levels of oral nitrate-
reducing bacteria were associated with lower insulin resistance, plasma glucose and mean systolic 
blood pressure cross-sectionally, but no associations were found with prediabetes and 
hypertension. Finally, as dietary nitrate intake influences the level of salivary nitrate in the mouth 
for the nitrate-reducing oral bacteria to act on, the associations between dietary nitrate and insulin 
resistance, plasma glucose, blood pressure, prediabetes and hypertension were assessed. No clear 
associations between higher dietary nitrate intake and the cardiometabolic outcomes were found. 
However, there was some indication that higher dietary nitrate intake was associated with lower 
systolic blood pressure. The interaction of dietary nitrate intake with nitrate-reducing oral bacteria 
was then considered, but no evidence of such interaction was found. Overall, the results of this 
dissertation suggest that higher levels of nitrate-reducing oral bacteria may confer health benefits 
across the range of bacterial levels likely observed in human populations. These findings help 
inform future public health research aimed at utilizing the enterosalivary pathway of nitric oxide 
generation to improve cardiometabolic health.
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Increasing evidence suggests that the digestive tract microbiome (i.e., bacteria colonizing the 
oral cavity and the gastro-intestinal tract) may be a contributing factor in the development  of 
insulin resistance1-3, Type 2 diabetes mellitus4,5, and hypertension6,7. A substantial body of 
evidence accumulated over the past 30 years has linked the oral microbiota to extra-oral 
outcomes8,9. Associations between the oral microbiome and extra-oral outcomes are most 
commonly hypothesized to result from a chronic inflammatory response to a dysbiotic 
subgingival microbiome10. However, an alternative mechanism hypothesized to link the oral 
microbiome to cardiometabolic risk is via the production of the physiologically important 
gaseous transmitter, nitric oxide (NO).  
 
Nitric oxide is an important signaling molecule involved in many physiological processes, 
including vasodilation, endothelial function, immune function and mitochondrial function11,12. 
NO plays a role in glucose metabolism and blood pressure control13, and a loss of NO production 
and bioavailability has been implicated in the pathogenesis of insulin resistance and 
hypertension14,15. NO production was thought to occur solely through the conversion of L-
arginine and oxygen into NO and L-citrulline by three nitric oxide synthases (NOSs): endothelial 
NOS, neuronal NOS, and inducible NOS11, and the endothelium is the main source of NO 
production for vasodilation and vascular hemostasis16. However, it has recently been discovered 
that NO production can also occur via the reduction of dietary or endogenous nitrates by oral 
bacteria, through what is known as the enterosalivary nitrate-nitrite-NO pathway12. 
 2
The enterosalivary nitrate-nitrite-NO pathway is a NOSs-independent pathway for NO 
generation, and represents a novel and biologically plausible mechanism by which oral bacteria 
may influence the systemic bioavailability of NO and related clinical cardiometabolic outcomes 
in humans12 (Figure 1.1). In this pathway, dietary nitrate is absorbed into the bloodstream 
through the gastrointestinal tract. Once in the bloodstream, the dietary nitrate is mixed with 
endogenously-produced nitrate and nitrites formed as byproducts from the metabolism of NO 
produced by nitric oxide synthases12. Twenty-five percent of the nitrates in the blood are taken 
up by the salivary glands, where they are concentrated and released into the saliva17. A small 
subset of oral bacteria then reduces salivary nitrates in the mouth to nitrites. The salivary nitrites 
are then swallowed and made systemically bioavailable for further reduction into NO in the 
blood vessels and tissues18,19. Thus, these nitrate-reducing oral bacteria while not directly 
producing NO, are critical for the first step of the nitrate-nitrite-NO pathway of NO generation – 
the conversion of salivary nitrate into nitrite.  
 
Experimental studies have been instrumental in demonstrating the cardiometabolic benefits of 
the enterosalivary nitrate-nitrite-NO pathway of NO generation. There is strong evidence from 
experimental studies suggesting that increased dietary nitrate intake has beneficial systemic 
cardiometabolic effects, such as lowering blood pressure20, blood glucose, and insulin 
resistance21-23. For example, a recent systematic review and meta-analysis of 16 studies lasting 2 
hours to 15 days, with a total of 254 participants, concluded that dietary nitrate supplementation 
is associated with a significant reduction in systolic blood pressure of ~4.4 mmHg24. Another 
review, this time of trials lasting 1 to 6 weeks and including 13 studies with a total of 325 
participants, corroborate these results, finding a ~4.1 mmHg and 2.0 mmHg reduction in systolic 
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and diastolic blood pressure, respectively25. While animal studies demonstrate beneficial effects 
of nitrate supplementation on blood glucose and insulin resistance26-29, the results of human 
studies are less conclusive30,31. Nevertheless, reduced plasma glucose and improved insulin 
sensitivity have been observed in some studies21-23,28, and there is great interest in the use of a 
nitrate-rich diet for the prevention and treatment of insulin resistance and hypertension32,33.  
 
At the same time, several small experimental studies support the direct role of nitrate-reducing 
oral bacteria in NO production through this enterosalivary pathway. For example, the blood 
pressure and plasma glucose reductions observed following experimental nitrate supplementation 
were significantly blunted by antibacterial mouthwash use in several studies22,23,34-37. Notably, 
even in the absence of exogenous nitrate supplementation, suppression of the oral bacteria with 
the use of antibacterial mouthwash was followed by a decrease in salivary and plasma nitrite 
(presumably due to reduced nitrate reduction by the oral bacteria) and a ~3 mmHg increase in 
systolic and diastolic blood pressure 36. The evidence therefore suggests a continuous 
physiological role for oral microbiota in blood pressure regulation through the nitrate-nitrite-NO 
pathway.  
 
While these aforementioned experimental studies assessed salivary and plasma nitrate/nitrite 
levels and blood pressure following interventions designed to broadly suppress oral 
microbiota34,36,37, they did not identify the bacteria species nor measure the change in species 
associated with the increase in blood pressure after mouthwash use34,38. Thus, most studies have 
not explicitly tested the mediational effect of decreased nitrate-reducing oral bacteria associated 
with higher blood pressure. In addition, these small experimental studies artificially suppress the 
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oral microbiome, causing an extreme change in bacterial levels. As there is little knowledge of 
the population distribution of nitrate-reducing bacteria, whether such differences in bacterial 
levels exist in a population setting is unknown, and it remains to be tested if variations in nitrate-
reducing oral bacteria within a population distribution are associated with differences in 
cardiometabolic outcomes as well. Most of the larger human studies reporting associations 
between measures of oral microbiota and insulin resistance, plasma glucose, diabetes, blood 
pressure and hypertension, have focused mainly on putative periodontal pathogens only5,7. Thus, 
there is little evidence of the role of the nitrate-reducing bacteria per se on cardiometabolic 
outcomes, and to the best of our knowledge, no study has directly investigated the relationship 
between specific oral microbiota with known nitrate-reducing capacity and cardiometabolic 
outcomes in a population-based setting. The advent of next-generation sequencing (NGS) 
technologies enables more accurate quantification of a larger set of bacterial taxa, allowing for a 
more detailed exploration of the overall nitrate-reducing capacity of oral bacteria as well as the 
identification of which taxa are potentially the strongest contributors to nitrate-reduction and 
cardiometabolic effects.  
 
In the same vein, although the results of the nitrate supplementation experimental studies are 
indicative of a beneficial effect of dietary nitrate intake on cardiometabolic outcomes, these 
studies were in highly-controlled settings, with relatively short-term intake. The experimental 
studies also had small sample sizes of between 7 to 69 participants per study20, limiting the 
generalizability of these findings to the wider general population. Very few studies have directly 
tested the association of total dietary nitrate intake and beneficial cardiometabolic outcomes 
more broadly in a population setting20,39,40. Most of the larger-scale observational studies 
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studying dietary nitrate intake have instead focused on the effects of dietary nitrates used as 
preservatives in processed meat and the increased risk of cancer41,42. Moreover, the lack of a 
widely applicable and comprehensive dietary nitrate database that can be used in epidemiologic 
research has made measuring nitrate intake from the diet difficult43-45. A few recent 
investigations using newly-developed dietary nitrate food databases have made some headway 
into examining the association between dietary nitrate intake and cardiometabolic outcomes, but 
these findings are sparse and inconclusive. In addition, the outcomes studied are limited, and 
early biomarkers prior to the onset of disease, such as insulin resistance and blood pressure, have 
yet to be examined.  
 
Importantly, the literature strongly supports the interaction of dietary nitrate intake and oral 
bacteria along the enterosalivary nitrate-nitrite-NO pathway to produce nitrite. A higher dietary 
nitrate intake increases the amount of salivary nitrate available for the nitrate-reducing bacteria 
to act on, in turn possibly increasing the amount of salivary nitrite produced. Correspondingly, 
an abundance of nitrate-reducing bacteria could increase the amount of nitrite formed from the 
same bolus of salivary nitrate. Examining the interaction of nitrate-reducing bacteria and dietary 
nitrate intake on cardiometabolic outcomes can help us gain a better understanding of this 
relationship, and elucidate the conditions needed for maximum salivary nitrate (and 
consequently, NO) formation. However, few studies have considered the role of oral microbiota 
in the association between dietary nitrate intake and cardiometabolic outcomes, and vice versa. 
Most studies do not assess comprehensive measures of both dietary intake and oral bacteria, and 
the interaction between dietary nitrate intake and nitrate-reducing oral bacteria remains to be 
formally tested.  
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Thus, the overall objective of this dissertation is to address the aforementioned gaps in 
knowledge and advance the understanding of the role of nitrate-reducing oral bacteria in 
cardiometabolic outcomes in a population setting. I do so using three aims. Specifically, I 
evaluate whether nitrate-reducing oral bacteria are associated with cardiometabolic outcomes in 
the existing literature (Aim 1); empirically test the associations between specific oral microbiota 
with known nitrate-reducing capacity and cardiometabolic outcomes using data from a 
population-based sample (Aim 2); empirically test the association between dietary nitrate intake 
and cardiometabolic outcomes from the same population, and investigate the interaction of 
dietary nitrate intake and nitrate-reducing oral bacteria on cardiometabolic outcomes (Aim 3). 
 
Therefore, Chapter 2 (Aim 1) presents the results of a systematic literature review conducted to 
identify and assess the associations between nitrate-reducing oral bacteria and insulin resistance, 
plasma glucose, diabetes, blood pressure and hypertension in the existing literature. 
 
Chapter 3 (Aim 2) is motivated by the lack of studies that directly examine the association 
between nitrate-reducing oral bacteria and cardiometabolic outcomes in a population setting. 
Next-generation sequencing microbial assessment techniques are utilized to examine the baseline 
cross-sectional associations between nitrate-reducing oral bacteria in the subgingival plaque and 
the cardiometabolic outcomes: a) insulin resistance; b) fasting plasma glucose; c) prediabetes; d) 




Chapter 4 (Aim 3) seeks to add to the still sparse findings from larger-scale observational studies 
investigating the association between dietary nitrate intake and cardiometabolic outcomes. We 
examine the cross-sectional relationship between total dietary nitrate intake and the 
cardiometabolic outcomes a) insulin resistance; b) fasting plasma glucose; c) prediabetes; d) 
systolic and diastolic blood pressure; and e) hypertension, in the cohort of diabetes-free 
participants. Furthermore, as to the best of our knowledge, no study has formally tested the 
interaction between dietary nitrate intake and nitrate-reducing oral bacteria, we then investigate 
whether the relationships between nitrate-reducing bacteria and the aforementioned 
cardiometabolic outcomes studied in Aim 2 are modified by dietary nitrate intake.  
 
Finally, a summary of the findings is provided in Chapter 5, along with a discussion of their 
implications and future research directions.
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Nitric oxide (NO) is an important gaseous transmitter involved in many physiological 
processes1,2, including vasodilation, endothelial function, immune function and mitochondrial 
function1,2. NO is also important in glucose metabolism and blood pressure control3, and a loss 
of NO production and bioavailability has been implicated in the pathogenesis of insulin 
resistance and hypertension4,5. The recent discovery of the enterosalivary nitrate-nitrite-NO 
pathway of NO generation is of great interest2,6, as it represents a novel and biologically 
plausible mechanism by which oral bacteria might influence the systemic bioavailability of NO 
and related clinical cardiometabolic outcomes in humans2. In this pathway, dietary nitrate is 
absorbed into the bloodstream through the gastrointestinal tract, mixed with endogenously-
produced nitrates, taken up by the salivary glands, and released into the saliva. A small subset of 
oral bacteria then reduces salivary nitrates in the mouth to nitrites. The salivary nitrites are 
swallowed and made systemically bioavailable for further reduction into NO in the blood vessels 
and tissues7,8. 
 
This enterosalivary mechanism of NO generation is thought to underlie the strong evidence from 
experimental studies suggesting that increased dietary nitrate intake has beneficial systemic 
cardiometabolic effects, such as lowering blood pressure9, blood glucose, and insulin 
resistance10-12. Evidence supporting the direct role of nitrate-reducing oral bacteria in NO 
production through the enterosalivary pathway has also been derived from several small 
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experimental studies. For example, the blood pressure and plasma glucose reductions observed 
following experimental nitrate supplementation were significantly blunted by antibacterial 
mouthwash use11-16. Notably, even in the absence of exogenous nitrate supplementation, 
suppression of the oral bacteria with the use of antibacterial mouthwash was followed by a 
decrease in salivary and plasma nitrite (presumably due to reduced nitrate reduction by the oral 
bacteria) and a ~3 mmHg increase in systolic and diastolic blood pressure15. This evidence 
therefore suggests a continuous physiological role for oral microbiota in blood pressure 
regulation through the nitrate-nitrite-NO pathway. 
 
While these aforementioned experimental studies assessed oral and plasma nitrate/nitrite levels 
and blood pressure following interventions designed to broadly suppress oral microbiota13,15,16, 
no study has directly investigated the relationship between specific oral microbiota with known 
nitrate-reducing capacity and cardiometabolic outcomes in a population-based setting. The 
experimental studies supporting the association between nitrate-reducing bacteria and 
cardiometabolic outcomes do not identify or measure the change in bacteria species associated 
with the increase in blood pressure after mouthwash use13,17. Thus, most studies have not 
explicitly tested the mediational effect of decreased nitrate-reducing oral bacteria associated with 
higher blood pressure. In addition, these small experimental studies artificially suppress the oral 
microbiome, causing an extreme change in bacterial levels. As there is little knowledge of the 
population distribution of nitrate-reducing bacteria, whether such differences in bacterial levels 
exist in a population setting is unknown, and it remains to be tested if variations in nitrate-
reducing oral bacteria within a population distribution are associated with differences in 
cardiometabolic outcomes as well. Most of the large human studies reporting associations 
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between clinical and bacterial measures of oral microbiota and insulin resistance, diabetes, blood 
pressure and hypertension, have focused mainly on putative periodontal pathogens18,19. While 
several systematic reviews regarding the association between periodontal disease and 
cardiometabolic outcomes such as arterial hypertension20, diabetes 21, and cardiovascular events 
have been conducted 22, no review has focused on nitrate-reducing oral bacteria with these 
outcomes.  
 
Therefore, the primary objective of this review was to systematically identify and describe 
observational studies that examine whether direct measures of nitrate-reducing oral bacterial 
species are associated with plasma glucose, insulin resistance, diabetes, blood pressure and 
hypertension. The second objective was to synthesize the statistical findings of the identified 
studies in order to assess if data from the published literature supports the hypothesis of a 




The a priori review protocol containing the methods and pre-specified inclusion criteria was 
registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 7 
August 2017 (registration number CRD42017068757). This report complies with the preferred 
reporting items of PRISMA for systematic reviews and meta-analyses23, and the location of each 
item on the checklist is presented in Appendix A.  
 
Study identification 
Studies were identified by searching Pubmed/MEDLINE, EMBASE and the Cochrane  
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Library databases with no date restriction (up to 24 June 2017). In addition, hand searching of 
the reference lists of the selected articles and relevant reviews found through the electronic 
searches was performed to enable inclusion of any studies not found by our primary search. CG 
developed and conducted the search in consultation with information specialists at Columbia 
University Medical Center Health Sciences Library. 
 
An example of the search queries used for all databases includes the predefined search terms 
(“oral” or “mouth”) AND (“microbiome” or “bacteria”) AND (“diabetes” or “insulin resistance” 
or “hypertension” or “blood pressure”). Similar searches using the corresponding MESH and 
EMTREE search terms were carried out in MEDLINE and EMBASE respectively. Boolean 
terms (AND, OR) and truncation (microb*) were used where appropriate to create search 
equations for each database. The full search equation for MEDLINE is reported in Appendix B.   
 
Eligibility criteria  
The eligibility criteria used in this systematic review are as follows:  
 
Types of studies.  Only English language publications were reviewed. Only original empirical 
research conducted in humans was included (observational studies or RCTs); overviews, 
reviews, case reports, editorials, and papers proposing medical hypotheses were excluded. 
Included studies had to permit a comparison of cardiometabolic outcomes by oral microbial 
levels or vice versa.  
Types of participants. We included only studies of adult participants (of any age) and included 
studies that examined healthy participants and/or patients with disease. 
Exposures. This review was limited to studies using direct microbial assessments, for example, 
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through culture, checkerboard DNA-DNA hybridization assessment, 16S rRNA sequencing or 
next-generation sequencing techniques. Studies that used clinical periodontal measures or serum 
antibodies against oral bacteria were excluded.  While elevated antibodies likely reflect an 
increased bacteria burden, they also represent a protective immune response to the microbial 
challenge, which can be influenced by other factors. This may complicate their interpretation and 
thus only direct bacteria assessments were included. We also excluded studies that looked at the 
effects of probiotic supplementation on our outcomes of interest, or studies focused on 
endodontic bacteria in the root canals.  
From the list of studies that contained direct microbial assessments and the relevant 
cardiometabolic outcomes, we then narrowed down the selection of studies to only those that 
studied bacteria genera or species that were previously identified as having potential nitrate-
reducing capacity (Appendix C)24,25. 
 
Outcome measures. The primary outcomes of interest were measures of plasma glucose levels, 
Hemoglobin A1c (HbA1c), plasma insulin levels, insulin resistance, systolic blood pressure and 
diastolic blood pressure. Secondary outcomes were hypertension and Type 2 diabetes (diagnosed 
or undiagnosed). Studies including Type 1 diabetes patients only were excluded and studies with 
ambiguous diabetes type were included as the majority of diabetes among adults is Type 2. Type 
1 diabetes was excluded because its etiology and pathogenesis are different from Type 2 
diabetes. A loss of NO bioavailability is thought to impair glucose metabolism contributing to 
the insulin resistance characteristic of the early natural history of progression towards 
prediabetes and Type 2 diabetes5. On the other hand, NO has been implicated in the killing of 
pancreatic beta-cells leading to the lack of insulin production characteristic of Type 1 diabetes26. 
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Furthermore, most of the research on the enterosalivary nitrate-nitrite-NO pathway investigates 
outcomes related to Type 2 diabetes, and the role of the enterosalivary nitrate-nitrite-NO 
pathway and the oral nitrate-reducing bacteria is unclear in Type 1 diabetes. Studies that 
examined hypertension and gestational diabetes mellitus complications in pregnant women were 
also excluded. 
 
Study Selection  
The records were first screened at the title and abstract level. The second round of review was at 
the full-text level. The study selection process was conducted in the software for systematic 
reviews Covidence27.  
 
Risk of bias of included studies 
The risk of bias was assessed using either the NIH Study Quality Assessment Tools for 
Observational Cohort and Cross-Sectional Studies, or Case-Control studies, where appropriate28. 
While all but one study had clearly reported research objectives, none were to assess the 
association of nitrate-reducing oral bacteria with cardiometabolic outcomes. Therefore we 
assessed the quality of the data available in the studies with regards to our question of interest, 
rather than the quality of the study per se. The data were assessed in terms of each study’s 
selection of the participants, exposure and outcome measurement, temporality, and confounding 
(Appendix D), and rated as “good”, “fair” or “poor” quality which corresponds to an increasing 
risk of bias. Appendix E describes the quality assessment score for the included studies, and the 
main sources of bias. Several studies did not report sufficient information to allow us to assess 
the threats to validity, and this was noted in Appendix D where applicable. As most studies 
adjusted for confounding for a different association than the one of interest in this review, most 
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comparisons in this review were unadjusted for confounding, and resulted only in a “fair” quality 
assessment. Only one study (Kulshrestha, 2011)29 was assessed as having a significant risk of 
bias, but was retained in the study.  
 
Data Extraction and Synthesis  
The first author (CG) extracted the data from the included studies. The following information 
was extracted: 1) the hypothesis of interest of the study, 2) outcome measures 3) sample size and 
characteristics of the participants, 4) study design and comparison groups of interest, 5) method 
and location of bacteria assessment, and number of bacteria species assessed, and 6) the main 
findings relevant to the nitrate-reducing bacteria. 
 
RESULTS  
Description of the results  
Figure 2.1 illustrates the study selection flow diagram for this review. A total of 1998 records 
from the 3 databases (Cochrane=196, Embase=1,117, Pubmed=685) were retrieved. 
Deduplication (both automatic and manually) in Endnote and Covidence removed 369 records.  
 
From the 1,629 records identified, 1,388 were discarded after screening the title and abstract as 
they clearly did not meet the inclusion criteria (See Figure 2.1).  
 
After reviewing the remaining 241 records at the full-text level, 46 were rejected because their 
outcomes were not cardiometabolic outcomes of interest, 41 involved Type 1 diabetes only, 21 
measured only serum antibodies, and another 28 records did not have measures of oral bacteria 
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(Figure 2.1 for the other reasons). We found 48 studies that had direct oral bacteria assessments 
and the cardiometabolic outcomes of interest (Appendix F). However, 34 of them were excluded 
as they did not assess any of the putative nitrate-reducing oral bacteria (Appendix C)24,25. 
Therefore, we had 14 studies remaining for data extraction and synthesis.  
 
Because we found so few studies of relevance, and the study populations, bacterial assessment 
methods, and taxa studied varied widely between studies, the main focus of this review is a 
qualitative summary rather than a meta-analysis. I will focus on the characteristics of the 
included studies and the direction of association (positive or inverse) for the cardiometabolic 
outcomes of interest with increasing nitrate-reducing bacteria exposure.  
 
Characteristics of the included studies 
The characteristics of the included studies are summarized in Table 2.1. Most studies examined 
oral bacteria from the subgingival plaque, with one study examining both supragingival and 
subgingival plaque30, and one study that did not clearly report where the oral bacteria were 
sampled from29. The method of microbial assessment varied; most studies (n=5) used a 
checkerboard DNA-DNA hybridization to identify target taxa, three used culture and 
biochemical tests for identification29,31,32, another two used a combination of culture and PCR 
assays33,34, and one study used fluorescence immunoassay35. Only 3 studies used 16S rRNA 
sequencing to identify a broad spectrum of bacteria species36-38.  
 
The majority of studies were interested in diabetes, with 10 studies comparing bacteria between 
diabetic participants and non-diabetic participants. Two studies included diabetes-free 
 20
participants only, and investigated the association of oral microbiota with insulin resistance and 
the prevalence of prediabetes as the cardiometabolic outcome of interest19,37. Conversely, one 
study included only participants with diabetes, and examined the influence of varying metabolic 
control (categorized by HbA1c levels) on oral bacteria35. Only one study looked at the 
association of oral bacteria with hypertension and blood pressure39. 
 
Studies with the hypothesis of oral bacteria affecting cardiometabolic outcomes 
Details of the included studies, such as the objective, study design, microbial assessment method, 
analytic methods and main findings are presented in Table 2.2. The majority of studies examined 
the impact of diabetes on oral microbiota, rather than the contribution of oral microbiota to the 
development of any of the cardiometabolic outcomes of interest. Thus, microbiota were often the 
outcome of interest rather than the exposure. Other studies’ aims included evaluating the effect 
of periodontal therapy on microbial composition in diabetes patients compared with controls32,40.  
 
Only three studies included in this review explicitly hypothesized that oral bacteria was involved 
in the development of hypertension39 or diabetogenesis19,37. Desvariuex et al.39 used a 
prospective population-based cohort study specifically designed to study the hypothesis that 
periodontal infections predispose to accelerated progression of cardiovascular disease outcomes. 
They were interested in oral bacteria thought to be etiologic for periodontitis, hypothesizing a 
positive association of these bacteria with hypertension, and higher blood pressure. In addition, 
they used groups of other bacteria deemed to be putatively associated with periodontal disease, 
or associated with a healthy periodontium, which contained some nitrate-reducing bacteria. For 
these other groups, they hypothesized either a null or inverse association with hypertension. 
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Demmer et al. (2015 & 2016)19,37 used baseline cross-sectional data from a young, diabetes-free 
cohort to study the association between oral microbiota and insulin resistance prior to clinical 
disease or diabetic medication use. The cohort had different waves of participant recruitment, 
and the data used in the two studies by Demmer et al.19,37 consisted of overlapping subsets of 
participants, with different microbial assessment methods (DNA-DNA checkerboard 
hybridization vs. 16S rRNA sequencing respectively), and different outcomes of interest 
(prediabetes vs. insulin resistance). Both studies explicitly hypothesized that oral bacteria may 
contribute to diabetogenesis and would thus be associated with measures of insulin resistance.  
 
Microbial assessment and number of bacteria species studied 
 
Most research examining associations between the oral microbiome and extra-oral outcomes 
focused on periodontal disease. Therefore, most of the oral bacterial species investigated were 
potential periodontal pathogens, and only a few studies investigated a broader spectrum of taxa. 
The number of taxa studied ranged from only 2 species identified through culture methods in 
Sanchez-Cordero et al. (1979)31 to 28 species in Ebersole et al. (2008)41 using checkerboard 
DNA-DNA hybridization (Table 2.2). Zhou et al. (2013)36 identified 1,141 species using next-
generation sequencing technologies. Four studies reported only the presence or absence of 
bacteria species of interest without quantifying the counts or levels of bacteria, and this may have 
to do with limitations of the technology at the time31,33,42,43.  
 
A synthesis of statistical evidence on the association between nitrate-reducing oral microbiota 
and cardiometabolic outcomes 
Twenty-two of the 28 previously identified nitrate-reducing bacteria species (Appendix C) were 
identified in the 14 included studies. The 11 studies that did not use 16S rRNA sequencing 
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measured an average of three nitrate-reducing bacteria species per study. Casarin et al. (2008)44, 
Demmer et al. (2016)37, and Zhou et al. (2013)45 were able to identify many more bacteria on 
average (113, 313, and 1,141 species, respectively), but only the top most prevalent or 
significantly different taxa between groups were reported and thus included in Table 2.3. It is 
likely that they measured several other nitrate-reducing bacteria species on our list, but these 
findings were not reported. 
 
In general, non-significant findings were found between nitrate-reducing oral bacteria and our 
cardiometabolic outcomes of interest. Half the included studies had small sample sizes ranging 
from 31 to 63 participants (Table 2.2). Only 13 statistically significant associations over 9 
bacteria species (Table 2.3) were found in five studies. Statistical tests used ranged from Chi-
square test30,34,46, Student t-tests38, Wilcoxon rank-sum test (Mann-Whitney)36,40, to Fisher’s 
exact test35,36. Some studies provided descriptive comparisons between groups but did not state 
whether formal comparisons using statistical tests were conducted32. The most common analysis 
used were simple bivariate analyses, and only a few studies utilized multivariable regression 
analyses to control for potential confounders19,33,37.  
 
Inverse associations were observed in three papers (Table 2.3). In Demmer et al. (2015)19, a 
higher tertile of the nitrate-reducer A. naeslundii was associated with a lower prevalence ratio, 
0.46 (95% CI: 0.25, 0.85), for prediabetes in an occupational cohort of healthy diabetes-free 
adults. When using a subset of patients from the same study with more comprehensive 16S 
rRNA sequencing microbial measures, Demmer et al. (2016)37 found an inverse association 
between the nitrate-reducer C. sputigena (3rd versus 1st tertile) and Homeostasis Model 
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Assessment for Insulin Resistance (HOMA-IR) values in multivariate regression controlling for 
age, sex, race/ethnicity, education, smoking, and BMI. Of the 121 subgingival taxa detected in at 
least 20% of the population, 16 other nitrate-reducing taxa were identified in Demmer et al. 
(2016)37. Nine of these taxa had inverse associations with insulin resistance as well, though the 
associations did not reach statistical significance (Table 2.3). Finally, Zhou et al.45 using 
bivariate analysis, observed significantly higher levels of the nitrate-reducers Neisseria 
flavescens and Corynebacterium matruchotii in periodontally healthy patients without diabetes 
compared to those who were periodontally healthy with diabetes. E. corrodens, as part of the 
putative periodontal bacteria score in Desvarieux et al.18, may also have an inverse association 
with hypertension, though the combination of other non-nitrate-reducing bacteria in the bacteria 
burden score complicates the interpretation of that finding.   
The remaining associations found in this review observed higher levels of nitrate-reducing 
bacteria associated with higher prevalence of diabetes or prediabetes status (Table 2.3). 
 
At the genus level (Table 2.2), Casarin et al.44, Zhou et al.45, and Kulshrestha et al.29,  reported 
increased genus of Actinomyces in those with periodontitis and diabetes compared to those with 
periodontitis but without diabetes. Casarin et al.44 additionally found genera Neisseria, 
Veillonella, Leptotrichia, Fusobacterium and Granulicatella to be significantly higher in 
diabetes. Christgau et al.32, on the other hand, found Veillonella to be higher in controls. A 
higher prevalence of Porphyromonas genus was also reported in patients with diabetes than 
those without diabetes in Kulshrestha et al.29, whereas Casarin et. al observed it to be higher in 
those without diabetes. In those without periodontitis, Zhou et al. found the genus Prevotella 
more prevalent in those without diabetes. 
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DISCUSSION 
In this systematic review, we identified only 14 studies that looked at the association of nitrate-
reducing oral bacteria with diabetes or prediabetes (n=11), insulin resistance (n=1), blood 
pressure and hypertension (n=1), or plasma glucose HbA1c (n=1). Overall, the studies focused 
mainly on subgingival plaque, with none of the studies assessing the microbiota of the tongue 
and saliva. No study was explicitly interested in nitrate-reducing bacteria per se with 
cardiometabolic outcomes, and the hypothesis of all but three studies were to assess the impact 
of the disease phenotype on microbial composition rather than the microbiota as the exposure of 
interest. All comparisons were cross-sectional. Thus, this review highlights the paucity of studies 
focused on the association between nitrate-reducing oral bacteria and cardiometabolic outcomes. 
Our hypothesis of interest was insufficiently tested in the literature, and we found no evidence to 
support the hypothesis of higher nitrate-reducing oral bacteria associated with better 
cardiometabolic outcomes.   
 
No direct hypothesis testing  
Only 3 studies (of which 2 used data from the same cohort) explicitly investigated the 
association between oral bacteria and hypertension, prediabetes or insulin resistance, with oral 
microbiota as the exposure of interest19,37,39. However, even within these studies, the authors 
hypothesized a mainly adversarial relationship between oral microbiota and cardiometabolic 
outcomes, resulting from the chronic inflammatory response to oral dysbiosis; the two nitrate 
reducing organisms (A. naeslundii and V. parvula) were included to serve as control taxa 
representative of better periodontal health. Therefore, none of the studies a) hypothesized the 
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beneficial effects of oral bacteria in the development of disease, or b) specifically investigated 
nitrate-reducing bacteria as the main exposure of interest.   
 
Sparse findings- limited outcomes of interest, small sample sizes, inconsistent results  
There was a paucity of studies examining cardiometabolic outcomes other than diabetes, with 
only one study examining the association of oral microbiota with hypertension. Only 4 studies 
used continuous physiological measures such as blood pressure, insulin resistance, and HbA1c.   
The associations between the nitrate-reducing bacteria species and cardiometabolic outcomes 
were largely non-significant. Many studies had small sample sizes, with half the studies having a 
sample size < 100, and may be underpowered to detect an association particularly after multiple 
comparisons adjustments. The findings at the genera or species level were inconsistent across 
studies. It is possible these inconsistencies reflect a true null association between the nitrate-
reducing oral bacteria and cardiometabolic outcomes. Differences between studies in bacterial 
assessment method, population selection, and confounding control may also explain the 
discrepancies. However, because so few relevant studies were found, we are unable to 
distinguish any patterns as to how such heterogeneity between studies impacted the results. 
 
Differences in operationalization of the microbial exposure – prevalence, absolute abundance 
and relative abundance 
The studies found in this review operationalized microbial exposure in different ways. Some 
studies used less granular quantifications of the abundance of a bacterial species, comparing 
bacterial prevalence between groups rather than absolute abundance (e.g. counts) or relative 
abundance31,33,42,43. Comparisons using prevalence of detection of a species may result in 
 26
misclassification, grouping together individuals with low counts of taxa with individuals with 
high colonization of that taxa. This misclassification is likely non-differential and may bias the 
estimates towards the null. Relative abundance is most commonly used in modern microbiome 
research, as determining the absolute abundance can be limited by laboratory methods47. It is 
unclear which operationalization is most appropriate for our hypothesis, but these different 
operationalizations could influence the interpretation of the findings. For example, diabetes or 
periodontal disease could result in an overgrowth of bacteria and biomass, thus increasing the 
absolute abundance of nitrate-reducers. However, due to the overgrowth of other bacteria species 
at the same time, the relative abundance of the nitrate-reducing bacteria may be decreased48.  
 
Different methods of microbial assessment  
A wide range of microbial assessment methods were used in the 14 studies found, including 
culture, fluorescence immunoassay, checkerboard DNA-DNA hybridization and 16S rRNA 
sequencing. A limitation of the older approaches is the lack of specificity. For example, 
checkerboard DNA-DNA hybridization is subject to cross reactivity to phylogenetically similar 
species, which may not be nitrate-reducers, thus misclassifying the exposure to nitrate-
reducers48. However, these misclassifications are likely non-differential by cardiometabolic 
outcome, underestimating the association.  
 
Lack of confounder adjustment  
The control of confounding is pertinent to our association of interest as there is some indication 
that the usual sociodemographic variables that predict cardiometabolic disease (e.g. age, sex, 
ethnicity) may also influence microbiota composition49-51, and may thus bias the association. For 
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example, several studies compared participants with diabetes mellitus versus healthy controls 
without diabetes. Populations with diabetes might differ from those without diabetes in many 
ways including older age, higher proportion of males, genetics, obesity, dietary and physical 
activity behaviors, and the use of prescription medications52. While some studies controlled for 
age and sex30,34, most used bivariate analysis without adjustment raising the strong possibility of 
confounding. The direction and magnitude of confounding is less clear, as few studies have 
examined the effect of the aforementioned variables on nitrate-reducing oral bacteria in 
particular. However, if older age is associated with more diabetes and lower nitrate-reducing 
bacterial levels, this might induce a spurious inverse association, threatening the validity of the 
inverse associations found for some bacteria in Zhou et al.45 that did not control for age. 
 
This review also highlights the lack of control for periodontal status. As periodontal disease is 
shown to predict future diabetes risk53-56, and periodontal disease can influence the oral 
microbiome through inflammation and deepened periodontal pockets57,58, this dissertation views 
periodontitis as a confounder. The direction of the relationship between clinical periodontitis and 
nitrate-reducing bacteria is not precisely known, and arguments for increased and reduced 
nitrate-reducing oral bacteria in periodontitis has been put forth6,59.  While the deeper pockets 
from periodontal tissue destruction may shift microbial communities towards an increased 
biomass and higher counts of nitrate-reducing bacteria, lower relative abundance of nitrate-
reducers such as A.naeslundii and V. parvula in the presence of periodontitis have been 
reported48,57,58. Thus, the direction of the confounding may depend on whether comparisons are 
made between relative abundance or absolute abundance. Demmer et al. (2015)19 initially only 
found significant associations between absolute abundance and prediabetes in 4 out of 11 oral 
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taxa, and this did not include the nitrate-reducer A. naeslundii. However, when additionally 
controlling for periodontitis status, A.naeslundii was inversely and significantly associated with 
the prevalence ratio of prediabetes19. Periodontitis in this example seems to cause positive 
confounding, biasing the inverse estimate towards the null19. 
 
Selection bias  
Furthermore, because many studies were driven to examine the influence of diabetic status on 
oral microbiota, in particular the periodontal microbiota, several studies looked only at patients 
with periodontitis, and sampled microbiota from periodontal sites32,33,40.  It is possible that 
enrolling only participants with periodontitis caused selection bias, as diabetes causes worse 
periodontitis60, and subgingival microbiota also cause periodontitis. This scenario raises the 
potential risk of collider stratification bias in which selection on a feature that is a joint result of 
two unrelated variables (microbiota and diabetes in the current example), can induce spurious 
associations between the two unrelated variables. Zhou et al. was one of the few studies to ensure 
that their study design included diabetes and non-diabetics patients with and without 
periodontitis allowing for different comparisons, and the first to apply next-generation 16S 
rRNA sequencing to those 4 groups within the same study36. Therefore, little information is 
available on the association of nitrate-reducing oral bacteria with cardiometabolic outcomes in 
those with healthy periodontium, or regardless of the periodontal status.  
 
Reverse causation  
All associations between microbiota and cardiovascular outcomes found in this review were 
cross-sectional. Thus, reverse causation threatens the validity of all associations found in this 
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review. In particular, most of the studies found in this review were of case-control designs, 
selecting prevalent diabetes cases. The diabetes phenotype itself may have strong impact on the 
microbiome, increasing the likelihood of reverse causation in these studies. In addition, diabetic 
medication has been shown to alter the microbiome, emphasizing the need to separate microbial 
signatures of disease from the effects of medication61. Only one study was conducted in a 
diabetes-free population, but high salivary glucose has been associated with a shift in the 
composition of the oral microbiome as well62, and reverse causation is still possible. However, 
the direction of a shift in nitrate-reducing bacteria due to reverse causation is unclear. If high 
blood glucose, diabetes, and diabetic medication leads to higher nitrate-reducing bacteria, this 
might explain positive associations found in some studies. Alternatively, if diabetes, medication 
or high blood glucose led to lower nitrate-reducing bacteria levels, this threatens the validity of 
some of the inverse associations found.  
 
There are several limitations to this review. Only 14 studies were included, and it is possible that 
articles which did not explicitly state the assessment of oral microbiota in the title or abstract 
level were missed in the literature search. For this reason, a broad search was conducted, with 
1,628 articles being screened at the abstract and title level, and 241 articles screened at the full 
text level. Second, because inclusion into the review was based on the assessment of a priori 
identified nitrate-reducing bacteria species (Appendix C)24,25, studies containing unidentified 
nitrate-reducers might have been excluded from this review. Even so, few studies with direct oral 
bacteria measures in Appendix F included more than the usual periodontal bacteria, and the 
number of studies potentially missed is low. Finally, we used a risk of bias tool to assess the 
quality of the studies included, and a limitation is that we might underestimate the quality of the 
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studies due to a lack of reporting rather than a real threat to validity. However, we did not 
exclude studies based on this quality assessment and presented the findings of all studies found. 
 
This review highlighted the paucity of data directly addressing the hypothesis that oral nitrate-
reducing bacteria might improve cardiometabolic health.  Therefore, there is a need for future 
research that can reduce threats to validity posed by selection bias, reverse causation, 
confounding and imprecision due to low sample sizes. Doing so can better inform the potential 
for interventions targeting nitrate-reducing organisms to improve cardiometabolic health.  
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1998 records identified 
through database search:  
Pubmed (685); Embase 
(1117); Cochrane (196) 




screened on title 
and abstract 
 
1388 records excluded based on title and abstract, 
with at least one reviewer using one of the reasons: 
Not assessing oral bacteria (535); Not relevant 
cardiometabolic outcomes (284); Review/Not 
research study (247); Oral administration (154); Not 
humans (30); Probotics (46); Fungi (88); Children 
(2); Duplicates (2).  
 
241 records assessed 
at the full-text level for 
eligibility after 
consensus 193 records excluded after reviewing the full-text, with at 
least one reviewer using the reason: Not cardiometabolic 
outcomes of interest (46); Type 1 diabetes (42); Oral 
bacteria not measured (28); Serum antibodies (21); 
Wrong comparison group (14); Children (12); Pregnancy 
(10); Insufficient Information (10); Endodontic (4); Review 
(4); Not human (2).  48 records included after 
full-text review that had 
direct oral bacteria 
assessments and 
cardiometabolic outcomes 
(Appendix C)  
34 records excluded because they did not contain nitrate-
reducing bacteria as previously identified by two studies. 
14 studies selected 
for data extraction 
and synthesis  
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Table 2.1. Summary characteristics of the 14 articles included in the systematic review  
Characteristics n 
Location  
Subgingival  13 
Supragingival 1 
Others 1 
Microbial assessment  




Others  6 
Cardiometabolic Outcomes   
Diabetes  10 
Prediabetes  1 
Insulin resistance (HOMA-
IR)   
1 
Metabolic control (based on 
HbA1c values)  
1 





Table 2.2. Summary of the 14 studies examining the association between direct microbial assessments of nitrate-reducing oral 





Study Population & 
Design 
Microbial Assessment 
Method & Taxa 
Measured 
Main findings related to 







The hypothesis was that 
diabetes and glycemia 
might affect the 
composition of the 
periodontal microbiota 
 
• n=33 (n=12 
uncontrolled type 2 
DM free of any other 
systemic disease; 
n=11 NDM good 
general health)  






selected from patients 
referred to 
periodontal clinic of 
university 
 
• 16S rRNA gene cloning 
and sequencing 
(Sequences compared 
with the HOMD 
database) 
 
• 5 subgingival samples 
from periodontal sites  
 
• 79 species (NDM), 113 
species (DM)  
• Statistically significant 
differences detected (T-test)  
 
• Species level:  
DM > NDM: E. corrodens , V. 
parvula, V. dispar. 
NDM> DM: No nitrate-reducing 
species  
NS: R. dentocariosa 
 






NS: Rothia, Propionobacter 
Only reported 















BOP: Bleeding on Probing; CAL: Clinical Attachment Loss; CDC/AAP: The Centers for Disease Control and Prevention /American Academy of 
Periodontology; DBP: Diastolic Blood Pressure; DM: Diabetes Mellitus; NDM: Non Diabetes Mellitus; NS: Non-Significant; P+: Periodontitis 













therapy in diabetics 
vs. healthy controls 




without diabetes)  
• Cases and controls 
matched on age, 
gender and severity of 
disease 
• All had moderate to 
advance periodontitis  
• Cases from endocrine 
clinic, controls from 
dental clinic of the 
same university 





microbiological data  
• Pooled subgingival 
samples from deepest 
periodontal pocket of 
each quadrant 
• Used culture to get 
number of colony 
forming units which 
was categorized into 3 






Veilonella sp.  
• Semi quantitative 
weighted % for the 
total load of bacterial 
species in the group 
• E. corrodens was identified 
in only one patient (control) 
and no comparison could be 
made 
• At the genera level: 60% of 
diabetic patients had 
Veilonella sp. vs. 95% in 
healthy controls  




purpose of the 
study was to look 













Interested too in the 
role of oral 
microflora in 
systemic disease 
and pockets as 
potential site for 
• n=46 (n=21 DM-
periodontitis (1 type 1 
patient); n=25 NDM-
periodontitis) 
• Patients from 
periodontal unit of 
dental hospital, and 
diabetes unit of a 
hospital  




healthy vs diseased 
periodontal sites and 
• Used culture to get 
total Capnocytophaga 
counts (CFU/ml), and 
16S rRNA for 
identification to 
species level (7 
species) 
• Subgingival plaque 
from 3 healthy and 3 
deepest diseased sites 
per patient 
 
• Odds ratio for C. sputigena= 
3.81 (0.63, 23.05) in 
multivariate MLM when 
comparing DM-periodontal 
healthy vs NDM-periodontal 
healthy sites as the reference  
• Has control for smoking, and 
healthy vs. diseased 
periodontal site 
• Reported the effect of DM 
alone, overall site prevalence 
of C. sputigena increased by 




modelling to split 
the correlation to 
within subjects 
(sites) and between 
subjects 






systemic entry of 
oral bacteria, testing 
the presence of 



















or impaired fasting 
plasma glucose 
100-125 mg/dL) 
• n=300 diabetes free 
participants, with no 
history of 
cardiovascular disease  
• Distinct young sample 
(mean age: 34 +/- 10 
yr) 
• Periodontal status 




• Prospective cohort 
study design, but used 
only cross sectional 




• Subgingival plaque 
(n=297, 4 samples per 
patient from most 
posterior tooth per 
quadrant excluding 
third molars)  
• 11 taxa measured 
• Primary exposure was 
the bacterial burden 
score (BBS) summing 
the standardized 
values of A.a, P.g, T.f, 
and T.d. 




• Multivariable modified 
Poisson regressions with 
robust error variance 
adjusting for age, sex, 
race/ethnicity, education, 
body mass index, smoking 
status, physical activity level, 
systolic blood pressure, HDL 
cholesterol, inflammatory 
score  
• OR (95% CI) for prevalence 
of prediabetes for the highest 
vs. lowest tertile of bacteria: 
E.c: 1.16 (0.61, 2.21); 
p=0.90; 
V.p: 2.42 (1.27, 4.62); p= 
0.02; 
       A.n: 0.83 (0.48, 1.45); p=0.81 
• When periodontitis and A. 
naeslundii were 
simultaneously adjusted for, 
E.c remained NS, and V.p 






regression analyses  
 
Explicit hypothesis  
that bacteria can 
lead to prediabetes, 




remained strongly positive  
• A. naeslundii, mutually 
adjusted for P. gingivalis and 
periodontitis: 0.46 (0.25, 





microbial would be 
related to both 
inflammatory 
measures and 










markers and insulin 
resistance (HOMA-
IR) 
• n=152 diabetes-free 
adults (subset of the 





• Design same as above 
(Demmer 2015) 
• Cross sectional 
comparison of tertiles 
of bacteria and insulin 
resistance 
• Analyzed using 
Human Oral Microbe 
Identification 
Microarray (HOMIM) 
16S rRNA sequencing 
• 2 subgingival samples 
per patient from index 
teeth  
• 313 species detected 
in at least one sample 
• Bacterial exposures 
operationalized as 
relative abundance of 
phyla or taxa and 
tertiled 
• Main exposure were the 
phyla but not presented here. 
Exploratory analyses for 
individual taxa 
• The 3rd vs 1st tertile of the 
relative abundance of 22 taxa 
were significantly associated 
with insulin resistance 
(HOMA-IR), adjusting for 
age, sex, race/ethnicity, 
education, smoking, BMI. 
(Though none met 
Bonferroni-adjusted 
significance.)  
• Capnocytophaga sputigena 
was one of these 22 taxa 
(Difference = -0.20 (-0.37, -
0.03; p=0.02) between 
highest and lowest tertile for 
Hypothesized a 








• 17 nitrate-reducing bacteria 
taxa also reported in the 121 
taxa that were prevalent in 













and is either 
unrelated or 
inversely related to 









(SBP & DBP) 
• n=653 dentate men 
and women with no 
history of stroke or 
myocardial infarction 
• Periodontal status 
using the CDC/AAP 
guidelines OR tertiles 
based on the 
percentage of sites 
with PD >=3mm  














• Subgingival plaque 
samples from two 
most posterior teeth in 
each quadrant 
• 11 taxa categorized 
into 3 bacterial burden 
scores:  
• Etiologic (A.a, P.g, 
T.f, T.d); Putative 
(C.r, E.c, F.n, M.m, 
P.i); Health-
associated (A.n, V.p)  
• Nitrate-reducing 
bacteria:  
E.c, V.p, A.n 
• No results for the individual 
bacteria 
• Regression analyses with 
hypertension, SBP and DBP 
as the dependent variables 
and highest vs lowest tertile 
of bacterial burden scores, 
adjusting for age, body-mass 
index, sex, race/ethnicity, 
education, smoking, physical 
activity level, diabetes, LDL-
cholesterol, HDL-cholesterol  
• The health-associated burden 
including the two nitrate 
reducers only (A. naeslundii, 
V. parvula) did not reach 
statistical significance 
whereas an inverse 
association between putative 
bacterial burden (including 
E.corrodens) in the highest 
tertile and hypertension (OR= 











adjusting for WBC 










periodontitis in a 
Hispanic American 
population with 
type 2 diabetes, and 
study the possible 
influence of 
diabetes on the 
periodontal 
• n=63 Hispanic 
Americans (n=39 
with, n=24 without 
Type 2 diabetes) from 
the general medical 
diabetic primary care 
clinic at university 









• 28 bacterial species 
(Microbial counts 
dichotomized at ≥105)  
 
• 4 samples (two 
healthy sites, 2 
periodontal sites)   
 
• Results presented in figure  
• Unclear if comparisons were 
made for both healthy and 
periodontal sites, and not all 
species were shown in the 
graph.  Assumed if not 
reported, not significant. 
• None of the relevant species 
(A. naeslundii (type1), 
Veillonella parvula, A. 
naeslundii (type 2), 
Selenomonas noxia, E. 
















samples across and 
within (healthy versus 
periodontal sites) 
disease groups 
 corrodens, and 
Capnocytophaga sputigena) 
were significantly different 
(X2 test) between DM and 
NDM patients in 
periodontitis or healthy sites. 
Hintao et 
al., 200730 
To compare the 
bacteria in saliva 
and supragingival 
and subgingival 
plaque in root 
surface caries 
versus coronal 
caries in adults with 
type 2 diabetes 
mellitus in 
comparison with a 
non-diabetic group 
• N=208 (n=105 




endocrine clinic and 
general practice clinic 
of hospital  
• Controls balanced by 
age-sex stratification 
with type 2 diabetes 
mellitus 
• Case-control design 
with cross-sectional 
comparisons DM and 
NDM 
• Severity and extent of 
periodontitis 





• Supragingival and 
subgingival plaque 
(only from people 
with >=4mm pocket) 
• 17 species identified  
• None of the 17 species, 
including the nitrate-reducing 
bacteria species (E.c, S.n, 
V.p, A.n genospecies 2) 
demonstrated an association 
with type 2 diabetes mellitus 
• X2 test was used to compare 
the percentage of each 
category of each species 
between DM and NDM, with 
Bonferroni correction 
Relatively small 
number of teeth 
available with deep 
(>6 mm) pockets 
that might reduce 







not clearly stated. 
Seemed to compare 







• N=50 (unclear how 
many were diabetic 
versus non-diabetic)  
• Selection criteria not 
reported 
• No mention of other 
potentially 
confounding factors 
• Unclear if the non-
diabetic patients had 
periodontitis 
• Oral swab, unclear 
about the location of 
sampling 
• Culture and 
identification by 
colony morphology, 
gram staining and 
biochemical reactions 
of genera of oral 
bacteria 
• Levels of genera in 
groups presented as 
categories of ~25, 50, 
75, 100 % presence 
• Genera level only 
• Actinomycetes higher in DM 
with periodontitis vs. NDM 
(~100% vs ~50%) 
• Porphyromonas higher in 
DM with periodontitis vs. 
NDM (~75% vs. ~25%) 
• No statistical test for 
comparison reported 











ecosystem of the 
oral cavity in 




• n=140 (n=40 young 




• Students and patients 
from a dental 
university and 
diabetic clinic or a 
hospital. 
• Case-control design 
• Comparison between 
1) controls-healthy 
gingiva 2) pooled 
control + non diabetes 
with periodontitis 3) 
diabetes with 
periodontitis 
• Some had periodontal 
status 
• Culture and other 
biochemical tests 
• Subgingival samples 
from the mesial aspect 
of the first mandibular 
right or left molar 
• Staphyloccocus genus, 
S. epidermis, S. 
saprophyticus  
 
Significant difference in the 
incidence of S. epidermis:  
DM/periodontitis > Pooled 
Control + NDM/periodontitis 
• No detail on statistical 
analyses, and no mention of 













findings were for 











To see if non-
surgical periodontal 
therapy has a 
different effect on 
microbiota in 
diabetes vs. controls 
• n=40 participants with 
chronic periodontitis 




controls) from the 
dental university 
clinic 
• Intervention design 
with follow-up at 3 
months 
• Comparison of 
interest is the DM vs 
controls at baseline 
• All participants had   





method to determine 
prevalence and levels 
(counts of bacteria 
cells)  
• Subgingival plaque 
from 4 deep sites 
(characterized as PD ≥ 
5 mm, CAL ≥ 4 mm, 
and BOP) in different 
non-adjacent teeth 
• 45 taxa  
• Categorized as: 0, not 
detected; 1, < 105 
cells; 2, 
approximately 105; 3, 
105-106 cells; 4, 
approximately 106; 




• At baseline, the prevalence 
and mean counts (in log 10 ± 
SEM) of nitrate-reducing 
bacteria (A. naeslundii. A. 
odontolyticus, V. parvula, E. 
corrodens, N. mucosa, P. 
acnes, P. melaninogenica, S. 
noxia) was not significantly 
different (using the Mann-
Whitney test) 
• This information was 





Though the study 
also does baseline 
to 3months within 
groups, and 3mths 
between groups, 
there is an 
interaction of 
periodontal therapy 






The impact of 
varying diabetic 






• n=107 All diabetes 
patients (n= 60 adults 
with Type 1, n=47 
adults with Type 2 
diabetes) from 
diabetes centers 
• Periodontal status 
ranged from healthy 
to periodontitis 
• Cross-sectional  
• Comparison between 
Type 1 DM vs Type 2 






• A,a, F.n,  E.c, P.g, P.i 
• Subgingival plaque 
from most inflamed 
site (participants most 
early periodontitis 
disease)  
• Presence if bacterial 
cells greater than 
• Prevalence of E.corrodens by 
metabolic control of diabetes 
(good, moderate, poor): 10.8, 
29.6, 33.3%, but NS with 
Fisher's exact test 
• Logistic regression analysis 
with microbe as outcome and 
age, duration, type and 
metabolic control of diabetes 
mellitus, probing depth at the 
sampled site and presence or 
absence of probing depths 
>=4 mm or >=6 mm at any 
Majority of the 
subjects (73%) 
were under good or 
moderate dia- betic 
control and only 





> 10 years; Metabolic 
control: Good (n=37), 
Moderate (n=27), 




other site as possible 
contributing factors was done 
• But metabolic control NS for 
E.c  
 
Yuan et al., 
200142 











• n= 246 (n=105 non-
insulin dependent 
DM, n= 141 NDM 
age and sex matched 
controls) 
• Compared in both 
healthy and disease 
sites. 
• Almost all have 
chronic periodontitis 
(101/105 DM) and 
(132/141 controls) 
• Case control study, 
with comparisons 
between DM vs NDM 
• Culture, and PCR 
technique with some 
randomly confirmed 
by Sanger sequencing 
• A.a, P.g, E.corrodens, 
T.denticola, 
C.albicans 
• One healthy site and 
one diseased 
subgingival sample 
• Detection (absence, 
presence) rather than 
counts 
 
• No significant difference in 
E.corrodens  prevalence in 
both healthy and diseased 
sites between DM and NDM  
(using Chi square test) 
 








Zhou et al., 
201345 
The aim of the 








• n=31 (n=11 NDM, 
n=5 NDM/P-, n=6 
NDM/P+, n=20 DM, 
n=8 DM/P-, n=12 
DM/P+) 






perio strata (NDM/P+ 
vs DM/P+ and 
NDM/P- vs DM/P-) 
 
 





• 1141 species level 
OTUs 
• Subgingival from 4 
deepest sites of the 
molars 
• Bivariate analysis of 
differential abundance or 
prevalence within strata of 
periodontitis (Wilcoxon rank-
sum test and Fisher’s exact 
test, respectively): 




subflava, Genus Prevotella,  
• P-DM> P-NDM: Genus 
Pseudomonas 
• P+DM> P+NDM: 
Capnocytophaga sputigena, 
Genus Actinomyces,  
• NS difference: Selenomonas 
noxia,  
Rothia dentocariosa, Veillonella 
dispar /Veillonella parvula, 
Haemophilus parainfluenzae, 
Actinomyces naeslundi 













Abbreviations for the bacteria species: Eikenella corrodens (E. corrodens), Veillonella parvula (V. parvula), Veillonella dispar (V. dispar), Rothia 
dentocariosa (R. dentocariosa) , Actinomyces naeslundii (A. naeslundii), Selenomonas noxia (S. noxia), Actinomyces odontolyticus (A. 
odontolyticus), Neisseria mucosa (N. mucosa), Propionibacterium acnes (P. acnes), Prevotella melaninogenica (P. melaninogenica), Neisseria 
flavescens (N. flavescens), Haemophilus parainfluenzae (H. parainfluenzae), Neisseria subflava (N. subflava), Corynebacterium matruchotii  (C. 
matruchotti).
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Table 2.3. Associations between nitrate-reducing oral bacteria species and cardiometabolic 
outcomes observed from the 12 studies included  
Findings at the genera level are not reported in this table (Thus Christgau et al.32 and Kulshrestha et. al29 not 
presented here). 
 
*Shaded cells for associations contrary to our hypothesis i.e. higher levels of nitrate-reducing bacteria associated 
with diabetes. Bold for statistically significant associations. 
  
Notes  A.naeslundii A. oris 
Casarin et al. 
2013* 
Mean prevalence ± SD; Values estimated 
from a figure   
  
Ciantar et al. 
2005 
Odds ratio for finding C.s for DM healthy 
sites vs NDM healthy sites; Prevalence of 
C.s at sites 
  
Demmer et al. 
2016 
Mean insulin resistance (HOMA-IR) 
difference between highest vs. lowest 
tertile of species in a diabetes-free 
population    
 -0.20 (-0.62, 0.22)  
 
Demmer et al. 
2015 
Odds ratio for prediabetes between 
highest vs. lowest tertile of species 
OR= 0.83 (0.48, 1.45);  
Sig OR=0.46 (0.25, 0.85) when 




al. 2010  
Odds ratios of hypertension between 
highest vs. lowest tertile of bacteria 
burden; Mean blood pressure values 
estimated from figure. 
(A.n and V. p together) OR = 
0.86 (0.54, 1.36); Mean SBP= 
137 (highest tertile) vs. 140 
(lowest) mmHg  
 
Ebersole et. al 
2008 
Comparisons of mean frequency of sites 
having levels of species ≥105 in the 
plaque; Estimated from figure   
 (Collapsed A.n with other 
Actinomyces. spp)  
Healthy: DM (76%) vs NDM 
(82%); Perio: DM (70%) vs 
NDM (90%) 





Hintao et al. 
2007  
Bacteria counts dichotomized, cutoff point 
either >105 or ≥ 106 
Supragingival: DM (100%), 
NDM (97.1%); Subgingival: 
DM (76.7%), NDM (66.1%) 
 
Sanchez-
Cordero et al. 
1979 
Comparing the incidence of presence of S. 





Comparing using baseline mean counts (in 
log 10 ± SEM). Rough estimates based on 
a figure. Also has mean prevalence. 
2.5, 1.5   2.5, 2.0 
Tervonen et al. 
1994 
Prevalence of species by metabolic 
control 
  
Yuan et al. 
2001 
Comparisons of the prevalence rates of 
the species  
  
Zhou et al. 
2013*  
Comparing relative abundance on the log 
10 scale. Values estimated from Figure. 
 
Healthy sites: DM>NDM (8 vs. 
2); Perio sites; DM>NDM (0.08 
vs 0)  
 
 45
Shaded cells for associations contrary to our hypothesis i.e. higher levels of nitrate-reducing bacteria associated with diabetes.  
Bold for statistically significant associations. 
 A.odontolyticus C.durum C.matruchotii C.sputigena E.corrodens 
Casarin et al. 2013 
    
 0.04±0.16 > 0.00±0.00 
Ciantar et al. 2005 
   
 OR= 3.81 (0.63, 23.05); Prevalence 
at Healthy sites: DM>NDM: 0.16 
(0.03, 0.53) vs. 0.05 (0.01, 0.18)  
Perio sites: NDM 0.08 (0.02, 0.32) 
DM 0.08 (0.01, 0.43)  
 




-0.10 (-0.28, 0.09)  -0.20 (-0.37, -0.03) -0.01 (-0.19, 0.16)  
Demmer et al. 2015 
    
OR=1.16 (0.61, 2.21); even 
when controlling for A.n 
and periodontitis 
Desvarieux et al. 2010  
    
Part of group incl (C.r, 
E.c, F.n, M.m, P.i); OR = 
0.54 (0.28-1.03); Mean 
SBP: 138 (highest) vs 
139.5 (lowest) mmHg 
Ebersole et. al 2008 
   
(Combined Capnocytophaga spp.) 
Healthy: DM (8%) vs. NDM (16%); 
Perio: DM (36%) vs. NDM (56%) 
Not reported in the figure 
Hintao et al. 2007  
    
Supra gingival: DM 
(75.2%) vs NDM (89.3%) 
Subgingival: DM(49.3%) 
vs NDM (45.8%)  
Sanchez-Cordero et al. 
1979 
     
Silva-Boghossian et al. 2014 3.25, 2.25  
  
2.75, 2.25  4.25, 3 
Tervonen et al. 1994 
    
 Good metabolic control 
10.8%, Moderate 29.6%, 
Poor 33.3%  
Yuan et al. 2001 
    
 Healthy sites: DM 65.7% 
vs NDM 72.3%; Diseased: 
DM 83.0% vs NDM 71.4%  
Zhou et al. 2013 
  
Healthy: NDM> 
DM (7 vs 6); Perio: 
DM> NDM (4 vs 
0.6)  
Perio: DM>NDM (8 vs 7); Healthy 




Shaded cells for associations contrary to our hypothesis i.e. higher levels of nitrate-reducing bacteria associated with diabetes. Bold for statistically significant 
associations. 
  G.adiacens H.parainfluenzae N.flavescens N.mucosa N.subflava P.acnes P.m P.salivae R.dentocariosa 
Casarin et al. 
2013 
        
0.07±0.04 > 
0.01±0.02 
Ciantar et al. 
2005 
         




















Demmer et al. 
2015 
         
Desvarieux et al. 
2010  
         
Ebersole et. al 
2008 
         
Hintao et al. 2007  
         
Sanchez-Cordero 
et al. 1979 
         
Silva-Boghossian 
et al. 2014 
   
 (5.75 vs 5)  
 
3 vs 2.5 4.0 vs 4.0  
  
Tervonen et al. 
1994 
         
Yuan et al. 2001 
         
Zhou et al. 2013  
 
Healthy: DM > 
NDM (5 vs. 0.6); 
Perio: DM> 
NDM (0.07 vs. 0)  
Healthy: 
NDM>DM (8 
vs 5); Perio : 
DM > NDM 






NDM (0.6 vs. 
0.09)  
   
Healthy: DM> 
NDM (9 vs. 3); 
Perio: NDM> 
DM (0.4 vs 
0.09)  
P.m abbreviation for P. melaninogenica.
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Shaded cells for associations contrary to our hypothesis i.e. higher levels of nitrate-reducing bacteria associated with diabetes. Bold for statistically significant 
associations. 
 
 R.mucilaginosa S.noxia S.epidermis V.atypica V.parvula V.dispar 
Casarin et al. 
2013 
    
 0.04±0.16 > 0.00±0.00 0.04±0.05 > 
0.00±0.00 
Ciantar et al. 
2005 
      









0.03 (-0.17, 0.23)  
*V.d HOT-160/V.p HOT-
161_Q67   
0.03 (-0.17, 0.23) 
*V.d HOT-
160/V.p HOT-
161_Q67   
Demmer et al. 
2015 
    
OR=2.42 (1.27, 4.62); even 
when controlling for A.n 
and periodontitis  
 
Desvarieux et al. 
2010  
    
(A.n and V.p together) OR 
= 0.86 (0.54, 1.36); Mean 
SBP 137 (highest tertile) 
vs. 140 (lowest) mmHg  
 
Ebersole et. al 
2008 
 
Healthy: DM (26%) NDM 
(8%); Perio: DM(72%) 
NDM(64%)  
  
Healthy: ~90% in both; 
Perio site: 88% in both   
 




(75.2%) vs. NDM 
(75.7%); Subgingival: DM 
(54.8%) vs NDM (49.2%) 
  
Supragingival: DM 
(90.5%), NDM (78.6%); 
Subgingival DM(58.9%), 
NDM (40.7%)  
 
Sanchez-Cordero 
et al. 1979 
  
21 isolates vs 4 
isolates  
   
Silva-Boghossian 
et al. 2014 
 
 2.5 vs 2 
  
1.75 > 0.5 
 
Tervonen et al. 
1994 
      
Yuan et al. 2001 
      
Zhou et al. 2013 
 
 
Healthy: NDM> DM (5 
vs.0.07); Perio: DM> 
NDM (2 vs. 0.3)  
   
Healthy: 




vs 0.4)  
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Appendix A. PRISMA checklist 
 




TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  12 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Reported 
separately 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  13 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
14 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
14 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
14-16 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
14-15 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
Appendix 
B 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 





10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
18 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
17-18 
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Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
17-18 
Appendix 
D & E  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
N/A 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
18-19, 
Figure 2.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
Table 2.2, 
2.3 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Appendix 
D & E  
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 2.2, 
2.3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
N/A 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
20-23 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
24-29 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 24-30 
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future research.  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 






Appendix B. PUBMED/MEDLINE search equation 
 
1. Oral cavity 
"Mouth"[Mesh] OR "Saliva"[Mesh] OR "Dental Plaque"[Mesh] OR "Tongue"[Mesh] OR 
"Periodontal Diseases"[Mesh] OR "Gingiva"[Mesh] OR subgingiv*[Title/Abstract] OR 
oral[Title/Abstract] OR mouth[Title/Abstract] OR saliva*[Title/Abstract] OR dental 
plaque[Title/Abstract] OR dental[Title/Abstract] OR tongue[Title/Abstract] OR 
periodont*[Title/Abstract] OR gingiv*[Title/Abstract] 
2. Microbiome  
"Microbiota"[Mesh] OR "Bacteria"[Mesh] OR "Biofilms"[Mesh] OR "Microbiology"[Mesh] 
OR "Microbial Consortia"[Mesh] OR microbio*[Title/Abstract] OR microbe[Title/Abstract] 
OR bacteria[Title/Abstract] OR biofilms[Title/Abstract] OR pathogen[Title/Abstract] OR 
flora[Title/Abstract]) OR microorganism[Title/Abstract] 
3. Cardiometabolic outcomes (Diabetes, Hypertension, Insulin resistance, Blood pressure)  
"Hypertension"[Mesh] OR "Blood Pressure"[Mesh] OR systolic pressure[Title/Abstract] OR 
diastolic pressure[Title/Abstract] OR hypertensi*[Title/Abstract] OR blood 
pressure[Title/Abstract] OR elevated blood pressure[Title/Abstract] OR increased blood 
pressure[Title/Abstract OR "Diabetes Mellitus"[Mesh] OR "Prediabetic State"[Mesh] OR 
"Diabetes Mellitus, Type 1"[Mesh] OR "Diabetes Mellitus, Type 2"[Mesh] OR "Insulin 
Resistance"[Mesh] OR "Insulin"[Mesh] OR "Blood Glucose"[Mesh] OR "Glucose 
Intolerance"[Mesh] OR "Hemoglobin A, Glycosylated"[Mesh] OR "Hyperglycemia"[Mesh] 
OR ((insulin sensitivity) OR homa-ir[Title/Abstract]) OR dm 2[Title/Abstract] OR dm 
1[Title/Abstract] OR dm i[Title/Abstract] OR dm ii[Title/Abstract] OR hba1c[Title/Abstract] 
OR a1c[Title/Abstract] OR hb a1c[Title/Abstract] OR blood sugar[Title/Abstract] OR blood 
glucose[Title/Abstract] OR glycemi*[Title/Abstract] OR hyperglyc*[Title/Abstract] OR 
hypoglyc*[Title/Abstract] OR (((glucose[Title] OR sugar[Title])) AND (level[Title] OR 
control[Title])))) OR glucose regulation OR insulin resistance OR impaired glucose tolerance 
 
Equation: 1 AND 2 AND 3 
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Appendix C. The list of previously identified oral bacteria species or genera with potential 
nitrate-reducing capacity.  
 
Genera 2 Species  
Actinomyces Actinomyces naeslundii 1 
Brevibacillus Actinomyces odontolyticus 1,2 
Fusobacterium Actinomyces oris/Actinomyces naeslundii 
genospecies-2 2 
Granulicatella Actinomyces viscious 1,2 
Haemophilus Brevibacillus brevis/ Bacillus brevis 2 
Leptotrichia Capnocytophaga sputigena 1 
Neisseria  Corynebacterium durum 1 
Porphyromonas Corynebacterium matruchotii 1 
Prevotella Eikenella corrodens 1 
Veillonella Granulicatella adiacens 1,2 
Unclassified genus of Gemellaceae family  Haemophilus parainfluenzae 1,2 
 Haemophilus segnis 1 
 Microbacterium oxydans 1 
 Neisseria flavescens 2 
 Neisseria mucosa 2 
 Neisseria sicca 2 
 Neisseria subflava 2 
 Prevotella melaninogenica 2 
 Prevotella salivae 2 
 Propionibacterium acnes 1 
 Rothia dentocariosa 1 
 Rothia mucilaginosa 1 
 Staphylococcus epidermidis 1 
 Staphylococcus hemolyticus 1 
 Selenomonas noxia 1 
 Veillonella dispar 1,2 
 Veillonella parvula 2 
 Veillonella atypica 1,2 
 
1 Doel et al. Evaluation of bacterial nitrate reduction in the human oral cavity. European Journal 
of Oral Sciences. 2005; 113(1):14-19. 
2 Hyde et al. Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: implications 
for nitric oxide homeostasis. PLos One. 2014;9:e88645 
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Appendix Table D.  National Heart, Lung, and Blood Institute Study Quality Assessment Tools 
(Observational Cohort and Cross-Sectional Studies OR Case-control studies (in italics)  
 
 
Criteria (Options: Yes, No, Other (CD, NR, NA)*) 
Quality Rating (Good, Fair, or Poor) 
*CD, cannot determine; NA, not applicable; NR, not reported 
† Question was asked in both tools 
 
  
1. Was the research question or objective in this paper clearly stated? †   
     
2. Was the study population clearly specified and defined? †     
  
3. Was the participation rate of eligible persons at least 50%? 
If less than 100 percent of eligible cases and/or controls were selected for the study, were the    
cases and/or controls randomly selected from those eligible?  
      
4. Were all the subjects selected or recruited from the same or similar populations (including the 
same time period)? Were inclusion and exclusion criteria for being in the study prespecified and 
applied uniformly to all participants? 
Were controls selected or recruited from the same or similar population that gave rise to the 
cases (including the same timeframe)? 
Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or 
select cases and controls valid, reliable, and implemented consistently across all study 
participants? 
Were the cases clearly defined and differentiated from controls? 
Was there use of concurrent controls?       
 
5. Was a sample size justification, power description, or variance and effect estimates provided? 
Did the authors include a sample size justification?       
    
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the 
outcome(s) being measured? 
Were the investigators able to confirm that the exposure/risk occurred prior to the development 
of the condition or event that defined a participant as a case? 
 
7. Was the timeframe sufficient so that one could reasonably expect to see an association 
between exposure and outcome if it existed?       
       
8. For exposures that can vary in amount or level, did the study examine different levels of the 
exposure as related to the outcome (e.g., categories of exposure, or exposure measured as 
continuous variable)? 
 
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and 
implemented consistently across all study participants? 
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Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently 
(including the same time period) across all study participants?       
       
10. Was the exposure(s) assessed more than once over time? 
       
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and 
implemented consistently across all study participants? 
 
12. Were the outcome assessors blinded to the exposure status of participants? 
Were the assessors of exposure/risk blinded to the case or control status of participants?    
   
13. Was loss to follow-up after baseline 20% or less? 
       
14. Were key potential confounding variables measured and adjusted statistically for their impact 
on the relationship between exposure(s) and outcome(s)? 
Were key potential confounding variables measured and adjusted statistically in the analyses? If 
matching was used, did the investigators account for matching during study analysis?    




Appendix Table E. Risk of bias assessment for the 14 included studies  
 
Article  2. 
Study 
population  






14. Confounding Quality 
rating  
Main sources of bias 




Yes Yes  Bacteria relative 
proportions 
Yes Somewhat – no 
adjusted 
comparisons but 
stated that no sig 
diff in gender, 
age, periodontal 
measures 
Good  Reverse causation, 


















et. al 1998 





of colony counts  
Yes Age, sex and 
periodontal 
disease matched.  
Fair No statistical test for 
comparisons, 
Misclassification; Small 
sample (n=40); reverse 
causation; selection bias 
Demmer et 
al., 2015 & 
2016 
Yes  Yes Relative 
abundance 
bacterial counts 
Yes  Yes, adjusted for 
several 
confounders 
Good Reverse causation 
Desvarieux 
et al., 2010 
Yes  Yes  Relative 
bacterial counts 
Yes  Yes, adjusted for 
several 
confounders 
Good Reverse causation; 





Yes  Lacking detail on 
inclusion and 
exclusion criteria  
Dichotomized 
microbial counts 
with a cutoff 
>105  




Fair Confounding, reverse 





Yes Yes Microbial counts 
dichotomized 
cutoff >105 or 
106 





















No details on 
diabetic status 
determination 
No reporting on 
any confounders 
Poor Unable to assess threats 
to validity; No statistical 












cases were patients 
at the hospital, 






No details on 
diabetic status 
determination 
but same for 
cases/controls 













et al. 2014 




Mean counts of 
bacteria 
Yes  No sig 
differences 
between gender 
and age, perio 
measures were 
worse for DM 
was sig diff and 
not controlled 
for. 
Fair  Confounding, Selection 
bias, reverse causation 
Tervonen et 
al., 1994 











Good Reverse causation; 
Misclassification; 
confounding 
Yuan et al., 
2001 









stated no sig diff 
between groups 
for age, gender, 


















Yes  Somewhat, no 
adjusted 
comparisons but 
reported no sig 
diff between 
groups on gender 
and age. 
Fair Reverse causation, 
small sample (n=31) 
 
Note: Q1 all studies had clearly reported research questions except Kulshrestha (2011). Q3 was concerned with whether the participation rate was 
reported and only Desvarieux (2010), Hintao (2007) and Yuan (2001) reported this. Q5 was about if a sample size justification was given, and 
most studies did not report this. Q6,7 are concerned with temporality; as all the comparisons were cross-sectional, all studies scored a Not 
Applicable, and reverse causation is a threat to validity for all the studies 
Similarly, Q10 and Q13 was excluded from this table as all studies did not assess the exposure more than once over time for our comparison of 
interest (Q10), nor had a follow-up (Q13).  
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Appendix F. The list of studies that contained comparisons of direct measures of oral 
bacteria (all types) with cardiometabolic outcomes  
 
1. Aemaimanan P, Amimanan P, Taweechaisupapong S. Quantification of key periodontal 
pathogens in insulin-dependent type 2 diabetic and non-diabetic patients with generalized chronic 
periodontitis. Anaerobe 2013;22:64-8. 
 
2. Bignozzi, I.; Ciobanu, G.; Quaranta, A.; Pompa, G. Dental implant sites in healthy versus diabetic 
subjects: A two-year clinical and bacteriological assessment. European Journal of Inflammation 
2013;11(3):813-823 
 
3. Bissong, M. E. A.; Fon, P. N.; Kamga, F. H. L.; Akenji, T. N. Microbiological profile of oral 
infections in diabetic patients and non-diabetic controls in southwest, Cameroon. African Journal 
of Clinical and Experimental Microbiology 2014;15(3):138-143 
 
4. Campus, G.; Salem, A.; Uzzau, S.; Baldoni, E.; Tonolo, G. Diabetes and periodontal disease: A 
case-control study. J Periodontol 2005;76(3):418-425 
 
5. Casarin, R. C. V.; Barbagallo, A.; Meulman, T.; Santos, V. R.; Sallum, E. A.; Nociti, F. H.; 
Duarte, P. M.; Casati, M. Z.; Gonçalves, R. B. Subgingival biodiversity in subjects with 
uncontrolled type-2 diabetes and chronic periodontitis. J Periodontal Res 2013;48(1):30-36 
 
6. Castrillon, C. A.; Hincapie, J. P.; Yepes, F. L.; Roldan, N.; Moreno, S. M.; Contreras, A.; Botero, 
J. E. Occurrence of red complex microorganisms and Aggregatibacter actinomycetemcomitans in 
patients with diabetes. J Investig Clin Dent 2015;6(1):25-31 
 
7. Christgau, M; Palitzsch, Kd; Schmalz, G; Kreiner, U; Frenzel, S. Healing response to non-
surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and 
immunologic results. J Clin Periodontol. 1998 Feb;25(2):112-24. 
 
8. Ciantar, M.; Gilthorpe, M. S.; Hurel, S. J.; Newman, H. N.; Wilson, M.; Spratt, D. A. 
Capnocytophaga spp. in periodontitis patients manifesting diabetes mellitus. J Periodontol 
2005;76(2):194-203 
 
9. Collin HL, Sorsa T, Meurman JH, et al. Salivary matrix metalloproteinase (MMP-8) levels and 
gelatinase (MMP-9) activities in patients with type 2 diabetes mellitus. J Periodontal Res. 
2000;35(5):259-265. 
 
10. Collin, H. L.; Uusitupa, M.; Niskanen, L.; Koivisto, A. M.; Markkanen, H.; Meurman, J. H. 
Caries in patients with non-insulin-dependent diabetes mellitus. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod 1998;85(6):680-685 
 
11. Collin, H. L.; Uusitupa, M.; Niskanen, L.; Kontturi-Närhi, V.; Markkanen, H.; Koivisto, A. M.; 
Meurman, J. H. Periodontal findings in elderly patients with non-insulin dependent diabetes 
mellitus. J Periodontol 1998;69(9):962-966 
 
12. Davila-Perez C, Amano A, Alpuche-Solis AG, et al. Distribution of genotypes of Porphyromonas 




13. Da Cruz, G. A.; De Toledo, S.; Sallum, E. A.; Sallum, A. W.; Ambrosano, G. M. B.; Sardi, J. D. 
C. O.; Da Cruz, S. E. B.; Gonçalves, R. B. Clinical and laboratory evaluations of non-surgical 
periodontal treatment in subjects with diabetes mellitus. J Periodontol 2008;79(7):1150-1157 
 
14. Demmer RT, Breskin A, Rosenbaum M, et al. The Subgingival Microbiome, Systemic 
Inflammation and Insulin Resistance: The Oral Infections, Glucose Intolerance and Insulin 
Resistance Study (ORIGINS). Journal of clinical periodontology. 2016. 
 
15. Demmer, R. T.; Jacobs, D. R., Jr.; Singh, R.; Zuk, A.; Rosenbaum, M.; Papapanou, P. N.; 
Desvarieux, M. Periodontal Bacteria and Prediabetes Prevalence in ORIGINS: The Oral 
Infections, Glucose Intolerance, and Insulin Resistance Study. J Dent Res Sep 2015;94(9 
Suppl):201s-11s 
 
16. Desvarieux, M.; Demmer, R. T.; Jacobs Jr, D. R.; Rundek, T.; Boden-Albala, B.; Sacco, R. L.; 
Papapanou, P. N. Periodontal bacteria and hypertension: The oral infections and vascular disease 
epidemiology study (INVEST). J Hypertens 2010;28(7):1413-1421 
 
17. Ebersole JL, Holt SC, Hansard R, et al. Microbiologic and immunologic characteristics of 
periodontal disease in hispanic Americans with type 2 diabetes. J Periodontol 2008;79(4):637-46. 
 
18. Field, C. A.; Gidley, M. D.; Preshaw, P. M.; Jakubovics, N. Investigation and quantification of 
key periodontal pathogens in patients with type 2 diabetes. J Periodontal Res 2012;47(4):470-478 
2012 
 
19. Heggendorn, F. L.; Gonçalves, L. S.; Dias, E. P.; Silva Junior, A.; Galvão, M. M.; Lutterbach, M. 
T. Detection of sulphate-reducing bacteria in human saliva. Acta Odontol Scand 
2013;71(6):1458-1463 
 
20. Hintao, J.; Teanpaisan, R.; Chongsuvivatwong, V.; Ratarasan, C.; Dahlen, G. The 
microbiological profiles of saliva, supragingival and subgingival plaque and dental caries in 
adults with and without type 2 diabetes mellitus. Oral Microbiol Immunol 2007;22(3):175-181 
 
21. Kamaraj, D. R.; Bhushan, K. S.; Laxman, V. K.; Mathew, J. Detection of odoriferous subgingival 
and tongue microbiota in diabetic and nondiabetic patients with oral malodor using polymerase 
chain reaction. 
Indian Journal of Dental Research 2011;22(2):260-265 
 
22. Kampoo, K.; Teanpaisan, R.; Ledder, R. G.; McBain, A. J. Oral Bacterial Communities in 
Individuals with Type 2 Diabetes Who Live in Southern Thailand. Appl Environ Microbiol 
2014;80(2):662-671 
 
23. Kulshrestha R, Neral A, Srinivasa TS, et al. Comparison of oral microflora of diabetic and non-
diabetic patients with periodontitis. Journal of Pure and Applied Microbiology 2011;5(2):883-6. 
 
24. Kumar, V. V.; Kumar, K. P.; Gafoor, A.; Santhosh, V. C. Evaluation of subgingival microflora in 
diabetic and nondiabetic patients. J Contemp Dent Pract 2012;13(2):157-162 
 
25. Li, C.; Liu, J.; Tan, L.; Yu, N.; Lin, L.; Geng, F.; Zhang, D.; Pan, Y. The sociodemographic 
characteristics, periodontal health status, and subgingival microbiota of patients with chronic 




26. Lydia Rajakumari, M.; Saravana Kumari, P. Isolation, identification and characterization of 
bacteria occurring in the oral cavity of diabetic and non diabetic individuals. Research Journal of 
Pharmaceutical, Biological and Chemical Sciences 2016;7(1):1294-1301 
 
27. Makiura N, Ojima M, Kou Y, Furuta N, Okahashi N, Shizukuishi S, Amano A. Relationship of 
Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following 
periodontal treatment. Oral Microbiol Immunol 2008: 23: 348–351.  
 
28. Matsushita, K.; Hamaguchi, M.; Hashimoto, M.; Yamazaki, M.; Yamazaki, T.; Asai, K.; Yamori, 
M.; Bessho, K.; Toda, H.; Hasegawa, G.; Nakamura, N.; Fukui, M. The novel association 
between red of oral microbe and body mass index in healthy Japanese: A population based cross-
sectional study. Journal of Clinical Biochemistry and Nutrition 2015;57(2):135-139 
 
29. Miranda, T. S.; Feres, M.; Retamal-Valdes, B.; Perez-Chaparro, P. J.; Maciel, S. S.; Duarte, P. M. 
Influence of glycemic control on the levels of subgingival periodontal pathogens in patients with 
generalized chronic periodontitis and type 2 diabetes. J Appl Oral Sci Jan-Feb 2017;25(1):82-89 
 
30. Närhi, T. O.; Meurman, J. H.; Odont, D.; Ainamo, A.; Tilvis, R. Oral health in the elderly with 
non-insulin-dependent diabetes mellitus. Spec Care Dentist 1996;16(3):116-122 
 
31. Noack, B.; Jachmann, I.; Roscher, S.; Sieber, L.; Kopprasch, S.; Lück, C.; Hanefeld, M.; 
Hoffmann, T. Metabolic diseases and their possible link to risk indicators of periodontitis. J 
Periodontol 2000;71(6):898-903 
 
32. Nonzee, V.; Manopatanakul, S.; Khovidhunkit, S. O. P. Xerostomia, hyposalivation and oral 
microbiota in patients using antihypertensive medications. Journal of the Medical Association of 
Thailand 2012;95(1):96-104 
 
33. Oliver RC, Tervonen T, Flynn DG, Keenan KM. Enzyme activity in crevicular fluid in relation to 
metabolic control of diabetes and other periodontal risk factors. J Periodontol. 1993;64(5):358-
362. 
 
34. Raj, S. C. B.; Sukumaran, G. Comparison of microflora in patients with controlled and 
uncontrolled diabetes. Research Journal of Pharmacy and Technology 2015;8(8):1184-1186 
 
35. Raslan, S. A.; Cortelli, J. R.; Costa, F. O.; Aquino, D. R.; Franco, G. C.; Cota, L. O.; Gargioni-
Filho, A.; Cortelli, S. C. Clinical, microbial, and immune responses observed in patients with 
diabetes after treatment for gingivitis: a three-month randomized clinical trial. J Periodontol 
2015;86(4):516-526 
 
36. Salminen, A.; Gursoy, U. K.; Paju, S.; Hyvarinen, K.; Mantyla, P.; Buhlin, K.; Kononen, E.; 
Nieminen, M. S.; Sorsa, T.; Sinisalo, J.; Pussinen, P. J. Salivary biomarkers of bacterial burden, 
inflammatory response, and tissue destruction in periodontitis. J Clin Periodontol May 
2014;41(5):442-50 
 
37. Sanchez-Cordero, S.; Hoffman, H.; Stahl, S. S. Occurrence of staphylococcus in periodontal 
pockets of diabetic and nondiabetic adults. J Periodontol Mar 1979;50(3):109-13 
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Increasing evidence suggests that the digestive tract microbiome (i.e., bacteria colonizing the 
oral cavity and the gastro-intestinal tract) may be a contributing factor in the development  of 
insulin resistance1-3, Type 2 diabetes mellitus4,5, and hypertension6,7. A substantial body of 
evidence accumulated over the past 30 years has linked the oral microbiota to extra-oral 
outcomes8,9. Associations between the oral microbiome and extra-oral outcomes are most 
commonly hypothesized to result from a chronic inflammatory response to a dysbiotic 
subgingival microbiome10. However, an alternative mechanism hypothesized to link the oral 
microbiome to cardiometabolic risk is via the production of the physiologically important 
gaseous transmitter, nitric oxide (NO).  
 
Nitric oxide is an important signaling molecule involved in many physiological processes, 
including vasodilation, endothelial function, immune function and mitochondrial function11,12. 
NO plays a role in glucose metabolism and blood pressure control13, and a loss of NO production 
and bioavailability has been implicated in the pathogenesis of insulin resistance and 
hypertension14,15. NO production was thought to occur solely through the conversion of L-
arginine and oxygen into NO and L-citrulline by nitric oxide synthases (NOSs). These nitric 
oxide synthases are found in the endothelium and other tissues11, and the endothelium is a major 
producer of NO for vasodilation and vascular hemostasis. However, it has recently been 
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discovered that NO production can also occur via the reduction of dietary or endogenous nitrates 
by oral bacteria, through what is known as the enterosalivary nitrate-nitrite-NO pathway. 
 
The enterosalivary nitrate-nitrite-NO pathway is a NOSs-independent pathway for NO 
generation, and represents a novel and biologically plausible mechanism by which oral bacteria 
might influence the systemic bioavailability of NO and related clinical cardiometabolic outcomes 
in humans12. In this pathway, dietary nitrate is absorbed into the bloodstream through the 
gastrointestinal tract, mixed with endogenously-produced nitrates, taken up by the salivary 
glands, and released into the saliva. A small subset of oral bacteria then reduces salivary nitrates 
in the mouth to nitrites. The salivary nitrites are swallowed and made systemically bioavailable 
for further reduction into NO in the blood vessels and tissues16,17. This enterosalivary mechanism 
of NO generation is thought to underlie the strong evidence from experimental studies 
suggesting that increased dietary nitrate intake has beneficial systemic cardiometabolic effects, 
such as lowering blood pressure18, blood glucose, and insulin resistance19-21. For example, a 
systematic review of 13 trials lasting 1 to 6 weeks found a ~4.1 mmHg and 2.0 mmHg reduction 
in systolic and diastolic blood pressure respectively following daily nitrate supplementation22. 
Reduced plasma glucose and improved insulin sensitivity following nitrate supplementation have 
also been observed in some studies19-21,23, though the results are less conclusive24,25. 
 
Evidence supporting the direct role of nitrate-reducing oral bacteria in NO production through 
the enterosalivary pathway is derived from several small experimental studies. For example, the 
blood pressure and plasma glucose reductions observed following experimental nitrate 
supplementation were significantly blunted by antibacterial mouthwash use20,21,26-29. Notably, 
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even in the absence of exogenous nitrate supplementation, suppression of the oral bacteria with 
the use of antibacterial mouthwash was followed by a decrease in salivary and plasma nitrite 
(presumably due to reduced nitrate reduction by the oral bacteria) and a ~3 mmHg increase in 
systolic and diastolic blood pressure28. This evidence therefore suggests a continuous 
physiological role for oral microbiota in blood pressure regulation through the nitrate-nitrite-NO 
pathway. 
 
While these aforementioned experimental studies assessed oral and plasma nitrate/nitrite levels 
and blood pressure following interventions designed to broadly suppress oral microbiota26,28,29, 
no study has directly investigated the relationship between specific oral microbiota with known 
nitrate-reducing capacity and cardiometabolic outcomes in a population-based setting. The 
support for the association between nitrate-reducing bacteria and cardiometabolic outcomes 
arises from experimental studies which artificially suppress the oral microbiome, causing an 
extreme change in bacterial levels. There is little knowledge of the population distribution of 
nitrate-reducing bacteria, and whether such differences in bacterial levels exist in a population 
setting is unknown. Therefore, whether variations in nitrate-reducing oral bacteria within a 
population distribution are associated with differences in cardiometabolic outcomes is unclear 
and remains to be tested. 
 
Interestingly, a small number of larger human studies have found inverse associations between 
the nitrate-reducers A. naeslundii and V. parvula  and adverse cardiometabolic outcomes5,7,30. 
However, the premise of those studies was not to investigate the association of nitrate-reducing 
bacteria with cardiometabolic outcomes. In addition, only two of at least 28 bacteria with 
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potential nitrate-reducing capacity were measured, and the microbial assessments were made 
using now outdated methods that have high cross-reactivity with phylogenetically similar, yet 
functionally distinct organisms31. The advent of next-generation sequencing (NGS) technologies 
enables more accurate quantification of a larger set of bacterial taxa, allowing for a more detailed 
exploration of the overall nitrate-reducing capacity of oral bacteria as well as the identification of 
which taxa are potentially the strongest contributors to nitrate-reduction and cardiometabolic 
effects. 
 
Thus, to address these prior limitations, we examine the cross-sectional relationship between 
nitrate-reducing bacteria in the subgingival plaque and the following outcomes a) insulin 
resistance; b) fasting plasma glucose; c) prediabetes; d) blood pressure; and e) hypertension, in 
diabetes-free adults enrolled in the Oral Infections, Glucose Intolerance, and Insulin Resistance 
Study (ORIGINS). We hypothesize that higher levels of nitrate-reducing oral bacteria will be 
associated with lower physiological measures of insulin resistance and blood pressure, as well as 




Description of ORIGINS 
ORIGINS is a cohort study investigating the relationship between subgingival microbial 
community composition and impaired glucose metabolism5. The cross-sectional data used in this 
study are from the baseline Wave 1 of n= 300 participants enrolled from February 2011 to 2013, 
with the following inclusion criteria: 1) aged 20-55 years; 2) no diabetes mellitus (T1 or T2) 
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based on participant self-report, HbA1c values <6.5% and fasting plasma glucose <126mg/dl; 
and 3) no history of myocardial infraction, congestive heart failure, stroke, or chronic 
inflammatory conditions based on participant self-report. The analyses include only the 
participants who had comprehensive assessments of their subgingival microbiota using next-
generation sequencing techniques made (n=281).  
Participants underwent oral examinations (including periodontal measurements), collection of 
oral bacteria specimens, blood draw after an overnight fast, and in-person anthropometric 
assessments. Detailed risk factor survey questionnaires on demographic data, health behaviors, 
medical conditions and dietary patterns were administered5.  
 
Bacterial assessment and identification  
Subgingival plaque samples (n=281) were collected from the second-most posterior tooth in the 
lower left quadrant (excluding third molars) of each participant using sterile curettes after 
removal of the supragingival plaque1,5. The samples were suspended in 300 µL of TE buffer (50 
mM Tris, 1 1mM EDTA; pH 7.6) and microbial DNA was extracted using the MasterPure™ 
Gram Positive DNA Positive Purification Kit (Epicentre, Madison, WI, USA)32. The median 
DNA concentration per sample obtained was 349 ng/ul (Interquartile range: 112, 779; Mean 
(SD)= 767(1179)). Next generation sequencing of the 16S rRNA gene was performed at the 
Forsyth Institute. The Human Oral Microbiome Identification using Next Generation Sequencing 
(HOMINGS) methodology is designed specifically for oral taxa and generates species level 
information with high precision. A modified protocol based on that described by Caporaso et 
al.33 was used34,35. Briefly, 16S rDNA (50 ng) was amplified using 341F/806R universal primers 
(V3-V4 region) and PCR products were purified using AMPure beads. 100 ng of each library 
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were pooled, gel-purified, and quantified using a bioanalyzer. 12 pM of the library mixture was 
spiked with 20% PhiX and run on a MiSeq (Illumina) platform. The 16S data curation pipeline 
was performed on a per-sample basis and included: 1) error correction and stitching paired-end 
reads to create 441nt sequences spanning the amplified region; 2) filtering and removal of non-
16S data; 3) de novo and reference-based detection and removal of chimeric sequences. Overall, 
18,531,931 sequences were generated for final analysis (median of 375,977 sequences per 
sample). 
HOMINGS follows an in silico hybridization process. A BLAST program, called “ProbeSeq for 
HOMINGS”, using in silico species-specific 16rRNA-based oligonucleotide probes, of which 
many were designed for the original HOMIM process36, was then used to identify species taxa 
and frequency. In ProbeSeq, an array is created using the raw sequence files, and the program 
loops through examining one sequence at a time, looking for a “string” that matches one of the 
probes35. Partial matches are not considered as a match. The total number of matches, or unique 
‘e’-hybridization events referred to as a ‘hit’ are than counted, with each ‘hit’ representing the 
conceptual identification of one bacterial cell35. ProbeSeq is an iterative process, and sequences 
that are not detected by a species-level probe are then processed against genus-level probes. 
HOMINGS is capable of species level identification of 600 oral bacterial taxa, and genus-level 
identification for 129 genera for the remaining sequences that were not uniquely e-hybridized to 
a species probe. The final HOMINGS data output for each individual are expressed as the 
relative abundance of each target taxa (by dividing the respective HOMINGS hits for that taxa 
by the sum of all taxa hits within the individual, i.e.% proportions of each target taxa). Using 
HOMINGS, 668 different taxa were identified in ORIGINS, with a mean of 182 (SD= 50) taxa 




Operationalization of nitrate-reducing oral bacteria exposure  
Exposure to nitrate-reducing oral bacteria was defined by creating a summary score comprised of 
oral bacteria previously identified in the literature as having potential nitrate-reducing capacity. 
From the list of 28 putative nitrate-reducing oral species (Appendix A), 20 taxa were identified 
in our population. The 20 nitrate-reducing bacteria overall showed low correlations with each 
other (Figure S1).  Because of the skewed distributional properties of using relative abundance 
(proportions), the relative abundance of each of the 20 nitrate-reducing taxa was first arcsin-
square root transformed, a variance-stabilizing transformation commonly used for microbiome 
analysis 37. The arcsin-square root transformed relative abundance of each taxa was then 
standardized via division by its standard deviation (SD) – i.e., a 1 unit change in each 
standardized taxa score represents a 1 SD change in the arcsin-square root transformed relative 
abundance. The standardized values for each nitrate-reducing taxa were then summed to create a 
summary score representing total exposure to the nitrate-reducing microbiota community in the 
sample. This score is highly correlated with the proportion of all taxa that are nitrate-reducing 
(Spearman correlation= 0.54, p<0.001) but due to the standardizing method, it cannot be directly 
interpreted in this way. Nevertheless, higher scores represent a higher proportion of nitrate-
reducers. 
 
The standardization was carried out as an a priori approach based on previous papers5. 
Standardization gives equal weight to each taxa in the score and prevents very high relative 
abundance taxa from dominating the score without complete knowledge of their nitrate-reducing 
capacity. A summary score created without standardization of taxa – which simply represents the 
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proportion of all taxa observed that are nitrate-reducing – is generally correlated only with the 
most abundant taxa (Table S1). In contrast, the relative abundances of individual nitrate-reducing 
taxa are more consistently correlated to the standardized score. 
 
To check the linearity of the association between the nitrate-reducing bacteria summary score 
and the cardiometabolic outcomes, tertiles of the summary score were created. Dose-
responsiveness of the association of tertiles of nitrate-reducing bacteria with cardiometabolic 
outcomes across tertiles was examined visually. As no meaningful difference in the information 
obtained was found, we present the main results using the nitrate-reducing summary score as a 




Insulin resistance and Plasma Glucose: Blood was collected following an overnight fast and 
plasma glucose and insulin levels were measured. Insulin resistance was measured using the 
Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) values calculated from 
fasting insulin and glucose levels38-41. Increased levels of HOMA-IR represent more insulin 
resistance and increased risk for future diabetes and cardiovascular disease. To address the 
skewed distribution of HOMA-IR values, insulin resistance was operationalized as natural log-
transformed HOMA-IR in the analyses. Geometric means are presented after back-transforming 
predicted means obtained in regression analyses described below. 
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Prediabetes: Prediabetes (yes/no) was defined in accordance with the American Diabetes 
Association (ADA) criteria as follows: i) Impaired fasting glucose (IFG)= fasting plasma glucose 
≥100 mg/dl and <126 mg/dl; OR ii) Hemoglobin A1c (HbA1c) ≥5.7% and <6.5%42.  
Systolic and diastolic blood pressure: Seated systolic and diastolic blood pressure were 
measured in triplicate and the last two measurements averaged to obtain our continuous 
measures of mean systolic and diastolic blood pressure (mmHg).  
Hypertension: Hypertension (yes/no) was defined in accordance with the most recent 2017 
American Heart Association criteria as follows: i) a systolic blood pressure (SBP) recording of 
≥130 mmHg; or ii) a DBP recording ≥80 mmHg (based on the average of the two last blood 
pressure measurements)43.  Participants who self-reported having a hypertension diagnosis were 
also classified as hypertensive. 
 
Potential confounders 
Information on the potential confounders of age, sex, race (non-Hispanic Black, non-Hispanic 
White, Hispanic, Other), education (high school completion, college or vocational training, 
advanced degrees), cigarette smoking status (current, former or never smoking), body mass 
index, leisure-time physical activity, dietary patterns, and alcohol use was obtained through 
detailed risk factor survey questionnaires. Body mass index (BMI) was calculated as weight in 
kilograms/height (meters2) obtained from in-person physical assessments and operationalized as 
a continuous measure, as categories of BMI (underweight, normal, overweight, obese) showed a 
linear relationship with the outcomes. 
Physical activity: Frequency and intensity of physical activity assessed in the questionnaire were 
operationalized by calculating metabolic equivalents (METs)44, which are a measure of exercise 
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intensity. Total METs per week were calculated [[(Number of times engaged in the activity in 
past 30 days * Average duration of activity * MET score for activity)/30 days] * 7 days], and 
categorized into 4 categories according to the 2008 Physical Activity Guidelines for Americans: 
no physical activity reported, low (0 to <500 MET min/week), moderate (500 to <1,000 MET 
min/week), or high (≥1,000 MET min/week)45.   
Dietary pattern: Overall dietary pattern was assessed using the Alternative Healthy Eating 
Index-2010 (AHEI-2010).  The AHEI-2010 was created based on foods and nutrients predictive 
of chronic disease risk in the literature46. The index consists of several components: vegetables, 
fruits, whole grains, nuts and vegetable protein, red/processed meat, sugar sweetened beverages 
and fruit juice, trans fats, polyunsaturated fats, long-chain fatty acids, sodium, and alcohol 
consumption. Each food group has a range of 0 to 10 points and points are summed to create an 
overall score which ranges from 0 to 110. In prior literature, a higher AHEI score was associated 
with lower risk of coronary heart disease and diabetes46.  
 
Alcohol consumption: Alcohol use was operationalized as average number of drinks/day and 
categorized into 3 categories (non-drinker, ≤ drink/day, > 1 drink/day).  
Periodontitis status: This dissertation views periodontitis as a confounder, and adjusts for it in 
our multivariable analyses. Periodontitis is shown to increase the risk for diabetes47-50 and 
hypertension51, and periodontitis can influence the oral microbiota. Specifically, we hypothesize 
that the pathobiology of periodontitis results in inflammation and deepened periodontal pockets 
which create an environment that increases the pathogenic bacteria that are known to cause 
inflammation and potentially cause cardiometabolic disease52,53. At the same time, the 
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overgrowth of pathogenic bacteria selects against nitrate-reducing oral bacteria and lowers their 
relative abundance. 
 
Measures of periodontitis were obtained from the clinical periodontal examinations. Periodontitis 
(none/mild, moderate, severe) was defined per the Centers for Disease Control and 
Prevention/American Academy of Periodontology (CDC/AAP) guidelines54. Previous 
methodological studies suggest clinical periodontal metrics such as percent of probing sites with 
attachment loss ≥ 3mm relate better to extra-oral disease than the periodontitis diagnosis 
classifications55,56. This is especially so in healthy populations, where these low threshold 
periodontal parameters correlate more closely with bacteria exposure than more severe 
periodontal measures57. In addition, the percent of probing sites with attachment loss ≥ 3mm is a 
more nuanced continuous measure of disease, with variation even in mild periodontal disease.  
Thus, we elected to adjust for periodontal status using percent of probing sites with attachment 
loss ≥ 3mm. Sensitivity analyses using the commonly used CDC/AAP periodontitis diagnostic 
criteria instead were also conducted. 
 
Statistical analysis  
Multivariable linear regression analyses regressed continuous measures of natural log-
transformed Homeostasis Model Assessment for Insulin Resistance (lnHOMA-IR), plasma 
glucose levels, systolic blood pressure, and diastolic blood pressure (dependent variables), on the 
continuous summary score for nitrate-reducing bacteria (NO3TSS). Because the outcomes of 
prediabetes and hypertension were common in our study population (18% and 33% 
respectively), relative risk regressions models using a modified Poisson regression with robust 
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error variance58, were used to calculate the prevalence ratios instead of odds ratios.  To avoid the 
possibility of behavioral modification and medications masking the association with the taxa 
summary scores, sensitivity analyses for mean systolic and diastolic blood pressure outcomes 
were conducted only in the 187 participants who did not have hypertension.  The mean systolic 
blood pressure and diastolic blood pressure was 117 (SD=12) mmHg and 75 (SD=10) mmHg 
respectively in the whole population (n=281); 112 (SD=9) mmHg and 70 (SD=6) mmHg 
respectively for those without hypertension (n=187); and 128 (SD=11) mmHg and 84 (SD=9) 
mmHg respectively for those with hypertension (n=93).  
 
Exploratory analyses of the relationship between the 20 individual bacteria taxa and the 
cardiometabolic outcomes of insulin resistance, plasma glucose, systolic and diastolic blood 
pressure, prediabetes, and hypertension were also conducted.  
 
Screening for the potential confounders of the association between nitrate-reducing bacteria 
and cardiometabolic outcomes  
Age, sex, race, and smoking status are known strong risk factors for cardiometabolic outcomes, 
and a handful of studies have also found age59, sex60-62, race63, smoking status64-66 to influence 
microbial composition. Based on their importance in the literature, we included these covariates 
a priori to our models.  
We screened the other potential confounders using bivariate regression models with the summary 
score of nitrate-reducing bacteria or insulin resistance, plasma glucose, systolic and diastolic 
blood pressure, prediabetes and hypertension as the dependent variables, and the potential 
confounders as the independent variables (Table S2). Only additional covariates associated with 
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both the summary score of nitrate-reducing bacteria and insulin resistance at a α=0.20 level of 
significance, were considered for inclusion in the final adjusted model.  
Body mass index, percent of probing sites with attachment loss ≥3mm, and dietary pattern met 
our criteria for inclusion as a confounder. Thus, the final multivariable regressions were adjusted 
for the potential confounders of age, sex, race, education, smoking status, BMI, percent of 
probing sites with attachment loss ≥3mm, and dietary pattern. Additional models controlling for 
alcohol use and physical activity were also conducted. Sensitivity analyses using multivariable 
models containing only the variables that met our criteria for inclusion without age, sex, race and 
smoking status were also carried out and included in Supplementary Materials. 
 
RESULTS  
Sample characteristics  
The demographic characteristics of the ORIGINS cohort (n=281) are shown in Table 3.1. Our 
study population was young (mean age ± SD = 34 ± 10 y), and disproportionately female (78%), 
college educated (67%) and never smokers (79%). ORGINS recruited mainly employees of 
Columbia University Medical Center, and this may explain the highly educated, non-smoking, 
and female sample. Almost half the participants were Hispanic (47%). Our population was 
periodontally healthy, and 42% of our participants had none or mild periodontitis. Moderate and 
severe periodontitis was present in 52% and 6% of participants, respectively. Among sites from 
which subgingival plaque was sampled, 95% of the sites had a probing depth ≤3 mm and the 
remaining 5% (11 sites) had a probing depth=4 mm. The prevalence of prediabetes and 
hypertension in this population was 18% (n=50) and 33% (n=93), respectively. The 
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characteristics of participants without hypertension were comparable to the whole sample (Table 
3.1).  
 
Prevalence of individual nitrate-reducing bacteria and mean summary score 
An average of 182 (SD=50) taxa were identified in each participant. The mean relative 
abundances of the 20 individual nitrate-reducing bacterial taxa are presented in Figure 3.1. 
Rothia dentocariosa had the highest mean relative abundance of 7.9% and Propionibacterium 
acnes had the lowest relative abundance of 0.0002% (Figure 3.1). Participants had a mean total 
relative abundance of nitrate-reducing taxa of 20% (SD=16%; Range: 0.09, 86%). Many of the 
nitrate-reducing bacteria were present in most of the plaque samples of participants (Figure 3.2). 
Rothia dentocariosa and Veillonella dispar were detected in all participants, whereas 
Propionibacterium acnes was detected in only 6% of people. The mean nitrate-reducing bacteria 
summary score NO3TSS was ~0 (SD=5.42). 
 
Association of nitrate-reducing bacteria summary score with insulin resistance, plasma 
glucose and prediabetes 
The medians (25th, 75th percentiles) of insulin resistance HOMA-IR and mean (SD) plasma 
glucose values in this population were 1.75 (1.22, 2.66) and 85 (7.6) mg/dl respectively. A 
higher NO3TSS was associated with lower insulin resistance and plasma glucose values.  In 
crude analyses, every 1 standard deviation higher NO3TSS was associated with a -0.10 [95% CI: 
-0.16, -0.03] lower natural log-transformed HOMA-IR (Table 3.2). After multivariable 
adjustment, every 1 standard deviation higher NO3TSS, was associated with a -0.09 [95% CI: -
0.15, -0.03] lower natural log-transformed HOMA-IR, representing an 9% decrease in mean 
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HOMA-IR, controlling for age, sex, race, education, BMI, smoking status, percent of probing 
sites with attachment loss ≥3mm, and dietary pattern (Model 5, Table 3.2). The geometric means 
of HOMA-IR values [95% CI] across increasing tertiles of NO3TSS were 1.90 [1.67. 2.18], 1.70 
[1.49, 1.95], 1.53 [1.33, 1.78] (Linear trend p value=0.005) in the adjusted multivariable models 
(Figure 3.3).  
 
Inverse associations were also observed between NO3TSS and baseline plasma glucose (Table 
3.2). In multivariable analyses, every 1 standard deviation higher NO3TSS was associated with a 
-1.03 (-1.90, -0.16)] lower plasma glucose level, controlling for age, sex, race, education, BMI, 
smoking status, percent of probing sites with attachment loss ≥3mm, and dietary pattern. 
NO3TSS exposure was not associated with prediabetes (0.79; 95% CI: 0.61, 1.03) (Table 3.2).  
 
Association of nitrate-reducing bacteria summary score with blood pressure and 
hypertension  
When examining the association between NO3TSS and blood pressure outcomes in the full 
sample (n=281), NO3TSS was not significantly associated with systolic or diastolic blood 
pressure (Table 3.3).  
 
However, in sensitivity analyses including those without hypertension only (n=187), the effect 
estimates were in the same inverse direction, but larger and statistically significant. A standard 
deviation higher NO3TSS was associated with a -1.53 (-2.82, -0.24) mmHg lower mean systolic 
blood pressure, controlling for age, sex, race, education, BMI, smoking status, percent of probing 
sites with attachment loss ≥3mm, and dietary pattern (Model 5, Table 3.3). Figure 3.3 illustrates 
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the adjusted means of systolic blood pressure [95% CI] across increasing tertiles of NO3TSS of 
117 (114, 120), 113 (111, 116), and 114 (111, 117) mmHg (Linear trend p value=0.06). The 
relationship between NO3TSS and mean diastolic blood pressure was inverse but not statistically 
significant (Table 3.3). Higher NO3TSS was not associated with the prevalence of hypertension 
(Table 3.4).  
 
Exploratory analyses for the 20 individual nitrate-reducing bacteria species  
When looking at the associations between the 20 individual nitrate-reducing bacteria taxa and 
insulin resistance and plasma glucose outcomes (Table 3.5), higher Actinomyces naeslundii and 
Neisseria flavescens were significantly associated with lower insulin resistance, whereas higher 
Haemophilus parainfluenzae was significantly associated with lower plasma glucose in 
multivariable models. Higher levels of Actinomyces viscosus and Capnocytophaga sputigena 
was associated with lower prevalence of prediabetes (Table 3.5).  
 
Higher Neisseria flavescens was associated with lower mean systolic blood pressure, and 
Haemophilus parainfluenzae and Neisseria sicca were inversely associated with both mean 
systolic blood pressure and diastolic blood pressure (Table 3.6). For example, a standard 
deviation higher z-score arcsin-sqrt relative abundance of Haemophilus parainfluenzae is 
associated with a -2.59 (-3.99, -1.18) mmHg lower systolic blood pressure, and -1.41 (-2.43, -
0.39) mmHg lower diastolic blood pressure. On the other hand, higher levels of Actinomyces 
naeslundii was associated with higher prevalence of hypertension (Table 3.6).  
 
Sensitivity analyses  
 
 82
Because the literature on potential confounders of the nitrate-reducing oral bacteria and 
cardiometabolic outcome association is still limited, sensitivity analyses adjusting for different 
confounders were conducted. When adjusting for the additional potential confounders of alcohol 
consumption and physical activity (Model 6 of Tables 3.2-3.4), the results were similar to our 
main results. When controlling for periodontal status according to CDC/AAP diagnosis 
classifications (none/mild vs. moderate/severe), the associations observed were not appreciably 
different from our main results as well (Table S3). Likewise, results from the multivariable 
models adjusting only for confounders that were associated with both exposure and outcome in 
the confounder screening, were similar to the main results (Table S3). Finally, associations 
between tertiles of nitrate-reducing bacteria summary score and the cardiometabolic outcomes 
are presented in Tables S4 and S5. The results for insulin resistance and plasma glucose show 
dose-responsiveness, with increasing differences in outcomes as the tertiles increase (Table S4). 
On the other hand, the highest tertile of NO3TSS showed a similar difference in systolic blood 




We found higher levels of nitrate-reducing oral bacteria to be associated with lower insulin 
resistance, plasma glucose and mean systolic blood pressure cross-sectionally. In exploratory 
analyses for the 20 individual nitrate-reducing taxa, mostly inverse statistically significant 
associations with the continuous outcomes of insulin resistance, plasma glucose and blood 




These results add to the current knowledge regarding the potential influence of oral bacteria on 
cardiometabolic outcomes via the enterosalivary nitrate-nitrite-NO pathway of NO generation. 
Most prior studies examining the association between oral bacteria and cardiometabolic 
outcomes focus mainly on putative periodontal pathogens1,5,7. The current study substantially 
expands the number of putative nitrate-reducing oral bacteria studied, and to the best of our 
knowledge, is the first study that directly examines a broad set of nitrate-reducing organisms in 
relation to cardiometabolic outcomes. The consistency of our results, in the direction expected 
based on experimental studies26,27,67, across the different cardiometabolic outcomes of insulin 
resistance, plasma glucose and mean systolic blood pressure, supports our theory of a potential 
beneficial effect of nitrate-reducing oral bacteria on cardiometabolic outcomes. 
 
These findings are of broad relevance because while all participants had some levels of nitrate-
reducing bacteria, there was substantial variation in the total mean relative abundance of nitrate-
reducing bacteria across participants (20%, SD=16%). Moreover, the results for insulin 
resistance and plasma glucose demonstrated dose-responsiveness across tertiles, suggesting that 
higher levels of nitrate-reducing organisms might confer health benefits across the spectrum of 
bacterial levels likely observed in human populations. Thus, if this relationship were causal, it 
suggests that interventions to manipulate nitrate-reducing bacteria levels may be a useful 






The magnitude of associations observed presently are of potential clinical and public health 
relevance. In a meta-analysis of 147 randomized controlled trials, a standard dose of blood 
pressure lowering medication (e.g. diuretics or angiotensin-converting enzyme inhibitors) among 
participants with evidence of mild hypertension (pretreatment systolic and diastolic blood 
pressure of 130 mmHg and 80 mmHg), was estimated to reduce systolic and diastolic blood 
pressure by 6.7 and 3.6 mmHg, respectively68. Importantly, it has also been estimated that 
reductions in systolic blood pressure as low as 4 mmHg can potentially reduce the risk of 
cardiovascular events as much as 12%68. Thus, the difference of ~4 mmHg in mean systolic 
blood pressure observed between the highest tertile compared with the lowest tertile of NO3TSS 
in our study is comparable to the effects of first-line antihypertensive medications and could 
potentially translate into clinically meaningful reductions in cardiovascular disease event rates. 
The clinical relevance of the currently observed differences in insulin resistance and fasting 
plasma glucose between high vs. low levels of nitrate-reducing bacteria is less clear but 
potentially meaningful. Previous studies found that an approximate 1.2 unit increase in HOMA-
IR, was associated with a 27% increase in the incidence of hypertension69, and others report a 1 
unit increase in HOMA-IR to be consistently associated with increased diabetes and 
cardiovascular disease incidence across the spectrum of HOMA-IR values70. Our results for 
fasting plasma glucose are much subtler (~0.4 unit lower HOMA-IR and ~3 mg/dl lower fasting 
plasma glucose between the highest and lowest tertiles of nitrate-reducing bacteria) and to our 
knowledge, differences of this magnitude have not been shown to be associated with diabetes or 
cardiovascular disease incidence. Future studies with longer follow-up times that allow for the 




Our finding that NO3TSS was not associated with prediabetes or hypertension was not consistent 
with the broader hypothesis. This may be due to a truly null hypothesis. Alternatively, nitrate-
reducing bacteria may be most relevant in the early preclinical stages of disease development 
before more advanced pathophysiological alterations (e.g., reduced β-cell function or increased 
arterial stiffness71) have occurred, at which point environmental risk factors might lose 
importance. Behavioral changes (e.g., improved diet and activity levels) or medical therapies that 
occur after identification of hypertension or prediabetes (or other comorbidities such as high 
cholesterol) might favorably influence both nitrate-reducing organisms and cardiometabolic 
health, masking the association. Our observation that NO3TSS was most strongly associated with 
systolic blood pressure among normotensive individuals supports this notion. 
 
Several important limitations should be noted. The cross-sectional design precludes temporal 
inference and reverse causation is a major threat to the validity of our study as insulin, glucose 
and blood pressure levels (even in the clinically normal range) might potentially influence 
microbial community composition. For example, high salivary glucose has been associated with 
a shift in the composition of the oral microbiome although the direct influence on nitrate-
reducing bacteria is unknown and most studies have considered glucose levels in the diabetic 
range72,73. Likewise, prescription medications or behavioral modification in diagnosed 
hypertension could influence microbial communities. It should also be noted that as we excluded 
people with hypertension from our sensitivity analyses of blood pressure outcome, our findings 
of higher levels of nitrate-reducing bacteria associated with lower blood pressure occur in a 
sample with only clinically normal blood pressure. Furthermore, as this data is drawn from a 
cohort study that excludes people with diabetes, there is a possibility that this exclusion criteria 
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may inadvertently select for people who have a lower probability for prediabetes or the other 
outcomes (e.g. hypertension), creating a selection bias for our cross-sectional analyses.  
 
There are some limitations in our measure of nitrate-reducing bacteria exposure. The use of 
microbial assessments from a single time point in these cross-sectional analyses might not 
accurately represent the typical daily exposure to nitrate-reducing bacteria as there has been 
much debate over the stability of the oral microbiome, with some authors reporting stability over 
weeks and months, whereas others report substantial variation in as little as a day74-77. There may 
also be measurement errors in our nitrate-reducing bacteria exposure. ORIGINS only measured 
20 out of the 28 bacteria previously identified in the literature as being associated with nitrate-
reduction capacity (Appendix A), and the relative importance of the unmeasured eight taxa might 
be high. It is also possible that not all relevant nitrate-reducing bacteria have been identified in 
the literature, as only two studies have sought to identify the oral nitrate-reducing bacteria78,79. 
Nevertheless, misclassification of the nitrate-reducing bacteria exposure is likely non-differential 
by the outcomes, thus biasing the estimates towards the null. 
 
In exploratory analyses considering the individual nitrate-reducing taxa, several taxa were found 
to be statistically significantly associated with the cardiometabolic outcomes. Two taxa, A. 
naeslundii and V. parvula, previously studied in subsamples of this ORIGINS cohort, yielded 
inconsistent findings when using different microbial assessment methods. When using DNA-
DNA checkerboard hybridization and 16S rRNA with an in vitro hybridization method to 
identify bacteria, inverse associations for prediabetes with A. naeslundii but positive associations 
with V. parvula, and no associations for insulin resistance with either bacteria, respectively, were 
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found1,5. On the other hand, in the current analyses using next-generation 16S rRNA sequencing 
technologies, neither taxa were associated with prediabetes, and A.naeslundii was inversely 
associated with insulin resistance. Measurement errors of the different microbial assessment 
methods may thus influence the associations found in these analyses, and the identification of the 
individual nitrate-reducing taxa most beneficially associated with cardiometabolic outcomes 
requires replication in future studies.  
 
Because of issues such as microbial horizontal gene transfer, differences in functional capacity 
between strains of the same species80, and different rates of nitrate-reduction between taxa78,79, 
utilizing a taxonomic classification of nitrate-reducing bacteria as we have done in this study 
may not adequately reflect the nitrate-reducing capacity of the oral microbiome.  The reduction 
of nitrate to nitrite is catalyzed by nitrate reductase produced by bacteria and can be subgrouped 
as respiratory nitrate reductase (Nar), periplasmic nitrate reductases (Nap) and assimilatory 
nitrate reductases (Nas)81. Functional classification using metagenomics by directly assessing the 
genes relevant to nitrate-reductase in the oral microbiome, or metatranscriptomics measuring 
gene expression may have a greater ability to differentiate between disease states82,83. Genes 
encoding for nitrate reductase include narG, narL, narJ, narQ, narI, napC, napB, napH, napD, 
napA, napG, and napF, of which narG is the most important gene for the detection of nitrate 
reductase in complex microbial samples, and have been used to identify nitrate-reducing bacteria 
species, or detect the presence of nitrate reductase within dental plaque79,84. Studies that can 
assess both the proportion of putative nitrate-reducing bacteria and the actual nitrate-reducing 
functional capacity of the microbiome would be useful. Likewise, including a biological measure 
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of systemic NO such as plasma or salivary nitrite taken at the same time as the bacteria and lab 
measures may be useful for mediation analyses.   
 
Presently, we have studied subgingival bacteria when the tongue is believed to be the main site 
of bacterial nitrate reduction in the mouth78. While the oral cavity is thought to contain distinct 
niches of microbiota, and the variability in microbial diversity and composition depends on the 
site sampled85-87, little is known about the correlation between nitrate-reducing bacteria in the 
subgingival plaque with that of the tongue. Future studies that can directly assess nitrate-
reducing bacteria on the tongue will be important to increase the relevance of the associations 
found.  
 
Our results also do not account for pathways involving the gut microbiome. As the gut is the site 
of many host-microbe interactions, and contains a greater biomass and more species of bacteria 
than the oral cavity, it likely also plays a role in the enterosalivary pathway and NO 
bioavailability 88,89. As part of the same digestive tract, it is possible that the gut microbiome 
influences the oral microbial composition and vice versa90. At the same time, nitrate reduction by 
gut bacteria have also been observed91,92. Thus, the associations observed in this study may be 
due to pathways of nitrate reduction by gut bacteria rather than oral bacteria. The precise 
percentage of total plasma nitrite contributed by the reduction of nitrate by oral bacteria is 
unknown. However, it is thought that the main site of nitrate reduction to nitrite occurs in the 
mouth, as dietary nitrate is efficiently absorbed into the circulation from the proximal 
gastrointestinal tract bypassing the nitrate-reducing bacteria residing in the distal gastrointestinal 
tract93. The evidence for this assumption arises from the several studies demonstrating the 
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abolition of the biological effects of dietary nitrate supplementation following antibacterial 
mouthwash26,28,67. In addition, a previous study examining the association between both oral and 
gut nitrate-reducing bacteria and migraines also suggests that oral nitrate-reducing bacteria may 
be more relevant than nitrate-reducing bacteria in the gut for NO bioavailability94. 
 
Nevertheless, bacteria in the gut (e.g. Lactobacilli sp., Bifidobacterium, Escherichia coli) can 
directly produce nitric oxide88,89, and could potentially influence blood flow, mucus generation, 
and thus the uptake of nitrate and nitrite in the gut89. Furthermore, the gut microbiome produces 
hydrogen sulfide (H2S), a physiologically important gaseous signaling molecule like NO. There 
is some evidence that the interplay of the two gases H2S and NO can have cardiovascular 
effects95, and H2S is involved in the formation of intestinal NO from nitrite
96. Thus, through 
these other pathways the gut microbiome may modify nitrite and NO bioavailability, and more 
research is needed to fully understand the role of the gut microbiome in the nitrate-nitrite-NO 
enterosalivary pathway. In the same vein, we did not account for local factors that may influence 
bacteria nitrate reduction. The oxygen content, pH level, and the virus and fungal population of 
the oral cavity can all influence bacterial nitrate reduction in the oral cavity89. For example, the 
common fungi Candida is capable of nitrate reduction as well.  
 
Importantly, the characteristics of the total bacterial community may be more relevant than just 
the relative abundance of nitrate-reducing species. For example, Hyde et al. suggests that the 
optimal bacterial community would be one that allows for nitrite accumulation79. Thus, in 
addition to the nitrate-reducing capacity of the oral bacterial community, assessment of the 
nitrite-reducing capacity may be useful, as oral bacteria can reduce salivary nitrite to nitric oxide 
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and thus influence the amount of bioavailable salivary nitrite swallowed and absorbed into the 
systemic circulation to act as a reservoir for NO generation78,79. As such, it may be the ratio of 
the nitrate-reducing capacity vs. the nitrite-reducing capacity of the oral microbiome that is the 
exposure of greatest interest. Further complicating matters is that some known nitrate-reducers 
(e.g. Prevotella melaninogenica, Neisseria mucosa, and Veillonella dispar) have been found to 
also have nitrite-reducing genes79.  
 
However, few studies have specifically explored the nitrite-reducing capacity of the oral cavity, 
and to the best of our knowledge the key bacteria species contributing to nitrite-reduction in the 
mouth has yet to be identified. Previous studies have identified Fusobacterium nucleatum and 
Streptococcus mutans to contain only nitrite-reducing genes79, but preliminary analyses using a 
ratio of our nitrate-reducing summary score over a summary score of these two bacteria did not 
yield any clear associations. A summary score of these two nitrite-reducing bacteria was not 
associated with any of the cardiometabolic outcomes as well. In order to identify more nitrite-
reducing oral bacteria, a list of important nitrite-reductase genes (nirB, nirD, nirS, nirK) in the 
oral cavity79,84 was used to search the EnsemblBacteria database97, which contains over 44,048 
genomes from 8244 bacteria species, for bacteria that contain these nitrite-reductase genes. 
Species (including at the strain level) were matched between ORIGINS and the EnsemblBacteria 
database using the unique NCBI Taxonomy ID98, and a list of nitrite-reducing oral bacteria 
obtained. A similar approach but using GreenGenes OTUs and Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PICRUSt) has previously been used to 
compare the abundance of nitrate and nitrite-reducing genes between migraineurs and non-
migraineurs94. Twenty-four nitrite-reducing oral bacteria were identified through this process but 
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contained 7 species that were also included in the NO3TSS as nitrate-reducing, and these were 
removed to create a summary score of 13 unique nitrite-reducing oral bacteria. Again, no clear 
associations were found with the cardiometabolic outcomes of interest. Future work to refine and 
validate the process of identifying nitrite-reducing bacteria using the EnsemblBacteria database 
could be carried out. Fusobacterium nucleatum and Streptococcus mutans were both not 
identified as nitrite-reducing despite being identified in previous studies79, and using this method 
identified 52 nitrate-reducing bacteria species of which only 12 were also included in the 
NO3TSS. Thus, mismeasurement of the nitrite-reducing capacity of individuals could bias the 
results towards the null and contribute to the lack of associations found. Further work needs to be 
done to identify the key nitrite-reducing bacteria in the oral cavity and to examine the interplay 
of nitrate and nitrite-reducing oral bacteria in the enterosalivary pathway of NO generation.  
 
Despite these limitations, several strengths should be noted. ORIGINS collected a robust set of 
risk factor data allowing for comprehensive control for hypothesized confounders. The use of 
next-generation sequencing techniques allowed for more precise identification of a larger set of 
nitrate-reducing bacteria, and the relatively young cohort, free of diabetes and other clinical 
cardiovascular diseases, minimizes reverse causality. 
 
To the best of our knowledge, this is one of the first studies to directly test the hypothesis of a 
priori identified nitrate-reducing oral bacteria affecting cardiometabolic outcomes. Our results 
support the hypothesis that oral nitrate-reducing bacteria play a beneficial role in blood pressure 
regulation and insulin resistance. Future longitudinal studies with repeated measures of the oral 
microbiome predicting progression of cardiometabolic risk biomarkers and incident clinical 
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disease will enhance the assessment of nitrate-reducing bacteria exposure and improve temporal 
inference necessary to inform causality.  
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Table 3.1. Characteristics of the 281 participants from the Oral Infections, Glucose 








Age (years) 34 (10) 32 (9) 
Female 78% 82% 
Race/ethnicity   
Hispanic 47% 43% 
Non-Hispanic White 22% 27% 
Black 17% 14% 
Other 13% 16% 
Education   
<Bachelor’s Degree 32% 28% 
Bachelor’s Degree 45% 47% 
>Bachelor’s Degree 22% 26% 
Smoking Status   
Never 79% 81% 
Former 12% 10% 
Current 9% 9% 
BMI (kg/m2) 27.0 (6.1) 25.7 (5.3) 
Periodontitis   
None/mild 42% 45% 
Moderate 52% 50% 
Severe 6% 5% 
% of sites with attachment loss ≥3mm 17 (14) 15 (13) 
Average alcohol consumption   
None 7% 7% 
≤1unit/day 79% 77% 
> 1 drink/day 14% 16% 
Physical activity (METS min/week)   
None 31% 31% 
Low 12% 15% 
Moderate 15% 13% 
High 41% 41% 
Alternate Healthy Eating Index Score 
(AHEI) 
49 (12) 50 (12) 
 
Values presented in mean (standard deviation) or percentages. n=1 missing for percent of 
probing sites with attachment loss ≥3mm; n=25 missing for alcohol use; n=6 missing for 
physical activity, n=27 missing for dietary pattern score.  
For those without hypertension: none missing for periodontitis and percent of probing sites with 
attachment loss ≥3mm; n=11, missing for alcohol use; n=17 missing for diet score; n=5 missing 
for physical activity.  
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Figure 3.2. Prevalence (%) of the 20 nitrate-reducing taxa measured in subgingival plaque samples among the 281 participants 




Table 3.2. Mean difference in natural log-transformed Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), 
plasma glucose levels, and prevalence ratio of prediabetes for every 1 standard deviation increase in nitrate-reducing taxa 
summary score (NO3TSS) 
 
 INSULIN RESISTANCE GLUCOSE 
PREDIABETES 
(Prevalence ratio) 
 NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) 
M1 -0.10 (-0.16, -0.03) -1.05 (-1.93, -0.16) 0.90 (0.66, 1.21) 
M2 -0.08 (-0.14, -0.02) -0.85 (-1.67, -0.04) 0.95 (0.74, 1.21) 
M3 -0.08 (-0.13, -0.02) -0.81 (-1.61, -0.02) 0.93 (0.73, 1.19) 
M4 -0.08 (-0.14, -0.02) -0.84 (-1.64, -0.03) 0.94 (0.73, 1.21) 
M5 -0.09 (-0.15, -0.03) -1.03 (-1.90, -0.16) 0.79 (0.61, 1.03) 
M6 -0.09 (-0.15, -0.02) -1.43 (-2.30, -0.58) 0.83 (0.63, 1.09) 
 
Model 1: Crude (n=281) 
Model 2: Adjusted for age, sex, race, education (n=281) 
Model 3: Adjusted for age, sex, race, education, BMI, smoking (n=281) 
Model 4: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm (n=280) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, and dietary 
pattern (n=253) 
Model 6: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, dietary pattern, 




Figure 3.3. Homeostasis Model Assessment for Insulin Resistance (HOMA-IR*) values 
[95%CI] and systolic blood pressure [95%CI] across increasing tertiles of nitrate-reducing 
taxa summary scores (NO3TSS)  
 
Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment 
loss ≥3mm, and dietary pattern. P values are of pairwise comparisons with the first tertile of 





*Geometric means presented for HOMA-IR 
Range of NO3TSS scores within tertiles of nitrate-reducing bacteria summary score: Lowest 
tertile (-12.0, -2.70); Middle tertile (-2.62, 1.64); Highest tertile (1.67, 15.57).  
Tertile 1 (n=93; n=58 without hypertension), Tertile 2 (n=94; n=70 without hypertension), 




TABLE 3.3. Mean difference in systolic and diastolic blood pressure for every 1 standard deviation increase in nitrate-
reducing summary score (NO3TSS) in the full sample (n=281) and in those without hypertension (n=187) 
 
 










 NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) 
M1 
-1.25 (-2.68, 0.18)  -0.59 (-1.71, 0.52) 
-1.70 (-3.00, -0.40) -0.69 (-1.58, 0.19) 
M2 
-0.87 (-2.22, 0.49) -0.31 (-1.37, 0.76) 
-1.60 (-2.84, -0.34) -0.62 (-1.51, 0.27) 
M3 
-0.76 (-2.07, 0.55) -0.23 (-1.28, 0.81) 
-1.51 (-2.74, -0.27) -0.60 (-1.49, 0.29) 
M4 -0.81 (-2.12, 0.50) -0.26 (-1.31, 0.79) -1.51 (-2.74, -0.27) -0.60 (-1.49, 0.29) 
M5 -0.66 (-2.04, 0.72) -0.12 (-1.22, 0.98) -1.53 (-2.82, -0.24) -0.60 (-1.54, 0.33) 
M6 -0.74 (-2.17, 0.69) -0.35 (-1.49, 0.79) -1.85 (-3.10, -0.61) -0.69 (-1.63, 0.25) 
 
Model 1: Crude (n=281; n=187 for without hypertension) 
Model 2: Adjusted for age, sex, race, education (n=281; n=187) 
Model 3: Adjusted for age, sex, race, education, BMI, smoking (n=281; n=187) 
Model 4: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm (n=280; n=187) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, and dietary 
pattern (n=253; n=170) 
Model 6: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, dietary pattern, 




TABLE 3.4. Prevalence ratio for hypertension for every 1 standard deviation increase in 
nitrate-reducing taxa summary score (NO3TSS)  
 
 Hypertension  
 NO3TSS (1 STD) 
M1 0.95 (0.80, 1.13) 
M2 0.99 (0.85, 1.15) 
M3 0.99 (0.86, 1.14) 
M4 1.00 (0.87, 1.16) 
M5 1.03 (0.89, 1.20) 
M6 0.98 (0.83, 1.16) 
 
Model 1: Crude (n=280) 
Model 2: Adjusted for age, sex, race, education (n=280) 
Model 3: Adjusted for age, sex, race, education, BMI, smoking (n=280) 
Model 4: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with 
attachment loss ≥3mm (n=279) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with 
attachment loss ≥3mm, and dietary pattern (n=252) 
Model 6: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with 




TABLE 3.5. Mean difference in natural log-transformed Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) 
and plasma glucose, and prevalence ratio for prediabetes, for every 1 standard deviation higher z-score arcsin-sqrt 
transformed relative abundance for the 20 individual nitrate-reducing bacteria taxa  

















-0.07 -0.13 0.00 -0.44 -1.33 0.45 0.73 0.50 1.06 
Actinomyces odontolyticus -0.03 -0.09 0.03 -0.33 -1.17 0.52 0.85 0.67 1.09 
Actinomyces viscosus -0.05 -0.11 0.02 -0.72 -1.63 0.19 0.65 0.46 0.93 
Capnocytophaga sputigena -0.03 -0.09 0.03 -0.76 -1.59 0.07 0.65 0.45 0.95 
Corynebacterium durum 
-0.06 -0.12 0.01 -0.70 -1.61 0.22 0.72 0.49 1.06 
Corynebacterium matruchotii 
-0.05 -0.12 0.01 0.04 -0.84 0.92 0.94 0.66 1.34 
Eikenella corrodens 
-0.03 -0.09 0.03 -0.30 -1.16 0.55 0.97 0.73 1.29 
Haemophilus parainfluenzae 
-0.05 -0.11 0.02 -0.96 -1.88 -0.05 0.87 0.64 1.20 
Neisseria flavescens -0.08 -0.14 -0.02 -0.73 -1.57 0.12 1.04 0.86 1.27 
Neisseria sicca -0.05 -0.11 0.01 -0.03 -0.87 0.80 0.54 0.22 1.37 
Neisseria subflava -0.01 -0.09 0.06 0.09 -0.91 1.09 1.16 0.94 1.44 
Prevotella melaninogenica 0.03 -0.03 0.09 -0.16 -1.00 0.68 1.09 0.79 1.51 
Prevotella salivae 
0.02 -0.04 0.08 -0.07 -0.93 0.78 1.24 0.98 1.57 
Propionibacterium acnes 
0.01 -0.05 0.07 0.47 -0.37 1.31 0.79 0.45 1.38 
Rothia dentocariosa 0.00 -0.06 0.06 0.31 -0.59 1.21 1.10 0.87 1.40 
Rothia mucilaginosa -0.03 -0.10 0.03 -0.34 -1.22 0.54 0.80 0.49 1.28 
Selenomonas noxia -0.03 -0.09 0.04 -0.78 -1.66 0.11 1.04 0.80 1.35 
Veillonella atypica 0.00 -0.06 0.06 0.01 -0.87 0.90 0.95 0.81 1.12 
Veillonella dispar -0.01 -0.07 0.06 -0.21 -1.07 0.65 0.83 0.60 1.17 
Veillonella parvula 0.01 -0.05 0.07 -0.03 -0.89 0.83 1.02 0.77 1.37 




TABLE 3.6. Mean difference in mean systolic and diastolic blood pressure, and prevalence ratio for hypertension, for every 1 
standard deviation higher z-score arcsin-sqrt transformed relative abundance for the 20 individual nitrate-reducing bacteria 
taxa.  

























1.21 -0.18 2.59 0.10 -0.90 1.09 1.17 1.03 1.32 
Actinomyces odontolyticus -1.16 -2.35 0.03 0.27 -0.59 1.13 0.99 0.84 1.17 
Actinomyces viscosus -0.35 -1.65 0.95 -0.28 -1.21 0.66 1.06 0.88 1.28 
Capnocytophaga sputigena -0.05 -1.35 1.26 0.56 -0.37 1.49 0.98 0.86 1.11 
Corynebacterium durum 
0.05 -1.31 1.41 -0.41 -1.38 0.56 1.19 0.99 1.42 
Corynebacterium matruchotii 
-0.72 -1.95 0.52 -0.37 -1.26 0.51 0.93 0.77 1.11 
Eikenella corrodens 
0.15 -1.26 1.57 0.51 -0.49 1.52 1.02 0.89 1.18 
Haemophilus parainfluenzae 
-2.59 -3.99 -1.18 -1.41 -2.43 -0.39 1.07 0.90 1.28 
Neisseria flavescens -1.35 -2.58 -0.12 -0.63 -1.52 0.26 0.97 0.77 1.22 
Neisseria sicca -1.37 -2.40 -0.35 -1.13 -1.86 -0.40 0.92 0.79 1.07 
Neisseria subflava -0.10 -1.33 1.12 -0.48 -1.35 0.39 1.06 0.87 1.27 
Prevotella melaninogenica 0.29 -0.82 1.39 0.03 -0.76 0.82 0.87 0.72 1.06 
Prevotella salivae 
0.29 -0.86 1.45 0.06 -0.77 0.89 1.01 0.85 1.20 
Propionibacterium acnes 
0.29 -0.80 1.38 0.73 -0.04 1.50 0.91 0.74 1.12 
Rothia dentocariosa -0.13 -1.39 1.12 0.41 -0.48 1.31 1.04 0.87 1.24 
Rothia mucilaginosa -0.86 -2.07 0.35 -0.75 -1.61 0.11 0.94 0.74 1.18 
Selenomonas noxia -0.08 -1.27 1.11 0.10 -0.75 0.95 0.90 0.74 1.09 
Veillonella atypica 0.16 -1.91 2.24 0.72 -0.76 2.20 1.02 0.96 1.08 
Veillonella dispar -0.26 -1.53 1.00 -0.16 -1.07 0.74 1.05 0.89 1.24 
Veillonella parvula -0.99 -2.44 0.45 -0.53 -1.57 0.51 1.11 0.96 1.28 
p <0.05 in bold. Results for systolic and diastolic blood pressure for the participants without hypertension, results for hypertension in 






Figure S1. Spearman correlations of the relative abundance levels for 20 nitrate-reducing subgingival bacteria (n=281) 
 





Table S1. Spearman correlations between the mean relative abundance for each of the 20 

















Rothia dentocariosa 7.91% 0.16 (<0.001) 0.63 (<0.001) 
Corynebacterium matruchotii 4.45% 0.24 (<0.001) 0.18 (0.003) 
Veillonella parvula 2.46% 0.32 (<0.001) 0.22 (<0.001) 
Haemophilus parainfluenzae 1.35% 0.46(<0.001) 0.25 (<0.001) 
Corynebacterium durum 0.96% 0.32 (<0.001) 0.33 (<0.001) 
Actinomyces naeslundii 0.79% 0.32 (<0.001) 0.17 (0.004) 
Rothia mucilaginosa 0.60% 0.28 (<0.001) 0.15 (0.01) 
Veillonella atypica 0.56% 0.35 (<0.001) 0.14 (0.02) 
Prevotella melaninogenica 0.49% 0.48 (<0.001) 0.16 (0.006) 
Selenomonas noxia 0.32% 0.20 (<0.001) -0.07 (0.25) 
Neisseria flavescens 0.26% 0.30 (<0.001) 0.09 (0.12) 
Capnocytophaga sputigena 0.11% 0.34 (<0.001) -0.02 (0.77) 
Eikenella corrodens 0.09% 0.22 (<0.001) -0.13 (0.02) 
Veillonella dispar 0.03% 0.42 (<0.001) 0.31 (<0.001) 
Prevotella salivae 0.02% 0.27 (<0.001) -0.02 (0.72) 
Actinomyces odontolyticus 0.01% 0.36 (<0.001) 0.15 (0.01) 
Actinomyces viscosus 0.01% 0.29 (<0.001) 0.33 (<0.001) 
Neisseria subflava 0.00% 0.14 (0.02) 0.04 (0.52) 
Neisseria sicca 0.00% 0.21 (<0.001) -0.06 (0.32) 
Propionibacterium acnes 0.00% 0.12 (0.04) -0.01 (0.90) 
 
Taxa are listed in descending order of mean relative abundance. The summary score without 
standardization was created by summing the relative abundances across the 20 individual nitrate-reducing 




Table S2. Associations of potential confounders with the exposure of nitrate-reducing 
bacteria summary score (NO3TSS) and cardiometabolic outcomes  
Variable Regression coefficient with 
NO3TSS as dependent 
variable 
Regression coefficient with  
insulin resistance as dependent 
variable 
 Crude Mean 
difference 
(95% CI)  
P value  Crude Mean 
difference 
(95% CI)  
P value  
Age (5 years) -0.11 (-0.43, 0.22)  0.52 0.06 (0.03, 0.09) <0.001 
Female 0.42 (-1.11, 1.96)  0.59 0.09 (-0.07, 0.25) 0.26 
Race/ethnicity   0.26  <0.001 
Hispanic Ref  - Ref - 
Non-Hispanic White 1.56 (-0.06, 3.18) 0.06 -0.44 (-0.61, -0.28) <0.001 
Black 0.001 (-1.76, 1.76)  1.00  -0.12 (-0.30, 0.05) 0.17 
Other -0.02 (-1.98, 1.94) 0.98 -0.24 (-0.44, -0.04) 0.02 
Education   0.07  0.005 
< Bachelor’s Degree Ref  - Ref  - 
Bachelor’s Degree 1.62 (0.18, 3.06) 0.03 -0.19 (-0.33, -0.04) 0.02 
> Bachelor’s Degree 1.56 (-0.16, 3.29) 0.08 -0.28 (-0.46, -0.10) 0.002 
Smoking Status   0.70  0.85 
Never Ref - Ref - 
Former -0.09 (-2.07, 1.89) 0.93 -0.01 (-0.22, 0.19) 0.89 
Current -0.97 (-3.21, 1.26) 0.39 -0.07 (-0.30, 0.17) 0.57 
BMI (kg/m2) -0.07 (-0.17, 0.04)  0.21 0.04 (0.03, 0.05) <0.001 
BMI categories  0.51  <0.001 
Underweight/Normal  Ref  Ref  
Overweight -0.43 (-1.89, 1.02) 0.56 0.35 (0.21, 0.48) <0.001 
Obese -0.96 (-2.59, 0.67) 0.25 0.63 (0.47, 0.78) <0.001 
Percent of sites with 
attachment loss ≥3mm  
(10% increase)  






None Ref  - Ref  - 
 ≤1unit/day 1.06 (-1.59, 3.71)  0.43 -0.13 (-0.41, 0.15)  0.38 
> 1 drink/day 3.09 (0.02, 6.17) 0.05 -0.26 (-0.58, 0.07)  0.12 
Physical activity  




None Ref - Ref  - 
Low 0.59 (-1.55, 2.73) 0.59 0.05 (-0.17, 0.27)  0.67 
Moderate 1.32 (-0.69, 3.32) 0.20 0.02 (-0.19, 0.23)  0.84 
High 0.19 (-1.32, 1.70) 0.80 -0.13 (-0.29, 0.03) 0.11 
Alternate Healthy Eating 
Index Score (AHEI) 
0.04 (-0.02, 0.10) 0.19 -0.01 (-0.01, -0.003) 0.004 
n=281; n=1 missing for percent of probing sites with attachment loss ≥3mm; n=25 missing for alcohol 
use; n=6 missing for physical activity, n=27 missing for dietary pattern score. Bold face used for p <0.20. 




Variable Regression coefficient with  
plasma glucose as dependent 
variable 
Regression coefficient with  
systolic blood pressure as 
dependent variable 
Regression coefficient with  
diastolic blood pressure as 
dependent variable 
 Crude Mean 
difference 
(95% CI)  
P value  Crude Mean 
difference 
(95% CI)  
P value  Crude Mean 
difference 
(95% CI)  
P value  
Age (5 years) 1.25 (0.82, 1.68) <0.001 1.10 (0.38, 1.82) 0.003 1.25 (0.70, 1.80) <0.001 
Female -1.78 (-3.93, 0.37) 0.10 -6.81 (-10.20, -3.42) <0.001 -3.37 (-6.05, -0.69) 0.01 
Race/ethnicity   0.002  0.006  0.005 
Hispanic Ref - Ref - Ref - 
Non-Hispanic White 3.50 (-5.74, -1.26) 0.002 -3.82 (-7.44, -0.19) 0.04 -3.17 (-5.99, -0.36) 0.03 
Black -2.77 (-5.19, -0.34) 0.03 3.04 (-0.90, 6.98) 0.13 3.09 (0.03, 6.14) 0.05 
Other 1.08 (-1.63, 3.78) 0.43 -4.29 (-8.67, 0.08) 0.05 -1.42 (-4.82, 1.98) 0.41 
Education   0.05  0.002  0.01 
< Bachelor’s Degree Ref - Ref - Ref - 
Bachelor’s Degree -2.52 (-4.55, -0.49) 0.01 -3.99 (07.22, -0.75) 0.02 -3.43 (-5.96, -0.90) 0.008 
> Bachelor’s Degree -1.24 (-3.66, 1.18) 0.31 -6.87 (-10.72, -3.01) <0.001 -3.78 (-6.80, -0.76) 0.01 
Smoking Status   0.52  0.22  0.29 
Never Ref - Ref - Ref - 
Former 1.08 (-1.70, 3.85) 0.45 3.81 (-0.65, 8.28) 0.09 2.18 (-1.29, 5.66) 0.22 
Current 1.50 (-1.64, 4.64) 0.35 1.67 (-3.39, 6.72) 0.52 2.26 (-1.67, 6.19) 0.26 
BMI (kg/m2) 0.28 (0.14, 0.43) <0.001 0.64 (0.41, 0.86) <0.001 0.42 (0.25, 0.60) <0.001 
BMI categories  <0.001  <0.001   
Underweight/Normal  Ref - Ref - Ref - 
Overweight 2.20 (0.21, 4.20) 0.03 4.92 (1.78, 8.05) 0.002 3.14 (0.68, 5.60) 0.01 
Obese 4.20 (2.07, 6.54) <0.001 9.92 (6.40, 13.43) <0.001 7.00 (4.25, 9.76) <0.001 
Percent of sites with 
attachment loss ≥3mm  
(10% increase)  






0.92  0.48 
None Ref - Ref - Ref - 
 ≤1unit/day -3.57 (-7.24, 0.09) 0.06 -1.25 (-7.45, 4.95) 0.69 -2.56 (-7.31, 2.18) 0.29 
> 1 drink/day -5.14 (-9.39, -0.89) 0.02 -0.97 (-8.16, 6.23) 0.79 -3.38 (-8.89, 2.13) 0.23 
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Physical activity  




0.01  0.03 
None Ref - Ref - Ref - 
Low -1.17 (-4.13, 1.80) 0.44 -5.31 (-10.08, -0.56) 0.03 -4.72 (-8.35, -1.08) 0.01 
Moderate -0.65 (-3.42, 2.13) 0.65 3.76 (-0.70, 8.22) 0.10 1.22 (-2.19, 4.62) 0.48 
High -2.26 (-4.35, -0.17) 0.03 -0.26 (-3.61, 3.10) 0.88 -1.16 (-3.72, 1.40) 0.37 
Alternate Healthy Eating 
Index Score (AHEI) 
-0.06 (-0.15, 0.02) 0.13 -0.17 (-0.30, -0.04) 0.01 -0.16 (-0.26, -0.06) 0.002 
 
n=281; n=1 missing for percent of probing sites with attachment loss ≥3mm; n=25 missing for alcohol use; n=6 missing for physical activity, n=27 




coefficient (β) with  
prediabetes as 
dependent variable 
P value  Regression coefficient (β) 
with  
prediabetes as dependent 
variable 
P value  
Age (5 years) 0.38 (0.28, 0.49) <0.001 1.36 (1.20, 1.55) <0.001 
Female 0.53 (-0.21, 1.28) 0.16 -0.36 (-1.03, 0.31) 0.30 
Race/ethnicity   <0.001  0.003 
Hispanic Ref - Ref - 
Non-Hispanic White -2.64 (-4.60, -0.67) 0.01 -1.48 (-2.90, -0.05) 0.04 
Black 0.16 (-0.40, 0.72) 0.57 0.55 (-0.09, 1.19) 0.09 
Other -0.33 (-1.13, 0.47) 0.42 -0.57 (-1.74, 0.59) 0.33 
Education   <0.001  0.01 
< Bachelor’s Degree Ref - Ref - 
Bachelor’s Degree -0.99 (-1.55, -0.43) <0.001 -0.37 (-1.00, 0.26) 0.25 
> Bachelor’s Degree -1.21 (-2.03, -0.39) 0.004 -1.37 (-2.55, -0.18) 0.02 
Smoking Status   0.33  0.24 
Never Ref - Ref - 
Former 0.47 (-0.16, 1.10) 0.14 0.67 (-0.09, 1.42) 0.09 
Current -0.35 (-1.45, 0.75) 0.53 0.61 (-0.26, 1.48) 0.17 
BMI (kg/m2) 0.06 (0.03, 0.09) <0.001 0.06 (0.03, 0.10) 0.006 
BMI categories  0.002  0.02 
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Underweight/Normal  Ref - Ref - 
Overweight 0.69 (0.01, 1.37) 0.05 -0.02 (-0.89, 0.85) 0.97 
Obese 1.17 (0.52, 1.82) <0.001 1.09 (0.39, 1.78) 0.002 
Percent of sites with 
attachment loss ≥3mm  
(10% increase)  







None Ref - Ref - 
 ≤1unit/day -0.34 (-1.25, 0.58) 0.47 -0.24 (-1.32, 0.85) 0.67 
> 1 drink/day -0.55 (-1.74, 0.63) 0.36 -1.88 (-4.07, 0.31) 0.09 
Physical activity  





None Ref - Ref - 
Low -0.04 (-0.75, 0.67) 0.92 -0.29 (-1.52, 0.94) 0.65 
Moderate -0.22 (-0.95, 0.50) 0.54 0.27 (-0.67, 1.21) 0.58 
High -0.93 (-1.60, -0.25) 0.007 0.18 (-0.56, 0.91) 0.64 
Alternate Healthy 
Eating Index Score 
(AHEI) 
-0.004 (-0.03, 0.02) 0.77 -0.02 (-0.05, 0.009) 0.18 
 
n=281; n=280 for hypertension.  n=1 missing for percent of probing sites with attachment loss ≥3mm; n=25 missing for alcohol use; n=6 missing 
for physical activity, n=27 missing for dietary pattern score. Bold face used for p <0.20  
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Table S3. Sensitivity analyses using multivariable models with different adjustments of covariates for the associations between 
nitrate-reducing taxa summary score (NO3TSS) and cardiometabolic outcomes  
 




MEAN SBP w/o 
HYPERTENSION 
MEAN DBP w/o 
HYPERTENSION 
HYPERTENSION 
 NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) NO3TSS (1 STD) 
Controlling for periodontitis status (none/mild vs. moderate/severe) as defined by the CDC/AAP guidelines  
M4 -0.07 (-0.13, -0.02) -0.82 (-1.62, -0.02) 0.94 (0.73, 1.19) -1.51 (-2.75, -0.26) -0.61 (-1.50, 0.28) 0.99 (0.86, 1.14) 
M5 -0.09 (-0.15, -0.03) -1.01 (-1.87, -0.14) 0.81 (0.62, 1.05) -1.60 (-2.91, -0.30) -0.62 (-1.56, 0.32) 1.03 (0.89, 1.19) 
M6 -0.08 (-0.15, -0.02) -1.45 (-2.31, -0.59) 0.84 (0.64, 1.10) -1.97 (-3.24, -0.71) -0.71 (-1.66, 0.24) 0.98 (0.84, 1.16) 
Adjusting for confounding using a minimal multivariable model* 
 -0.08 (-0.15, -0.03) -1.08 (-2.00, -0.15)† 1.02 (0.79, 1.32) -1.65 (-3.00, -0.29) -0.63 (-1.56, 0.30) 1.05 (0.88, 1.25)† 
 
Controlling for periodontitis status (none/mild vs. moderate/severe) as defined by the CDC/AAP guidelines  
Model 4: Adjusted for age, sex, race, education, BMI, smoking, periodontitis (none/mild vs. moderate/severe) (n=281) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, periodontitis (none/mild vs. moderate/severe), and dietary pattern (n=254) 
Model 6: Adjusted for age, sex, race, education, BMI, smoking, periodontitis (none/mild vs. moderate/severe), dietary pattern, alcohol use and 
physical activity (n=227)  
Note: For the hypertension outcome, the sample size of the models are as follows: (n=255; 273; 252; 226)  
For the mean systolic and diastolic blood pressure outcomes, the sample size of the models are as follows: (n=187; 170; 155 
hypertension (n=252).  
 
Adjusting for confounding using a minimal multivariable model 
Sensitivity analyses using multivariable models controlling only for covariates associated with both the summary score of nitrate-reducing bacteria 
and the cardiometabolic outcome of interest at a α=0.20 level of significance (Table S2). Therefore, the multivariable analyses controlling for 
education, BMI, percent of probing sites with attachment loss ≥3mm, and dietary pattern only. 
† Additional adjustment for alcohol use as it was associated with both nitrate-reducing bacteria score and plasma glucose/hypertension in bivariate 
analysis (Table S2). 
‡ Adjusting only for education, BMI, and percent of probing sites with attachment loss ≥3mm (Table S2). 




Table S4. Mean difference in natural log-transformed Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), 
plasma glucose levels, and prevalence ratio of prediabetes for tertiles 2 and 3 (vs. 1) of the nitrate-reducing taxa summary 
score (NO3TSS) 
 
  INSULIN RESISTANCE GLUCOSE PREDIABETES 
 Tertile 1 
NO3TSS 





















































































Range of NO3TSS scores within tertiles of nitrate-reducing bacteria summary score:  
Lowest tertile (-12.0, -2.70); Middle tertile (-2.62, 1.64); Highest tertile (1.67, 15.57)  
Tertile 1 (n=93), Tertile 2 (n=94), Tertile 3 (n=94) 
 
Model 1: Crude (n=281) 
Model 2: Adjusted for age, sex, race, education (n=281) 
Model 3: Adjusted for age, sex, race, education, BMI, smoking (n=281) 
Model 4: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm (n=280) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, and dietary pattern (n=253) 
Model 6: Model 5 + alcohol use and physical activity (n=226)  
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Table S5. Mean difference in mean systolic blood pressure, diastolic blood pressure, and prevalence ratio of hypertension for 
tertiles 2 and 3 (vs. 1) of the nitrate-reducing taxa summary score (NO3TSS) 
 
  Systolic BP for those without 
hypertension 
Diastolic BP for those without 
hypertension 
HYPERTENSION 
 Tertile 1 
NO3TSS 





















































































Range of NO3TSS scores within tertiles of nitrate-reducing bacteria summary score:  
Lowest tertile (-12.0, -2.70); Middle tertile (-2.62, 1.64); Highest tertile (1.67, 15.57) 
Tertile 1 (n=93; n=58 without hypertension), Tertile 2 (n=94; n=70 without hypertension) , Tertile 3 (n=94;  n=59 without hypertension) 
 
Model 1: Crude (n=187; n=280 for hypertension) 
Model 2: Adjusted for age, sex, race, education (n=187; n=280 for hypertension; n=280 for hypertension) 
Model 3: Adjusted for age, sex, race, education, BMI, smoking (n=187; n=280 for hypertension) 
Model 4: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm (n=187; n=280 for 
hypertension) 
Model 5: Adjusted for age, sex, race, education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, and dietary pattern (n=170; 
n=252 for hypertension) 
Model 6: Model 5 + alcohol use and physical activity (n=155; n=226 for hypertension)  
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Appendix A. The list of previously identified oral bacteria species or genera with potential 
nitrate-reducing capacity.  
 
Genera 2 Species  
Actinomyces Actinomyces naeslundii 1 
Brevibacillus Actinomyces odontolyticus 1,2 
Fusobacterium Actinomyces oris/Actinomyces naeslundii 
genospecies-2 2 
Granulicatella Actinomyces viscious 1,2 
Haemophilus Brevibacillus brevis/ Bacillus brevis 2 
Leptotrichia Capnocytophaga sputigena 1 
Neisseria  Corynebacterium durum 1 
Porphyromonas Corynebacterium matruchotii 1 
Prevotella Eikenella corrodens 1 
Veillonella Granulicatella adiacens 1,2 
Unclassified genus of Gemellaceae family  Haemophilus parainfluenzae 1,2 
 Haemophilus segnis 1 
 Microbacterium oxydans 1 
 Neisseria flavescens 2 
 Neisseria mucosa 2 
 Neisseria sicca 2 
 Neisseria subflava 2 
 Prevotella melaninogenica 2 
 Prevotella salivae 2 
 Propionibacterium acnes 1 
 Rothia dentocariosa 1 
 Rothia mucilaginosa 1 
 Staphylococcus epidermidis 1 
 Staphylococcus hemolyticus 1 
 Selenomonas noxia 1 
 Veillonella dispar 1,2 
 Veillonella parvula 2 
 Veillonella atypica 1,2 
 
1 Doel et al. Evaluation of bacterial nitrate reduction in the human oral cavity. European Journal 
of Oral Sciences. 2005; 113(1):14-19. 
2 Hyde et al. Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: implications 
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The association between dietary nitrate intake and cardiometabolic outcomes and the 




Vegetables are the main source of dietary nitrate intake in humans, contributing up to 
80% of daily nitrate intake1,2. In particular, green leafy vegetables (e.g. rocket and spinach) and 
beetroot are the richest sources of nitrate in the diet2,3. Several studies have shown an increased 
consumption of vegetables to be associated with improved cardiometabolic outcomes such as 
hypertension4-6 and diabetes7,8, with green leafy vegetables found to have the strongest protective 
effects over other categories of fruits and vegetables6-9. While the cardiometabolic benefits 
observed may be attributed to the several beneficial nutrients in green leafy vegetables (e.g. 
Vitamin C, iron, and folate), the high nitrate content of these vegetables may also be a 
contributing factor10.  
 
One important pathway through which dietary nitrate intake can influence 
cardiometabolic health is via the enterosalivary nitrate-nitrite-nitric oxide pathway of nitric oxide 
(NO) generation11. In this pathway, dietary nitrate is absorbed into the bloodstream through the 
gastrointestinal tract, and 25% of the nitrates in the blood are taken up by the salivary glands, 
where they are concentrated and released in the saliva12. Salivary nitrate is acted on by nitrate-
reducing oral bacteria to form nitrites, which are then swallowed and made systemically 
bioavailable for the production of NO in the blood and tissues11,13,14. NO is an important 
signaling molecule involved in many physiological processes, including glucose metabolism, 
vasodilation, and blood pressure control 15. A loss of NO bioavailability has been implicated in 
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the pathogenesis of insulin resistance and hypertension16,17 . Thus, the enterosalivary nitrate-
nitrite-NO pathway of NO generation represents a way for dietary nitrate and nitrate-reducing 
oral bacteria to influence the bioavailability of NO, and there is great interest in the use of a 
nitrate-rich diet for the prevention and treatment of insulin resistance and hypertension18,19.  
 
Increasing evidence supports the beneficial effects of dietary nitrate intake on cardiometabolic 
outcomes20,21. Experimental trials have shown a myriad of cardiometabolic benefits following 
nitrate supplementation, in particular reductions in blood pressure20,21. For example, a recent 
systematic review and meta-analysis of 16 studies lasting 2 hours to 15 days, with a total of 254 
participants, concluded that dietary nitrate supplementation is associated with a significant 
reduction in systolic blood pressure of ~4.4 mmHg22. Another review, this time of trials lasting 1 
to 6 weeks and including 13 studies with a total of 325 participants, corroborate these results, 
finding a ~4.1 mmHg and 2.0 mmHg reduction in systolic and diastolic blood pressure, 
respectively23. Fewer studies have examined the effect of dietary nitrate intake on glucose 
metabolism, and while animal studies demonstrate overall beneficial effects on blood glucose 
and insulin resistance24-27, the results of human studies are less conclusive28,29. Nevertheless, 
some studies have observed reduced plasma glucose and improved insulin sensitivity following 
nitrate supplementation26,30-32, and there is strong evidence to suggest that dietary nitrate intake 
lowers blood pressure. 
 
However, these studies were in highly-controlled settings, with relatively short-term intake. The 
experimental studies also had small sample sizes of between 7 to 69 participants per study21, 
limiting the generalizability of these findings to the wider general population. Very few studies 
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have directly tested the association of total dietary nitrate intake and beneficial cardiometabolic 
outcomes more broadly in a population setting21,33,34. Most of the larger-scale observational 
studies studying dietary nitrate intake have focused on dietary nitrates used as preservatives in 
processed meat and the increased risk of cancer and cardiovascular disease mortality35,36. While 
compelling arguments for the contribution of dietary nitrate content to the blood pressure-
lowering effects of the Dietary Approaches to Stop Hypertension (DASH) diet have been made2, 
dietary nitrate intake was not measured in that study4. Moreover, the lack of a widely applicable 
and comprehensive dietary nitrate database that can be used in epidemiologic research has made 
measuring nitrate intake from the diet difficult37. Recent investigations using newly developed 
dietary nitrate databases have found increased dietary nitrate intake to be inversely associated 
with atherosclerotic vascular disease mortality and ischemic cerebrovascular disease events3,38,39. 
On the other hand, other studies found no association between dietary nitrate and incidence of 
hypertension and diabetes40,41.  Thus, the findings from large observational studies investigating 
the association between chronic exposure to high dietary nitrate intake and beneficial 
physiological cardiometabolic effects in the general population setting are sparse and 
inconclusive. In addition, the outcomes studied are limited, and early biomarkers prior to the 
onset of disease, such as insulin resistance and blood pressure, have yet to be examined. 
 
Importantly, the literature strongly supports the interaction of dietary nitrate intake with 
oral bacteria along the enterosalivary nitrate-nitrite-NO pathway to produce nitrite. A higher 
dietary nitrate intake increases the amount of salivary nitrate available for the nitrate-reducing 
bacteria to act on, in turn possibly increasing the amount of salivary nitrite produced. 
Correspondingly, an abundance of nitrate-reducing bacteria could increase the amount of nitrite 
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formed from the same bolus of salivary nitrate. Examining the interaction of nitrate-reducing 
bacteria with dietary nitrate intake on cardiometabolic outcomes can help us gain a better 
understanding of this relationship, and elucidate the conditions needed for maximum salivary 
nitrate (and consequently, NO) formation. However, few studies have considered the role of oral 
microbiota in the association between dietary nitrate and cardiometabolic outcomes, and vice 
versa. Most studies do not assess comprehensive measures of both dietary intake and oral 
bacteria, and the interaction between dietary nitrate intake and nitrate-reducing oral bacteria 
remains to be formally tested.  
 
Therefore, the objectives of this study are two-fold. First, we examine the cross-sectional 
relationship between total dietary nitrate intake and the cardiometabolic outcomes a) insulin 
resistance; b) fasting plasma glucose; c) prediabetes; d) systolic and diastolic blood pressure; and 
e) hypertension, in diabetes-free adults enrolled in the Oral Infections, Glucose Intolerance, and 
Insulin Resistance Study (ORIGINS). We hypothesize that higher total dietary nitrate intake will 
be associated with lower prevalence of prediabetes and hypertension, as well as lower 
physiological measures of insulin resistance, fasting plasma glucose and blood pressure. 
Secondly, we examine whether the relationship between nitrate-reducing bacteria and the 
aforementioned cardiometabolic outcomes are modified by dietary nitrate intake. We 
hypothesize that higher levels of nitrate-reducing bacteria will be associated with greater 
reductions in cardiometabolic outcomes in the presence of high dietary nitrate intake. 
 
METHODS   
 
Description of ORIGINS 
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ORIGINS is a cohort study investigating the relationship between the subgingival microbial 
community composition and impaired glucose metabolism42. The cross-sectional data used for 
the main dietary nitrate analyses are from the baseline Wave 1 n=300 participants enrolled from 
February 2011 to 2013 for whom dietary data and oral microbial assessments were available 
(n=241), and additional Wave 2 participants enrolled from January 2016 – May 2018, who only 
had dietary data available at the time of this writing (n=178). Participants were enrolled with the 
following inclusion criteria: 1) aged 20-55 years; 2) no diabetes mellitus (T1 or T2) based on 
participant self-report, HbA1c values <6.5% and fasting plasma glucose <126 mg/dl; 3) no 
history of myocardial infraction, congestive heart failure, stroke, or chronic inflammatory 
conditions based on participant self-report.  
 
Participants underwent oral examinations (including periodontal measurements), collection of 
oral bacteria specimens, blood draw after an overnight fast, and in-person anthropometric 
assessments. Detailed risk factor survey questionnaires on demographic data, health behaviors, 
medical conditions and dietary patterns were administered42.  
 
Exposure: Dietary nitrate intake and operationalization  
Baseline dietary patterns were assessed via a detailed 134-item semi-quantitative food frequency 
questionnaire (FFQ) based on the National Cancer Institute Diet History Questionnaire (NCI-
DHQ)43. Previous studies demonstrate the validity and reproducibility of the DHQ in a multi-
ethnic population similar to the study population used in this dissertation44. Participants were 
asked whether they had consumed a particular food item in the past 12 months, the portion sizes, 
and the frequency of intake. There were ten predefined frequency categories ranging from never 




Total dietary nitrate intake was calculated by summing the nitrate amount of each individual 
food item using values from a recently established US database for the nitrate content of foods. 
This database was developed and validated utilizing an earlier version of the NCI-DHQ than the 
one used in our study45. The nitrate content of foods in the database was assigned based on a 
literature review, focusing on US and Canadian data, but drawing on data from other countries 
where needed45. Where multiple studies were available, the means of the published values were 
weighted by the number of samples45. Values for newer food items in the FFQ used in ORIGINS 
were added in consultation with an author of the US database according to the method previously 
described (Table S1)45,46. Values for mixed dish food items (e.g. Mexican mixtures) were 
calculated using standardized recipes from the US Department of Agriculture’s 1994-1996 
Continuing Survey of Food Intakes by Individuals (CSFII) for relevant foods47 and weighted 
averages of the nitrate content of the foods in the recipe.   
 
The FFQ in our study was processed using the National Cancer Institute’s Diet*Calc software 
specifically created to analyze DHQ data and generate nutrient and food group intake 
estimates48. The Diet*Calc software consists of a food database, and we added nitrate values for 
each food item. The software then generated total daily nitrate intake for each individual based 
on the FFQ responses. 
 
Total energy intake is associated with the disease outcomes (e.g. high calorie intake is associated 
with diabetes and hypertension), and total energy intake is likely associated with the intake of 
dietary nitrates (e.g. people who eat more calories eat more nitrates). Therefore, we viewed total 
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energy intake as a confounder of the relationship between dietary nitrate intake and 
cardiometabolic outcomes. Dietary nitrate intake was adjusted for total energy intake 
(kilocalories) using the residual method, to create an energy-adjusted nitrate intake variable49. In 
addition to total dietary nitrate intake, we calculated nitrate intake from plant, processed meat 
and red meat, and other animal sources separately. The median dietary nitrate intake from plant 
sources, from processed meat and red meat sources, from other animal sources, and the median 
total dietary nitrate intake from all sources was 112 mg/day, 0.70 mg/day, 0.86 mg/day, and 125 
mg/day, respectively. The list of food items within each category of dietary nitrate sources is 





Insulin resistance and Plasma Glucose: Blood was collected following an overnight fast and 
plasma glucose and insulin levels were measured. Insulin resistance was measured using the 
Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) values calculated from 
fasting insulin and glucose levels50-53. Increased levels of HOMA-IR represent more insulin 
resistance and increased risk for future diabetes and cardiovascular disease. To address the 
skewed distribution of HOMA-IR values, insulin resistance was operationalized as natural log-
transformed HOMA-IR in the analyses. Geometric means are presented after back-transforming 
predicted means obtained in regression analyses described below. 
Prediabetes: Prediabetes (yes/no) was defined in accordance with the American Diabetes 
Association (ADA) criteria as follows: i) Fasting plasma glucose ≥100 mg/dl and <126 mg/dl; or 
ii) Hemoglobin A1c (HbA1c) ≥5.7% and <6.5%54.  
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Systolic and diastolic blood pressure: Seated systolic and diastolic blood pressures were 
measured in triplicate and the last two measurements averaged to obtain our continuous 
measures of mean systolic and diastolic blood pressure (mmHg).  
Hypertension: Hypertension (yes/no) was defined in accordance with the most recent 2017 
American Heart Association criteria as follows: i) a systolic blood pressure (SBP) recording of 
≥130 mmHg; or ii) a DBP recording ≥80 mmHg (based on the average of the two last blood 
pressure measurements)55. Participants who self-reported having a hypertension diagnosis, were 
also classified as hypertensive. 
 
Potential confounders  
 
Information on the potential confounders of the dietary nitrate intake and cardiometabolic 
outcome association – age, sex, race (non-Hispanic Black, non-Hispanic White, Hispanic, 
Other), education (high school completion, college or vocational training, advanced degrees), 
cigarette smoking status (current, former or never smoking), body mass index, leisure-time 
physical activity, dietary patterns, and alcohol use – was obtained through detailed risk factor 
survey questionnaires. Body mass index (BMI) was calculated as weight in kilograms/height 
(meters2) obtained from in-person physical assessments and operationalized as a continuous 
measure. 
Physical activity: Frequency and intensity of physical activity assessed in the questionnaire were 
operationalized by calculating metabolic equivalents (METs)56, which are a measure of exercise 
intensity. Total METs per week were calculated [[(Number of times engaged in the activity in 
past 30 days * Average duration of activity * MET score for activity)/30 days] * 7 days], and 
categorized into 4 categories according to the 2008 Physical Activity Guidelines for Americans: 
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no physical activity reported, low (0 to <500 MET min/week), moderate (500 to <1,000 MET 
min/week), or high ( ≥1,000 MET min/week)57.   
Dietary pattern: Overall dietary pattern was assessed using the Alternative Healthy Eating 
Index-2010 (AHEI-2010).  The AHEI-2010 was created based on foods and nutrients predictive 
of chronic disease risk in the literature58. The index consists of several components: vegetables, 
fruits, whole grains, nuts and vegetable protein, red/processed meat, sugar sweetened beverages 
and fruit juice, trans fats, polyunsaturated fats, long-chain fatty acids, sodium, and alcohol 
consumption). Each food group has a range of 0 to 10 points and points are summed to create an 
overall score which ranges from 0 to 110.  In prior literature, a higher AHEI score was associated 
with lower risk of coronary heart disease and diabetes58.  
Alcohol consumption: Alcohol use was operationalized as average number of drinks/day and 
categorized into 3 categories (non-drinker, ≤ drink/day, > 1 drink/day).  
 
For the interaction analyses, we also controlled for potential confounders between nitrate-
reducing bacteria and cardiometabolic outcomes, which match the potential confounders for the 
main dietary nitrate association, with the addition of periodontitis status59.  
Periodontitis status: Measures of periodontitis were obtained from the clinical periodontal 
examinations. Periodontitis (none/mild, moderate, severe) was defined per the Centers for 
Disease Control and Prevention/American Academy of Periodontology (CDC/AAP) 
guidelines59. Previous methodological studies suggest clinical periodontal metrics such as 
percent of probing sites with attachment loss ≥ 3mm relate better to systemic disease than the 
periodontitis diagnosis classifications60,61. This is especially so in healthy populations, where 
these low threshold periodontal parameters are correlated more closely with bacteria exposure 
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than more severe periodontal measures62. In addition, the percent of probing sites with 
attachment loss ≥ 3mm is a more nuanced continuous measure of disease, with variation even in 
mild periodontal disease. Thus, we elected to adjust for periodontal status using the measure 
percent of probing sites with attachment loss ≥ 3mm.  
 
Nitrate-reducing oral bacterial assessments and operationalization for the interaction 
analyses 
Subgingival plaque samples (n=281) were collected from the second-most posterior tooth in the 
lower left quadrant (excluding third molars) of each participant using sterile curettes after 
removal of the supragingival plaque42,63.  Microbial analysis of DNA samples was performed 
using the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) 
method. HOMINGS can identify more than 600 oral bacterial taxa, and the method used has 
been previously published64,65. Briefly, amplified 16S ribosomal RNA (rRNA) gene sequences 
are processed using high throughput Illumina MiSeq. An ‘in silico hybridization process’ with 
16S rRNA-based in silico probes is then used to identify the taxa and frequency. Each unique 
‘e’-hybridization event is referred to as a ‘hit’65 and represents the conceptual identification of 
one bacterial cell. The final HOMINGS data output for each individual are expressed as the 
relative abundance of each target taxa (by dividing the respective HOMINGS hits for that taxa 
by the sum of all taxa hits within the individual, i.e. % proportions of each target taxa). Using 
HOMINGS, 668 different taxa were identified in ORIGINS, with a mean of 182 (SD= 50) taxa 




Exposure to nitrate-reducing bacteria was defined by creating a summary score comprised of 
nitrate-reducing bacteria previously identified in the literature. Twenty taxa with putative nitrate-
reducing capacity were identified in our population. Because of the skewed distributional 
properties of using relative abundance (proportions), the relative abundance of each of the 20 
nitrate-reducing taxa was first arcsin-square root transformed, a variance-stabilizing 
transformation commonly used for microbiome analysis66. The arcsin-square root transformed 
relative abundance of each taxa was then standardized via division by its standard deviation (SD) 
– i.e., a 1 unit change in each standardized taxa score represents a 1 SD change in the arcsin-
square root transformed relative abundance. The standardization was carried out as an a priori 
approach based on previous papers42. Standardization gives equal weight to each taxa in the 
score and prevents very high relative abundance taxa from dominating the score without absolute 
knowledge as to their nitrate-reducing capacity. The standardized values for each nitrate-
reducing taxa were then summed to create a summary score representing total exposure to 
nitrate-reducing microbiota community in the sample.  
 
Statistical analysis  
Dietary nitrate and cardiometabolic outcomes  
We examined the linearity of dietary nitrate intake exposure with the cardiometabolic outcomes 
of interest. For the continuous outcomes, we visually examined scatterplots of dietary nitrate 
intake with the outcomes and did not note any major deviations from linearity. We examined the  
relationship between dietary nitrate intake and the prevalence ratio of prediabetes and 
hypertension non-parametrically with restricted cubic splines67, and the tests for non-linearity 
were not significant (p=0.56 and p=0.39, respectively). 
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Thus, energy-adjusted dietary nitrate intake exposure was operationalized as a continuous 
measure. Tertiles of dietary intake based on percentile cutoffs defined within the study (Total 
nitrate: 74.5, 182.2 mg/day; Plant nitrate: 65.3, 175.7 mg/day; Processed and red meat nitrate: 
0.40, 1.12 mg/day; other Animal nitrate: 0.50, 0.89 mg/day) were also created and presented. 
 
Multivariable linear regression analyses regressed natural log-transformed Homeostasis Model 
Assessment for Insulin Resistance (HOMAIR) levels, plasma glucose levels, systolic and 
diastolic blood pressure (dependent variables), on the energy-adjusted total dietary nitrate intake. 
For all models, including crude models, we adjusted for total energy intake (kcal) when using the 
energy-adjusted nitrate exposures. Because the outcomes of prediabetes and hypertension are 
common in our study population (18% and 33% respectively), relative risk regressions models 
using a modified Poisson regression with robust error variance68, were used to calculate the 
prevalence ratios instead of odds ratios. To avoid the possibility of behavioral modification and 
medications masking the associations with the total dietary nitrate intake, sensitivity analyses for 
systolic and diastolic blood pressure outcomes were conducted in only the 269 participants who 
did not have hypertension. The mean systolic blood pressure and diastolic blood pressure was 
118 (SD=13) and 75 (SD=9) mmHg respectively in the total sample, and 112 (SD=9) mmHg and 
70 (SD=6) mmHg for those without hypertension. The multivariable regressions were adjusted 
first for potential demographic confounders, such as age, sex, race, education, followed by the 
lifestyle confounders such as BMI, smoking status, and physical activity. Next, we additionally 





The effect of dietary nitrate intake on health outcomes is thought to vary by the food sources of 
nitrate37,69. Dietary nitrate from fruits and vegetables are thought to be beneficial because 
antioxidant vitamins (e.g. Vitamin C and E) present in fruits and vegetables inhibit the formation 
of harmful nitrosamine products70, whereas red meat contains amines and heme iron that 
increases the nitrosation of dietary nitrate71. Thus, sensitivity analyses using specific exposures 
of dietary nitrate from plant sources only, processed meat and red meat sources only, as well as 
other animal sources only (including poultry, fish/seafood and dairy sources), were used to 
assess the consistency of the associations. These multivariable analyses adjusted for nitrate 
intake from the other two sources to account for the possibility that people who consumed more 
nitrate from plant sources were consuming less nitrate from processed and red meat or other 
animal sources. 
 
Interaction between nitrate-reducing oral bacteria and dietary nitrate intake  
The interaction analyses include only the Wave 1 participants who had comprehensive 
assessments of the subgingival microbiota using next-generation sequencing techniques (n=281) 
and had dietary nitrate intake measures (n=40 participants missing dietary information). 
Therefore, the total sample size for the interaction analyses was n=241, and n=160 in analyses 
examining systolic and diastolic blood pressure outcomes for those without hypertension.  
 
Multivariable linear regression analyses regressing continuous measures of natural log-
transformed Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) levels, plasma 
glucose levels, systolic blood pressure, and diastolic blood pressure (dependent variables) on the 
continuous summary score for nitrate-reducing bacteria (NO3TSS), controlling for the potential 
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confounders of age, sex, race, education, BMI, smoking status, percent of probing sites with 
attachment loss ≥3mm, and dietary patterns were previously done in Aim 2. Relative risk 
regression models using a modified Poisson regression with robust error variance 68, were used 
to calculate the prevalence ratios for the dichotomous outcomes of prediabetes and hypertension.  
 
To assess the interaction between nitrate-reducing oral bacteria and dietary nitrate intake, an 
interaction term was added into the fully adjusted multivariable model for Aim 2. Interaction was 
assessed on the additive scale as recommended for better representation of biologic interaction72, 
and deemed present if the X2 test for the interaction term was significant at a 5% level. The 
summary score for nitrate-reducing bacteria was dichotomized into high vs. low nitrate-reducing 
bacteria score intake based on the median values of NO3TSS (-0.01; IQR: -3.60, 3.58) in the 
n=241 participants, and tertiles of nitrate intake created (71, 172 mg/day). For systolic and 
diastolic blood pressure, interaction was assessed only in the 160 participants without 
hypertension. For the relative risk models for prediabetes and hypertension which are on the 
multiplicative scale, the Relative Excess Risk due to Interaction (RERI) was calculated from the 
results using the spreadsheet tool provided by Knol and Vanderweele72. For ease of interpretation 
of additive interaction, dichotomous dietary nitrate (high/low) and dichotomous nitrate-reducing 
bacteria score (high NO3TSS/ low NO3TSS) were used to present the interaction results for the 
binary outcomes prediabetes and hypertension. 
 
RESULTS 
Dietary nitrate intake in our ORIGINS population  
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In our population, the median total dietary nitrate intake was 125 mg/day (Interquartile range 
(IQR): 61-223 mg/day. Plant sources contributed the majority of dietary nitrate intake (Median= 
112 mg/day; IQR: 50-217), with other animal sources (Median =0.67 mg/day; IQR: 0.42, 1.04) 
and processed meat and red meat (Median=0.70; IQR: 0.28, 1.42) contributing less than 1% of 
the total nitrate intake. The correlations of dietary nitrate intake from plant sources with 
processed and red meat sources, and other animal sources were -0.11 (p=0.02) and -0.01 
(p=0.72), respectively. The major contributors to total dietary nitrate intake are presented in 




The demographic characteristics of the ORIGINS cohort (n=419) are shown in Table 4.2. Our 
population was highly educated, majority female and non-smoking. Almost half the participants 
were Hispanic (42%), and the mean dietary pattern score 47 (SD=12) was comparable to 
previous reports for a US population58. The prevalence of prediabetes and hypertension in this 
population was 17% (n=70) and 36% (n=150), respectively.  
 
More physical activity, healthier eating patterns, and higher education were associated with 
higher dietary nitrate intake (Table 4.3). Hispanics had lower dietary nitrate intake than other 
races. A lower mean nitrate-reducing summary score was found in the lowest tertile of dietary 
nitrate intake, but the nitrate-reducing bacteria summary score was not statistically different 
across tertiles of dietary nitrate intake (Table 4.3). Higher dietary nitrate intake was likewise not 





Association between dietary nitrate intake and insulin resistance, plasma glucose and 
prediabetes 
Higher total dietary nitrate consumption was significantly associated with lower insulin 
resistance in the crude model; every 1 standard deviation (STD) (170 mg/day) higher total 
dietary nitrate intake was associated with a -0.08 [95% CI: -0.14, -0.02] lower natural log-
transformed insulin resistance (HOMA-IR) (Table 4.4). Upon adjustment for potential 
confounders, the association was attenuated and no longer statistically significant, but still 
inverse, -0.05 [95% CI: -0.11, 0.01] (Model 5; Table 4.4). The geometric means of insulin 
resistance HOMA-IR values [95% CI] across increasing tertiles of dietary nitrate intake were 
1.71 [1.54. 1.90], 1.61 [1.46, 1.77], 1.57 [1.41, 1.74] (Linear trend p value=0.27) in the fully 
adjusted multivariable models controlling for age, sex, race, education, BMI, smoking status, 
physical activity, dietary pattern, and alcohol consumption. 
 
When examining nitrate intake by sources of nitrate, adjusting for other sources of nitrate, higher 
dietary nitrate intake from processed and red meat was found to be associated with higher insulin 
resistance. A 1 STD higher dietary nitrate from processed or red meat (1.39 mg/day) was 
associated with a 0.07 [95% CI: 0.00, 0.14] higher natural log-transformed insulin resistance in 
the fully adjusted model (Table 4.4). On the other hand, every 1 STD higher plant nitrate intake 





We did not find any statistically significant associations between dietary nitrate intake and 
plasma glucose (Table 4.5) or the prevalence of prediabetes (Table 4.6). 
 
Association between dietary nitrate intake and mean systolic and diastolic blood pressure 
and hypertension  
When examining the association between dietary nitrate intake and blood pressure in the full 
sample (n=419), total dietary nitrate was not associated with systolic blood pressure or diastolic 
blood pressure (Table 4.7 and 4.8).  
 
In sensitivity analyses including those without hypertension only (n=269), a trend towards lower 
mean systolic blood pressure among those with higher total dietary nitrate intake was observed. 
Every 1 STD higher total dietary nitrate intake was associated with a -0.95 [95% CI: -1.96, 0.05] 
lower mean systolic blood pressure in the fully adjusted model, and though the confidence 
intervals included the null they were skewed towards the negative (Table 4.9). Tertiles of total 
dietary nitrate intake likewise showed trends towards an inverse association, with the second 
tertile of total dietary nitrate intake being associated with a -4.08 (-6.66, -1.51) lower systolic 
blood pressure compared with the first tertile. When looking at tertiles of different sources of 
dietary nitrate intake, an inverse association between dietary nitrate intake from plant sources 
and systolic blood pressure was observed in the fully adjusted model, -4.22 [95% CI: -6.82, -
1.61] mmHg lower systolic blood pressure in the second vs. first tertile. On the other hand, 
processed and red meat sources showed a positive association, with a 2.51 [95% CI: -0.02, 5.00] 




Higher dietary nitrate was not associated with mean diastolic blood pressure, -0.15 [95% CI: -
0.85, 0.55] in the fully adjusted model (Table 4.10). Overall, dietary nitrate was not associated 
with hypertension, though contrary to our hypothesis, tertiles of total dietary nitrate intake and 
plant sources of dietary nitrate intake showed a trend towards higher prevalence of hypertension 
with higher dietary nitrate intake (Table 4.11). On the other hand, higher tertiles of dietary nitrate 
intake from animal sources were associated with a lower prevalence ratio of hypertension, 0.61 
[95% CI: 0.44, 0.84] and 0.56 [95% CI: 0.40, 0.79]. 
 
Interaction between nitrate-reducing bacteria summary score and dietary nitrate intake on 
insulin resistance, plasma glucose and prevalence of prediabetes 
Figure 4.1 shows the mean insulin resistance, plasma glucose, systolic and diastolic blood 
pressures values for high versus low nitrate-reducing bacteria within each strata of dietary nitrate 
intake. 
 
The mean insulin resistance, plasma glucose and prevalence ratios for prediabetes between high 
vs. low nitrate-reducing oral bacteria, by tertiles of dietary nitrate intake (low/medium/high) are 
presented in Tables 4.12, 4.13 and 4.14 respectively. The interaction terms testing for the 
interaction between nitrate-reducing oral bacteria and dietary nitrate intake for insulin resistance 
(Table 4.12) and plasma glucose (Table 4.13) were not statistically significant. Likewise for 
prediabetes, the RERI for additive interaction was not statistically significant (Table 4.14). 
 
Interaction between nitrate-reducing bacteria summary score and dietary nitrate intake on 
mean systolic and diastolic blood pressure, and prevalence of hypertension 
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None of the interaction terms in the linear models for blood pressure outcomes nor the RERI for 
additive interaction for hypertension were statistically significant (Tables 4.15, 4.16, 4.17).  
 
There was some indication that the difference in mean systolic and diastolic blood pressure 
values between the high and low nitrate-reducing bacteria groups was most pronounced in the 
highest tertile of dietary nitrate. In the highest dietary nitrate tertile, having high NO3TSS was 
associated with -5.3 [95% CI: -9.5, -1.1] mmHg lower mean systolic blood pressure and -3.8 
[95% CI: -7.0, -0.59] mmHg mean diastolic blood pressure, compared to a difference of -1.2 
[95% CI: -5.6,  3.2] mmHg systolic blood pressure and -2.3 [95% CI: -5.7, 1.1] mmHg diastolic 
blood pressure in the middle tertile, and -0.7 [95% CI: -4.9, 3.5] mmHg systolic blood pressure 
and -0.5 [95% CI: -3.7, 2.7] mmHg diastolic blood pressure difference in the lowest dietary 
nitrate tertile, in the fully-adjusted model (Table 4.15 and 4.16). However, as the interaction 
terms were not statistically significant, we have no evidence to say if these differences-in-
differences are meaningful, or merely a reflection of imprecise estimates.  
The RERI for the interaction of nitrate-reducing bacteria and dietary nitrate intake on 
hypertension showed some indication of positive interaction but the confidence intervals 
included the null (Table 4.17). 
 
DISCUSSION 
In these cross-sectional analyses, we did not find any clear evidence of an association between 
higher dietary nitrate intake and insulin resistance, plasma glucose, systolic and diastolic blood 
pressure, hypertension, or prediabetes. There was some indication that higher dietary nitrate 
consumption was associated with lower insulin resistance and systolic blood pressure, though the 
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effect estimates for insulin resistance were small, and the confidence intervals for both outcomes 
were imprecise and require replication in larger studies. These inverse associations were most 
evident when focusing on dietary nitrate intake from plant sources, while dietary nitrate intake 
from processed meat and red meat sources were generally not associated with cardiometabolic 
outcomes. We found no evidence of interaction between nitrate-reducing oral bacteria and 
dietary nitrate intake.  
 
Our findings extend previous experimental research in some meaningful ways. First, prior 
studies show reduction in blood pressure following generally high-dose experimental dietary 
nitrate supplementation (ranging from 155 to 600 mg/day21) over relatively short time periods of 
a few hours, days, or weeks. Our mean daily nitrate intake 171 (SD=170) mg/day, while on the 
high side of previous US population estimates of 92 (SD=69) mg/day73 or 40-100 mg/day2, 
suggests that average dietary nitrate intake levels in the population are much lower than the 
doses of nitrate supplementation used in experimental studies. Moreover, the difference between 
the median dietary nitrate intake levels of the first versus the second and third tertiles in this 
study was 80 mg/day and 328 mg/day, respectively. Thus, if the observed trends towards lower 
insulin resistance and systolic blood pressure are true, our results suggest that more modest 
differences in nitrate consumption reflective of real-world intakes might have cardiometabolic 
benefits. Second, the majority of prior studies used nitrate supplementation from plant sources 
alone – typically beetroot juice – and did not consider animal or other nitrate sources. 
 
Our finding of a possible inverse association between dietary nitrate intake and systolic blood 
pressure and insulin resistance is consistent with some previous observational studies. In a 15-
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year follow up of 1,226 older women, increased consumption of vegetable nitrate intake (1 STD 
increase of 29 mg/day) was associated with a 17% (95% CI: 3, 30%) decreased risk for ischemic 
cerebrovascular events, and a 21% (95% CI: 7, 34%) decreased risk for atherosclerotic vascular 
disease mortality38,39. On the other hand, increased dietary nitrate intake was not associated with 
a reduced risk of hypertension or diabetes in a separate cohort study of more than 2,000 adults 
from Iran40,41. Thus, there is heterogeneity in the findings from the handful of observational 
studies examining this hypothesis, and our results add to the still nascent literature. 
 
 There is some speculation in the literature of a threshold for the beneficial effects of increased 
dietary nitrate intake. A plateauing of risk reduction for ischemic cerebrovascular disease and 
atherosclerotic vascular disease mortality in the aforementioned study was observed in 
participants consuming >76mg/day of dietary nitrate versus 53-76 mg/day, when compared to 
the lowest tertile of dietary nitrate consumption <53mg/day38,39. Likewise, our findings also 
showed a pattern in which differences in systolic blood pressure and insulin resistance among 
participants in the 2nd tertile (75-182 mg/day) versus the 1st tertile (<75 mg/day) were similar to 
those observed in the 3rd (>183 mg/day) versus the 1st tertile of nitrate consumption. This 
suggests that potential benefits of nitrate consumption wane at higher levels of dietary nitrate 
intake. If true, the threshold effect may explain the lack of association found between dietary 
nitrate intake and the risk of hypertension and diabetes in the aforementioned Iranian cohort 
study40,41, as the Iranian population in that study had a high mean dietary nitrate intake of ~400 
mg/day, with a median nitrate intake of 291 mg/day even in the lowest tertile40. However, 
whether this threshold effect is a chance finding in our study or truly exists remains to be 




In this study, we observed some association between higher dietary nitrate intake and lower 
systolic blood pressure, but not diastolic blood pressure. This is consistent with the literature, as 
the reduction of diastolic blood pressure in dietary nitrate supplementation clinical trials tends to 
be modest and more variable than findings for systolic blood pressure. For example, a systematic 
review of experimental studies found the reduction associated with dietary nitrate 
supplementation ranging from 4.0 to 8.1 mmHg for systolic blood pressure, and 2.4 to 12 mmHg 
for diastolic blood pressure21.  
 
Dietary nitrate intake was also not associated with plasma glucose. Elevated plasma glucose 
levels are seen in later stages of disease progression towards diabetes, resulting from an inability 
to maintain glucose homeostasis through increased insulin production. In our diabetes-free 
sample however, most individuals still have the capacity for increased production of insulin to 
maintain glucose homeostasis, keeping glucose levels within a clinically normal range. Thus, 
although dietary nitrate intake was not significantly associated with insulin resistance, the trend 
towards a lower insulin resistance with higher dietary nitrate intake may reflect its greater 
relevance as an outcome for this study population. No association was found between dietary 
nitrate intake and prediabetes, and in general, for hypertension. A possible explanation is that 
dietary nitrate intake may be most clinically relevant in the early preclinical stages of disease 
development, and even preclinical diagnoses such as prediabetes may already involve some early 
physiological or structural changes (e.g. reduced β-cell function or increased arterial stiffness) 
that affect the association between dietary nitrate intake and cardiometabolic outcomes. 
Experimental evidence for the lowering of blood pressure with dietary nitrate supplementation in 
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hypertensive patients or those with elevated blood pressure is less conclusive than for healthy 
participants21, with some studies observing a reduction in blood pressure74,75, whereas others 
observe no change34,76. Finally, the observation of higher prevalence of hypertension with higher 
tertiles of nitrate intake from plant sources, and lower prevalence of hypertension with higher 
tertiles of nitrate intake from animal sources was inconsistent with our hypothesis. It is possible 
that this observation and the other null associations found may represent a true association, and 
need to be replicated in future studies. Likewise, it is also entirely possible that the observed 
indications of inverse associations between dietary nitrate intake and insulin resistance and 
systolic blood pressure are truly null associations as the confidence intervals include the null. 
 
No interaction between nitrate consumption and nitrate-reducing bacteria was observed in our 
study. While this might be due to limited power arising from our small sample size (n=241), the 
overall data patterns observed did not suggest that the associations between nitrate-reducing 
bacteria and cardiometabolic outcomes were meaningfully different across levels of nitrate 
consumption. It is also possible that the null findings for interaction resulted from the overall 
lack of association observed between dietary nitrate intake and the cardiometabolic outcomes. 
However, further exploration of the potential interaction between dietary nitrate intake and 
nitrate-reducing oral bacteria may be valuable for several reasons. Most notably, there is 
substantial heterogeneity in findings from dietary nitrate supplementation19, and while many 
possible reasons for this observation have been discussed77, the role of inter-individual variations 
in the nitrate-reducing capacity of the oral microbiome has not been adequately considered. 
Incorporating measures of the nitrate-reducing oral bacteria in future dietary nitrate 




This study has several important limitations. Our study uses cross-sectional data and we are 
unable to establish temporality. Reverse causation is thus possible. Those with hypertension and 
prediabetes could change their diet to consume healthier foods like green leafy vegetables which 
are high in nitrates. This would result in an association between dietary nitrate intake and 
cardiometabolic outcomes in the opposite direction from what we hypothesize, biasing the main 
effect estimate towards the null. Thus, reverse causation may explain the null association for 
dietary nitrate intake with prediabetes, or the unexpected associations seen with hypertension. It 
is important to also note that the eligibility criteria for the ORIGINS study excludes diabetes 
patients, and this may inadvertently select for people who have a lower risk for cardiometabolic 
disease, creating a selection bias for our cross-sectional analysis.  
 
There may be a few sources of measurement error in our dietary nitrate intake exposure. First of 
all, an important limitation of the dietary nitrate intake measurement is that the FFQ was 
measured only at a single time, and represents the “average intake over an extended period of 
time” for the individual78. Thus, our results can be interpreted as supporting the hypothesis that 
sustained dietary nitrate intake has beneficial effects on insulin resistance and systolic blood 
pressure, only if the diet reported in the FFQ represents chronic patterns of dietary nitrate intake. 
In addition, variations in the acute diet may have led to short-term changes in cardiometabolic 
outcomes (e.g. having a beetroot salad the night before the clinical measures were taken). 
Misclassification of dietary exposure would likely be reduced if multiple assessments of the FFQ 




Secondly, the nitrate content of vegetables can vary substantially depending on growth factors 
(e.g. the use of nitrogen-containing fertilizers, rainfall37, and region79), and we do not have 
information on vegetable growth factors. Thus, despite our use of a US database, measurement 
error for dietary nitrate intake may still be present. However, our study population is not 
geographically diverse (mainly residing within the NYC Tri-state area), and likely consumes 
vegetables from similar sources. It should also be noted that the dietary nitrate database did not 
have nitrate values for all food items in the FFQ, and substitutions and derivations were made 
where possible. We also did not account for the nitrate levels of drinking water which in some 
cases can be a major contributor of nitrate intake80. Nevertheless, these possible mismeasurement 
errors in dietary nitrate intake are likely to be non-differential to the outcome of interest, 
underestimating the effect estimates between dietary nitrate and the cardiometabolic outcomes.  
 
Dietary nitrate intake strongly correlates with the number of servings of vegetables in our study 
(Pearson’s r = 0.88), and as reported by other authors39. Thus, we are unable to separate the 
effects of dietary nitrate intake from the many other beneficial nutrients found in a high 
vegetable diet, and residual confounding is possible. Similarly, the observation that higher nitrate 
intake from processed and red meat sources was associated with higher systolic blood pressure 
may reflect previously described negative effects of red meat on diabetes and cardiovascular 
outcomes attributed to other nutritional constituents such as cholesterol, high sodium, or heme 
iron81,82. Therefore, while sensitivity analyses showed a protective association with 
cardiometabolic outcomes for nitrate intake from plant sources and not for processed and red 
meat sources, further studies need to be done to isolate dietary nitrate intake exposure. 
Additional research to establish updated US-based nitrate values for all the food items of 
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commonly used food frequency questionnaires such as the NCI-DHQ, will be important for more 
precise assessment of dietary nitrate intake levels. Future studies could use “local” estimates of 
nitrate content as recommended by the recent National Heart, Lung, and Blood Institute 
workshop on dietary nitrate research37, and carried out in some recent studies83. In addition, 
analysis of actual dietary nitrate exposure through the use of biological (plasma, urine or saliva) 
nitrate levels together with the assessment of the dietary nitrate content of foods could help 
address the limitations of assessing dietary nitrate intake accurately37, and may be useful for 
mediation analysis. 
 
As noted in Chapter 3 (page 82-84), there are several limitations of the nitrate-reducing bacteria 
exposure used in our interaction analyses. Briefly, misclassification of the nitrate-reducing 
function of the individuals may have occurred as not all the nitrate-reducing bacteria in the oral 
cavity have been identified, and ORIGINS contains only 20 out of the 28 bacteria previously 
identified in the literature. In the same vein, we identified nitrate-reducing bacteria based on the 
taxonomic classifications, which might not reflect the true nitrate-reducing function of the oral 
microbiome. Microbial assessment was taken only at a single time point, and it is unknown 
whether this snapshot of oral nitrate-reducing bacteria reflects a persistent composition. 
Nevertheless, measurement error in this study is likely to be non-differential, resulting in an 
underestimation of the effect estimate. Finally, although the tongue is the main site of nitrate-
reduction in the mouth, we only had bacteria from the subgingival plaque.  
 
Our study had several strengths. First, our FFQ was comprehensive and there was a wide range 
of dietary nitrate intake in the study population. Second, we were also able to separate out dietary 
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nitrate intake from plant, processed and red meat, and other animal sources, which gave us 
greater specificity in our exposure. Third, ORIGINS participants are young and free of diabetes 
and other clinical cardiovascular diseases that might lead to reverse causality or introduce 
complex confounding patterns related to changing health behaviors after disease diagnosis. 
Fourth, ORIGINS has a robust set of risk factor data collection allowing for comprehensive 
control for hypothesized confounders. Finally, to the best of our knowledge, this study is unique 
in testing the interaction of the oral microbiome with dietary nitrate intake on cardiometabolic 
outcomes. 
 
In conclusion, we did not find a clear association between dietary nitrate and the cardiometabolic 
outcomes of interest. We found some preliminary support for the hypothesis that higher total 
dietary nitrate is associated with lower insulin resistance, and to a greater extent with mean 
systolic blood pressure. However, we did not observe the association between nitrate-reducing 
oral bacteria and cardiometabolic outcomes to be conditional on levels of dietary nitrate, 
although this pattern might differ in populations with different distributions of nitrate-reducing 
oral bacteria. These findings require replication in future larger, longitudinal studies with long-
term follow-up and more precise assessments of dietary nitrate exposure, to determine if the 
influence of nitrate consumption on blood pressure (in the clinically normal range) and insulin 
resistance among diabetes-free individuals translates into clinically meaningful results.  
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Table 4.1. Top 10 food items contributing to the mean total dietary nitrate intake assessed by the FFQ in the ORIGINS study 
(n=419)  
 
Food item from the FFQ 
Mean intake (mg/day) 
(SD) 
% of daily intake 
Cooked spinach/greens  83.1 (129.8) 36.6% 
Lettuce 42.1 (53.9) 18.6% 
Raw spinach/greens 19.8 (33.1) 8.7% 
Broccoli 14.5 (24.4) 6.4% 
Other vegetables*  10.8 (19.7) 4.7% 
Avocado, guacamole 5.6 (0.18) 2.5% 
String beans  4.6 (7.7) 2.0% 
Tomato/Vegetable juice 4.2 (7.7) 1.9% 
Vegetable medley  3.3 (6.0) 1.5% 
Cauliflower/Brussel sprouts  2.6 (4.9)  1.1% 
 
*Vegetables other than those listed on the FFQ, such as cucumber, celery and radish (taken from the list of CSFII foods) 
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Table 4.2. Characteristics of the 418 participants from the Oral Infections, Glucose 
Intolerance, and Insulin Resistance Study (ORIGINS) with dietary information. 
 
Variable Total (n=419)  








<Bachelor’s Degree  33% 
Bachelor’s Degree 48% 
>Bachelor’s Degree 17% 




BMI (kg/m2) 27.0±6.1 
BMI   
Underweight/Normal  45% 
Overweight 34% 
Obese 21% 
Average alcohol consumption  
None 5% 
 ≤1unit/day 79% 
> 1 drink/day 16% 







Alternate Healthy Eating Index Score 
(AHEI) 
47±12 
Total Caloric Intake (kcal/day) 1738±892 
Nitrate-reducing bacteria score 
(NO3TSS)*  
0.11±5.41 
Values presented in mean ± SD or percentages. Missing values: n=51 for alcohol use; n=24 for physical 
activity.  
*For the n=241 participants in the interaction analyses with nitrate-reducing bacteria score and dietary 























Tertile 2 of 





Tertile 3 of nitrate 
intake 
 (Range: 183.3-














31% 33% 35% 0.23 
Race/ethnicity      
Hispanic 134 
±122 
43% 34% 24%  
Non-Hispanic White 203 ± 
188 
23% 37% 39% 0.001 
Black 168 ± 
154 
34% 32% 34%  
Other 225 ± 
233 
21% 29% 50%  
Education      
<Bachelor’s Degree  142±133 42% 29% 29%  
Bachelor’s Degree 181±171 30% 35% 35% 0.06 
>Bachelor’s Degree 199±213 24% 38% 37%  
Smoking Status      
Never 179±178 32% 34% 35%  
Former 151±121 31% 36% 33% 0.21 
Current 116 
±108 
50% 29% 21%  
BMI (kg/m2) - 27.1±6.5 27.1±.6.5 26.1±5.3 0.30 
BMI       
Underweight/Normal  181±181 32% 34% 34%  
Overweight 164 
±157 
34% 31% 35% 0.87 
Obese 162 
±164 




    
None 159±143 41% 29% 29%  
 ≤1unit/day 171±181 34% 34% 32% 0.52 
> 1 drink/day 193±154 27% 31% 42%  
Physical activity  
METS min/week  
 
    
None 155±175 41% 31% 28%  
Low 114±86 48% 35% 18% 0.004 
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Moderate 175±161 25% 44% 31%  
High 197±183 25% 34% 41%  
Alternate Healthy 
Eating Index Score 
(AHEI) 
- 41±10 48±11 52±12 0.0001 
Total Caloric Intake 
(kcal/day) 




- -0.23±5.34 0.27±5.38 0.31±5.55 0.78 
Values presented in mean ± SD or percentages. P values are for ANOVA F statistics or X2   tests for 
differences in dietary nitrate intake between levels of covariates. Missing values: n=51 for alcohol use; 
n=24 for physical activity.  
*For the n=241 participants in the interaction analyses with nitrate-reducing bacteria score and dietary 
data: n=80 in Tertile 1; n=81 in Tertile 2; n=80 in Tertile 3.
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Table 4.4. Association between Dietary Nitrate Intake and natural log-transformed Homeostasis Model Assessment for Insulin 
Resistance (HOMA-IR) Derived from Generalized Linear Regression Models 
 
 Linear Model Difference in Insulin Resistance between Tertiles of Nitrate consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 -0.08 (-0.14, -0.02) Ref -0.06 (-0.20,0.09) -0.10 (-0.24, 0.05) 
M2 -0.05 (-0.11, 0.01) Ref -0.01 (-0.16, 0.14) -0.02 (-0.17, 0.13) 
M3 -0.05 (-0.11, 0.00) Ref -0.03 (-0.17, 0.10) -0.06 (-0.20, 0.08) 
M4 -0.04 (-0.10, 0.01) Ref -0.02 (-0.15, 0.12) -0.03 (-0.17, 0.11) 
M5 -0.05 (-0.11, 0.01) Ref -0.06 (-0.20, 0.08) -0.09 (-0.24, 0.07) 
Dietary nitrate intake from Plant sources§ 
M1 -0.07 (-0.13, -0.01) Ref -0.02 (-0.17, 0.13) -0.05 (-0.20, 0.11) 
M2 -0.05 (-0.11, 0.01) Ref 0.02 (-0.13, 0.16) -0.001 (-0.15, 0.15) 
M3 -0.05 (-0.10, 0.01) Ref -0.02 (-0.15, 0.11) -0.07 (-0.21, 0.07) 
M4 -0.04 (-0.10, 0.01) Ref -0.01 (-0.15, 0.12) -0.04 (-0.19, 0.10) 
M5 -0.05 (-0.11, 0.00) Ref -0.06 (-0.20, 0.09) -0.07 (-0.23, 0.08) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 0.06 (0.00 0.13) Ref 0.09 (-0.06, 0.24) 0.16 (0.00, 0.32) 
M2 0.05 (-0.01, 0.11) Ref 0.06 (-0.09, 0.20) 0.10 (-0.06 0.26) 
M3 0.05 (-0.01, 0.11) Ref 0.04 (-0.09, 0.17) 0.04 (-0.11, 0.19) 
M4 0.05 (-0.02, 0.11) Ref 0.02 (-0.12, 0.16) 0.01 (-0.15, 0.16) 
M5 0.07 (0.00, 0.14) Ref 0.04 (-0.11, 0.18) 0.04 (-0.13, 0.21) 
Dietary nitrate intake from other Animal sources   
M1 0.01 (-0.05, 0.07) Ref -0.13 (-0.28, 0.02) -0.10 (-0.25, 0.05) 
M2 0.00 (-0.06, 0.06) Ref -0.09 (-0.24, 0.05) -0.10 (-0.24, 0.05) 
M3 -0.01 (-0.06, 0.04) Ref -0.07 (-0.20, 0.07) -0.13 (-0.26, 0.01) 
M4 -0.01 (-0.06, 0.05) Ref -0.06 (-0.19, 0.07) -0.12 (-0.25, 0.01) 




Insulin resistance defined by Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). 
*β-coefficient from linear model with dietary nitrate intake modeled continuously. Coefficient represents mean difference in 
lnHOMA-IR for every 1 STD increase in dietary nitrate intake (mg/day).  
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 
§Models using plant, processed and red meat, or animal sources of nitrate intake, concurrently adjusts for the other sources of nitrate.  
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Table 4.5. Association between Dietary Nitrate Intake and Plasma Glucose (mg/dl) Derived from Generalized Linear 
Regression Models 
 
 Linear Model Difference in Plasma Glucose between Tertiles of Nitrate consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 -0.61 (-1.37, 0.16) Ref -1.43 (-3.30, 0.44) -1.21 (-3.07, 0.66) 
M2 -0.32 (-1.05, 0.41) Ref -0.90 (-2.66, 0.86) -0.55 (-2.34, 1.24) 
M3 -0.25 (-0.97, 0.48) Ref -0.99 (-2.73, 0.75) -0.76 (-2.59, 1.07) 
M4 -0.13 (-0.88, 0.62) Ref -0.85 (-2.60, 0.91) -0.46 (-2.36, 1.44)  
M5 -0.01 (-0.77, 0.74) Ref -1.01 (-2.87, 0.85)  0.33 (-1.68, 2.34)  
Dietary nitrate intake from Plant sources§ 
M1 -0.46 (-1.23, 0.30) Ref -0.81 (-2.68, 1.07)  -0.49 (-2.73, 1.40) 
M2 -0.26 (-0.99, 0.47) Ref -0.34 (-2.12, 1.44) -0.23 (-2.04, 1.57) 
M3 -0.18 (-0.91, 0.54) Ref -0.40 (-2.16, 1.36) -0.48 (-2.33, 1.37) 
M4 -0.14 (-0.88, 0.61) Ref -0.33 (-2.10, 1.43) -0.27 (-2.18, 1.63) 
M5 -0.02 (-0.77, 0.74) Ref -0.38 (-2.26, 1.50) 0.39 (-1.61, 2.40) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 1.04 (0.25, 1.83) Ref -0.82 (-2.67, 1.202) 2.36 (0.39, 4.33) 
M2 0.69 (-0.09, 1.47) Ref -1.08 (-2.82, 0.67) 1.21 (-0.71 3.14) 
M3 0.76 (-0.02, 1.55) Ref -0.85(-2.59, 0.88) 1.12 (-0.81, 3.05) 
M4 0.69 (-0.14, 1.53) Ref -1.04 (-2.82, 0.74) 0.82 (-1.22, 2.86) 
M5 0.66 (-0.27, 1.58) Ref -0.11 (-2.00, 1.79) 1.15 (-1.05, 3.35) 
Dietary nitrate intake from other Animal sources   
M1 0.24 (-0.52, 0.99) Ref -1.59 (-3.43, 0.26) 0.36 (-2.12, 1.44) 
M2 0.11 (-0.60, 0.82) Ref -1.11 (-2.87, 0.64) 0.42 (-1.33, 2.17) 
M3 0.17 (-0.87, 0.53) Ref -0.94 (-2.68, 0.80) -0.18 (-1.92, 1.57) 
M4 -0.16 (-0.86, 0.54) Ref -0.89 (-2.64, 0.85) -0.11 (-1.86 1.63) 




*β-coefficient from linear model with dietary nitrate modeled continuously. Coefficient represents mean difference in plasma 
glucose for every 1 STD increase in dietary nitrate (mg/day). 
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 




Table 4.6. Association between Dietary Nitrate Intake and Prevalence Ratio of Prediabetes Derived from Modified Poisson 
Regression Models with robust error variance 
 
 Prevalence Ratio for Prediabetes (95% CI) 
 
1 STD increase in nitrate 
Tertile 1 Nitrate intake† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 0.95 (0.75, 1.21) Ref 0.78 (0.46, 1.33) 0.88 (0.53, 1.46) 
M2 1.03 (0.81, 1.32) Ref 0.90 (0.54, 1.48) 1.03 (0.62, 1.70) 
M3 1.03 (0.81, 1.31) Ref 0.91 (0.54, 1.51) 0.98 (0.57, 1.67) 
M4 1.06 (0.83, 1.34) Ref 0.92 (0.55, 1.53) 1.02 (0.59, 1.74) 
M5 1.04 (0.79, 1.37) Ref 0.84 (0.46, 1.55) 0.93 (0.51, 1.70) 
Dietary nitrate intake from Plant sources§ 
M1 0.96 (0.76, 1.22) Ref 0.84 (0.49, 1.43) 0.87 (0.52, 1.44) 
M2 1.02 (0.80, 1.31) Ref 1.00 (0.60, 1.69) 0.89 (0.54, 1.49) 
M3 1.03 (0.81, 1.31) Ref 1.05 (0.62, 1.80) 0.91 (0.52, 1.59) 
M4 1.05 (0.82, 1.34) Ref 1.05 (0.62, 1.50) 0.83 (0.47, 1.46) 
M5 1.05 (0.79, 1.38) Ref 0.98 (0.52, 1.87) 0.81 (0.44, 1.50) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 1.03 (0.82, 1.28) Ref 0.97 (0.57, 1.65) 1.08 (0.63, 1.85) 
M2 1.03 (0.82, 1.29) Ref 0.95 (0.58, 1.54) 0.99 (0.57, 1.74) 
M3 1.04 (0.86, 1.27) Ref 1.00 (0.59, 1.69) 1.19 (0.66, 2.14) 
M4 1.02 (0.82, 1.27) Ref 1.05 (0.62, 1.76) 1.12 (0.59, 2.10) 
M5 0.93 (0.65, 1.34) Ref 1.10 (0.60, 2.03) 1.19 (0.51, 2.75) 
Dietary nitrate intake from other Animal sources   
M1 1.01 (0.84, 1.21) Ref 0.62 (0.34, 1.13) 1.23 (0.75, 2.02) 
M2 1.01 (0.84, 1.22) Ref 0.69 (0.40, 1.21) 1.27 (0.80, 2.01) 
M3 0.96 (0.79, 1.18) Ref 0.67 (0.38, 1.19) 1.12 (0.70, 1.79) 
M4 0.97 (0.79, 1.19) Ref 0.68 (0.38, 1.21) 1.12 (0.70, 1.79) 





(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 




Table 4.7. Association between Dietary Nitrate Intake and Mean Systolic Blood Pressure Derived from Generalized Linear 
Regression Models in all participants (n=419)  
 
 Linear Model 
Difference in Mean Systolic Blood Pressure between Tertiles of Nitrate 
consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 -1.17 (-2.37, 0.03) Ref -1.23 (-4.18, 1.71) -2.15 (-5.09, 0.78) 
M2 -0.76 (-1.91, 0.38) Ref -0.31 (-3.07, 2.44) -0.97 (-3.78, 1.84) 
M3 -0.74 (-1.84, 0.35) Ref -0.90 (-3.54, 1.74) -1.41 (-4.18, 1.36) 
M4 -0.71 (-1.85, 0.42) Ref -0.84 (-3.51, 1.82) -1.30 (-4.19, 1.59) 
M5 -0.74 (-1.92, 0.44) Ref -1.02 (-3.91, 1.88) -1.91 (-4.32, 1.94) 
Dietary nitrate intake from Plant sources§ 
M1 -1.01 (-2.21, 0.20) Ref -0.97 (-3.95, 2.01) -1.25 (-4.25, 1.74) 
M2 -0.72 (-1.87, 0.42) Ref -0.19 (-3.00, 2.62) -0.66 (-3.51, 2.19) 
M3 -0.70 (-1.80, 0.40) Ref -0.79 (-3.47, 1.88) -1.38 (-4.19, 1.43) 
M4 -0.72 (-1.85, 0.42) Ref -0.78 (-3.47, 1.90) -1.35 (-4.25, 1.55) 
M5 -0.75 (-1.93, 0.42) Ref -0.74 (-3.65, 2.17) -1.21 (-4.31, 1.89) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 1.44 (0.19, 2.68) Ref 1.51 (-1.42, 4.44) 3.89 (0.75, 7.02) 
M2 0.40 (-0.82, 1.63) Ref 1.09 (-1.67, 3.85) 1.31 (-1.74, 4.35) 
M3 0.54 (-0.66, 1.73) Ref 1.21 (-1.43, 3.84) 0.34 (-2.59, 3.28) 
M4 0.57 (-0.70, 1.83) Ref 1.18 (-1.53, 3.89) 0.30 (-2.81, 3.41) 
M5 0.62 (-0.81, 2.05) Ref 2.04 (-0.89, 4.97) 0.75 (-2.66, 4.16) 
Dietary nitrate intake from other Animal sources   
M1 0.34 (-0.85, 1.52) Ref -2.08 (-5.02, 0.86) -0.36 (-3.31, 2.58) 
M2 0.07 (-1.05, 1.19) Ref -1.85 (-4.62, 0.93) -0.68 (-3.45, 2.09) 
M3 -0.27 (-1.33, 0.79) Ref -1.87 (-4.51, 0.78) -1.76 (-4.41, 0.89) 
M4 -0.27 (-1.33, 0.79) Ref -1.86 (-4.51, 0.79) -1.75 (-4.41, 0.91) 




*β-coefficient from linear model with dietary nitrate modeled continuously. Coefficient represents mean difference in mean 
systolic blood pressure for every 1 STD increase in dietary nitrate (mg/day). 
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 
§Models using plant, processed/red meat, or other animal sources of nitrate intake, concurrently adjusts for the other sources of nitrate.  
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Table 4.8. Association between Dietary Nitrate Intake and Mean Diastolic Blood Pressure Derived from Generalized Linear 
Regression Models in all participants (n=419)  
 
 Linear Model 
Difference in Mean Diastolic Blood Pressure between Tertiles of Nitrate 
consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 -0.72 (-1.61, 0.17) Ref 0.23 (-1.94, 2.40) -1.16 (-3.32, 1.01) 
M2 -0.35 (-1.20, 0.49) Ref 0.95 (-1.08, 2.99) -0.22 (-2.29, 1.85) 
M3 -0.47 (-1.29, 0.36) Ref 0.43 (-1.55, 2.42) -0.88 (-2.97, 1.20) 
M4 -0.38 (-1.23, 0.48) Ref 0.56 (-1.44, 2.57) -0.62 (-2.79, 1.55) 
M5 -0.29 (-1.18, 0.61) Ref 0.50 (-1.70, 2.70) -0.46 (-2.83, 1.92) 
Dietary nitrate intake from Plant sources§ 
M1 -0.56 (-1.45, 0.32) Ref 0.51 (-1.69, 2.72) -0.37 (-2.58, 1.85) 
M2 -0.30 (-1.14, 0.55) Ref 1.17 (-0.90, 3.23) 0.08 (-2.02, 2.18) 
M3 -0.41 (-1.24, 0.41) Ref 0.60 (-1.41, 2.62) -0.68 (-2.80, 1.43) 
M4 -0.39 (-1.24, 0.47) Ref 0.69 (-1.33, 2.71) -0.43 (-2.61, 1.75) 
M5 -0.28 (-1.17, 0.61) Ref 0.75 (-1.47, 2.97) -0.24 (-2.61, 2.13) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 1.23 (0.31, 2.15) Ref -0.54 (-2.71, 1.63) 2.41 (0.10, 4.73) 
M2 0.70 (-0.20, 1.61) Ref -1.02 (-3.05, 1.01) 0.62 (-1.62, 2.85) 
M3 0.69 (-0.21, 1.58) Ref -0.79 (-2.78, 1.20) -0.04 (-2.25, 2.18) 
M4 0.64 (-0.31, 1.60) Ref -1.01 (-3.05, 1.03) -0.40 (-2.75, 1.94) 
M5 1.11 (0.02, 2.19) Ref -0.57 (-2.80, 1.67) 0.13 (-2.47, 2.73) 
Dietary nitrate intake from other Animal sources   
M1 0.12 (-0.75, 1.00) Ref -0.86 (-3.03, 1.31) -0.15 (-2.32, 2.03) 
M2 -0.05 (-0.87, 0.78) Ref -0.44 (-2.48, 1.60) -0.29 (-2.33, 1.75) 
M3 -0.26 (-1.06, 0.54) Ref -0.11 (-2.11, 1.88) -0.86 (-2.86, 1.14) 
M4 -0.25 (-1.05, 0.54) Ref -0.06 (-2.06, 1.94) -0.78 (-2.79, 1.22) 





*β-coefficient from linear model with dietary nitrate modeled continuously. Coefficient represents mean difference in mean 
diastolic blood pressure for every 1 STD increase in dietary nitrate (mg/day). 
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 




Table 4.9. Association between Dietary Nitrate Intake and Mean Systolic Blood Pressure Derived from Generalized Linear 
Regression Models in those without hypertension (n=269)  
 
 Linear Model 
Difference in Mean Systolic Blood Pressure between Tertiles of Nitrate 
consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=90) 
Tertile 2 Nitrate intake† 
(n=89) 
Tertile 3 Nitrate intake† 
(n=90) 
Total dietary nitrate intake 
M1 -0.95 (-1.96, 0.05) Ref -2.77 (-5.30, -0.34) -2.29 (-4.81, 0.24) 
M2 -0.92 (-1.90, 0.06)  Ref -3.17 (-5.59, -0.76) -1.99 (-4.48, 0.50) 
M3 -0.83 (-1.82, 0.16) Ref -3.43 (-5.88, -0.99) -1.92 (-4.53, 0.68) 
M4 -0.87 (-1.87, 0.14) Ref -3.54 (-6.01, -1.06) -2.10 (-4.79, 0.59) 
M5 -0.95 (-1.96, 0.05) Ref -4.08 (-6.66, -1.51)  -2.45 (-5.24, 0.34) 
Dietary nitrate intake from Plant sources§ 
M1 -0.93 (-1.93, 0.08) Ref -3.32 (-5.89, -0.75) -2.45 (-5.04, 0.14) 
M2 -0.94 (-1.92, 0.04) Ref -3.66 (-6.11, -1.21) -2.02 (-4.52, 0.49) 
M3 -0.87 (-1.86, 0.12) Ref -3.74 (-6.22, -1.25) -1.98 (-4.59, 0.63) 
M4 -0.93 (-1.94, 0.07) Ref -3.80 (-6.29, -1.32) -2.18 (-4.86, 0.50) 
M5 -1.01 (-2.01, -0.01) Ref -4.22 (-6.82, -1.61) -2.55 (-5.31, 0.20) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 0.99 (-0.04, 2.02) Ref 1.36 (-1.11, 3.83) 1.56 (-1.19, 4.31) 
M2 0.22 (-0.82, 1.25) Ref 1.32 (-1.01, 3.66) 0.20 (-2.49, 2.89) 
M3 0.41 (-0.62, 1.45) Ref 1.94 (-0.44, 4.31) 0.39 (-2.30, 3.09) 
M4 0.53 (-0.56, 1.63) Ref 2.12 (-0.32, 4.56) 0.70 (-2.16, 3.55) 
M5 0.10 (-1.15, 1.35) Ref 2.51 (-0.02, 5.00) 0.93 (-2.08, 3.94) 
Dietary nitrate intake from other Animal sources   
M1 0.23 (-0.91, 1.38) Ref 1.11(-1.49, 3.71) 0.88 (-1.78, 3.54) 
M2 0.41 (-0.69, 1.52) Ref 0.44 (-2.08, 2.95) 1.33 (-1.22, 3.87) 
M3 0.23 (-0.89, 1.35) Ref -0.07 (-2.64, 2.51) 0.52 (-2.05, 3.09) 
M4 0.21 (-0.91, 1.34) Ref -0.06 (-2.64, 2.51) 0.46 (-2.12, 3.04) 




*β-coefficient from linear model with dietary nitrate modeled continuously. Coefficient represents mean difference in mean 
systolic blood pressure for every 1 STD increase in dietary nitrate (mg/day). 
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=269) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=269) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=255) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=255) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=227) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 




Table 4.10. Association between Dietary Nitrate Intake and Mean Diastolic Blood Pressure Derived from Generalized Linear 
Regression Models in those without hypertension (n=269)  
 
 Linear Model 
Difference in Mean Diastolic Blood Pressure between Tertiles of Nitrate 
consumption 
 
β-coefficient* Tertile 1 Nitrate intake
† 
(n=90) 
Tertile 2 Nitrate intake† 
(n=89) 
Tertile 3 Nitrate intake† 
(n=90) 
Total dietary nitrate intake 
M1 -0.20 (-0.87, 0.47) Ref 0.36 (-1.32, 2.05) -0.49 (-2.17, 1.19) 
M2 -0.20 (-0.88, 0.48) Ref 0.34 (-1.33, 2.02) -0.35 (-2.08, 1.38) 
M3 -0.16 (-0.82, 0.50) Ref -0.05 (-1.69, 1.60) -0.47 (-2.23, 1.27) 
M4 -0.15 (-0.82, 0.52) Ref -0.03 (-1.69, 1.63) -0.45 (-2.26, 1.36) 
M5 -0.15 (-0.85, 0.55) Ref -0.21 (-2.02, 1.60) -0.61 (-2.58, 1.37) 
Dietary nitrate intake from Plant sources§ 
M1 -0.18 (-0.85, 0.49) Ref 0.17 (-1.56, 1.89) -0.41 (-2.15, 1.32) 
M2 -0.21 (-0.89, 0.47) Ref 0.20 (-1.51, 1.92) -0.28 (-2.03, 1.48) 
M3 -0.18 (-0.84, 0.48) Ref -0.21 (-1.89, 1.47)  -0.52 (-2.28, 1.25) 
M4 -0.19 (-0.86, 0.48) Ref -0.19 (-1.88, 1.49) -0.46 (-2.28, 1.35) 
M5 -0.19 (-0.89, 0.51) Ref -0.40 (-2.25, 1.45) -0.64 (-2.60, 1.32) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 0.55 (-0.13, 1.23) Ref -0.09 (-1.75, 1.56) 0.56 (-1.29, 2.40) 
M2 0.27 (-0.45, 0.99) Ref -0.32 (-1.95, 1.32) -0.13 (-2.02 1.75) 
M3 0.20 (-0.49, 0.89) Ref 0.08 (-1.53, 1.68) -0.44 (-2.26, 1.39) 
M4 0.21 (-0.52, 0.94) Ref 0.03 (-1.63, 1.68) -0.51 (-2.45, 1.42) 
M5 0.32 (-0.55, 1.19) Ref 0.42 (-1.37, 2.21) -0.29 (-2.43, 1.85) 
Dietary nitrate intake from other Animal sources   
M1 -0.08 (-0.85, 0.68) Ref 0.23 (-1.51, 1.98) -0.34 (-2.12, 1.45) 
M2 -0.12 (-0.89, 0.64) Ref 0.00 (-1.76, 1.76) -0.27 (-2.05, 1.51) 
M3 -0.25 (-1.00, 0.50) Ref 0.15 (-1.60, 1.89) -0.48 (-2.22, 1.26) 
M4 -0.25 (-1.00, 0.50) Ref 0.15 (-1.60, 1.89) -0.46 (-2.21, 1.28) 





*β-coefficient from linear model with dietary nitrate modeled continuously. Coefficient represents mean difference in mean 
diastolic blood pressure for every 1 STD increase in dietary nitrate (mg/day). 
(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=269) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=269) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=255) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=255) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=227) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 




Table 4.11. Association between Dietary Nitrate Intake and Prevalence Ratio of Hypertension Derived from Modified Poisson 
Regression Models with robust error variance (n=419)  
 
 Prevalence Ratio for Hypertension (95% CI) 
 
1 STD increase in nitrate 
Tertile 1 Nitrate intake† 
(n=139) 
Tertile 2 Nitrate intake† 
(n=140) 
Tertile 3 Nitrate intake† 
(n=140) 
Total dietary nitrate intake 
M1 0.97 (0.85, 1.11) Ref 1.03 (0.76, 1.42) 1.01 (0.74, 1.39) 
M2 1.05 (0.93, 1.20) Ref 1.19 (0.88, 1.61) 1.23 (0.91, 1.66) 
M3 1.05 (0.93, 1.18) Ref 1.20 (0.88, 1.63) 1.22 (0.88, 1.70) 
M4 1.04 (0.92, 1.18) Ref 1.19 (0.87, 1.64) 1.21 (0.86, 1.71) 
M5 1.06 (0.94, 1.21) Ref 1.28 (0.90, 1.82) 1.35 (0.92, 1.98) 
Dietary nitrate intake from Plant sources§ 
M1 0.98 (0.86, 1.12) Ref 1.17 (0.84, 1.62) 1.18 (0.86, 1.63) 
M2 1.06 (0.93, 1.20) Ref 1.33 (0.98, 1.82) 1.35 (0.99, 1.84) 
M3 1.04 (0.92, 1.18) Ref 1.32 (0.95, 1.82) 1.32 (0.93, 1.88) 
M4 1.04 (0.92, 1.18) Ref 1.31 (0.94, 1.81) 1.30 (0.91, 1.85) 
M5 1.07 (0.94, 1.21) Ref 1.47 (1.02, 2.10) 1.48 (0.99, 2.22) 
Dietary nitrate intake from Processed meat/Red meat sources  
M1 1.07 (0.95, 1.20) Ref 1.02 (0.73, 1.44) 1.50 (1.08, 2.09) 
M2 0.98 (0.87, 1.10) Ref 0.94 (0.69, 1.28) 1.18 (0.86, 1.61) 
M3 0.94 (0.82, 1.08) Ref 0.91 (0.66, 1.26) 1.04 (0.75, 1.46) 
M4 0.95 (0.82, 1.09) Ref 0.93 (0.67, 1.28) 1.08 (0.76, 1.55) 
M5 0.95 (0.82, 1.11) Ref 0.93 (0.64, 1.34) 1.14 (0.76, 1.72) 
Dietary nitrate intake from other Animal sources   
M1 0.99 (0.86, 1.14) Ref 0.60 (0.44, 0.84) 0.75 (0.55, 1.01) 
M2 0.97 (0.85, 1.11) Ref 0.63 (0.46, 0.87) 0.73 (0.55, 0.97) 
M3 0.97 (0.83, 1.12) Ref 0.64 (0.47, 0.87) 0.68 (0.51, 0.91) 
M4 0.97 (0.83, 1.12) Ref 0.64 (0.47, 0.86) 0.67 (0.50, 0.90) 




(1 STD of Total nitrate intake: 170 mg/day; Plant nitrate intake: 168.7 mg/day; Processed/red meat nitrate intake: 1.39 mg/day; 
Animal nitrate intake: 0.75 mg/day)  
 
Model 1: Crude, adjusted for total energy (kcal) (n=419) 
Model 2: Adjusted for total energy (kcal), age, sex, race, education (n=419) 
Model 3: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity (n=395) 
Model 4: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern (n=395) 
Model 5: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking status, physical activity, dietary pattern, alcohol 
consumption (n=347) 
 
† The median nitrate intake and (Max-Min) range for each tertile of total nitrate intake: Tertile 1=44.9 (7.45-74.4); Tertile 2=124.78 
(74.5-182.3); Tertile 3= 282.8 (183.3-1566.4) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of plant nitrate intake: Tertile 1=35.5 (2.34-64.4); Tertile 2=112.13 
(65.3-175.7); Tertile 3=276.0 (175.8 -1456.8) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of processed meat/red meat nitrate intake: Tertile 1=0.14 (0, 0.39); 
Tertile 2=0.70 (0.40, 1.12); Tertile 3=1.72 (1.13, 11.66) mg/day. 
The median nitrate intake and (Max-Min) range for each tertile of animal nitrate intake: Tertile 1=0.31(0, 0.49); Tertile 2=0.66 (0.50, 
0.89); Tertile 3=1.36 (0.90, 7.24) mg/day. 
 
§Models using plant, processed/red meat, or other animal sources of nitrate intake, concurrently adjusts for the other sources of nitrate.  
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Figure 4.1. Mean outcome levels for each strata of dietary nitrate intake (high/medium/low) 
and nitrate-reducing bacteria (high/low), controlling for total energy (kcal), age, sex, race, 
education, BMI, smoking, percent of probing sites with attachment loss ≥3mm, physical 








*  indicates a p<0.05 for the difference between high and low NO3TSS within strata 
Note: Systolic and diastolic blood pressure outcomes for those without hypertension (n=269) 
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Table 4.12.  Mean Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) (95% CI) values by High vs. Low 




*Model 1: Crude, adjusting for total energy (kcal) (n=241); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking, 
percent of probing sites with attachment loss ≥3mm (n=240); Model 3: Model 2 + physical activity (n=235); Model 4: Model 2 + physical activity 
+ dietary pattern (AHEI) (n=235); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=215) 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-70.0mg/day); Medium Dietary 
Nitrate (71.4 – 171 mg/day) High Dietary Nitrate (172.7-1566.4 mg/day)  
 
‡P-value for difference between high and low NO3TSS groups within strata of dietary nitrate 
§P-value for interaction with ordinal Dietary Nitrate*NO3TSS interaction term 
 
LOW DIETARY NITRATE† 
(n=80) 
MEDIUM DIETARY NITRATE 
(n=81) 




























































































Table 4.13.  Mean plasma glucose (95% CI) values by High vs. Low Nitrate-reducing Taxa Summary score (NO3TSS) 




*Model 1: Crude, adjusting for total energy (kcal) (n=241); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking, 
percent of probing sites with attachment loss ≥3mm (n=240); Model 3: Model 2 + physical activity (n=235); Model 4: Model 2 + physical activity 
+ dietary pattern (n=235); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=215) 
 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-70.0mg/day); Medium Dietary 
Nitrate (71.4 – 171 mg/day) High Dietary Nitrate (172.7-1566.4 mg/day)  
 
‡P-value for difference between high and low NO3TSS groups within strata of dietary nitrate 
§P-value for interaction with ordinal Dietary Nitrate*NO3TSS interaction term 
 
LOW DIETARY NITRATE† 
(n=80) 
MEDIUM DIETARY NITRATE 
(n=81) 



























































































Table 4.14.  Prevalence Ratios for Prediabetes by High vs. Low Nitrate-reducing Taxa Summary score (NO3TSS) stratified by 





















*Model 1: Crude, adjusting for total energy (kcal) (n=241); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, 
smoking, percent of probing sites with attachment loss ≥3mm (n=240); Model 3: Model 2 + physical activity (n=235); Model 4: 
Model 2 + physical activity + dietary pattern (n=235); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=215) 
 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 
15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-119.0mg/day); High 
Dietary Nitrate (119.9-1566.3 mg/day)  
 
§P-value for multiplicative interaction with ordinal Dietary Nitrate*NO3TSS interaction term 
 
LOW DIETARY NITRATE† 
(n=120) 































0.58 0.28  
(-0.57, 1.12) 
2. Ref 0.58 

































Table 4.15.  Mean systolic blood pressure (95% CI) values in those without hypertension by High vs. Low Nitrate-reducing 
Taxa Summary score (NO3TSS) stratified by Dietary Nitrate Intake (n=160) 
 
 
*Model 1: Crude, adjusting for total energy (kcal) (n=160); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking, 
percent of probing sites with attachment loss ≥3mm (n=160); Model 3: Model 2 + physical activity (n=156); Model 4: Model 2 + physical activity 
+ dietary pattern (n=156); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=147) 
 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-70.0mg/day); Medium Dietary 
Nitrate (71.4 – 171 mg/day) High Dietary Nitrate (172.7-1566.4 mg/day)  
 
‡P-value for difference between high and low NO3TSS groups within strata of dietary nitrate 
§P-value for interaction with ordinal Dietary Nitrate*NO3TSS interaction term 
 
LOW DIETARY NITRATE† 
(n=56) 
MEDIUM DIETARY NITRATE 
(n=50) 

































































































Table 4.16.  Mean diastolic blood pressure (95% CI) values in those without hypertension by High vs. Low Nitrate-reducing 
Taxa Summary score (NO3TSS) stratified by Dietary Nitrate Intake (n=160) 
 
 
*Model 1: Crude (n=160), adjusting for total energy (kcal); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, smoking, 
percent of probing sites with attachment loss ≥3mm (n=160); Model 3: Model 2 + physical activity (n=156); Model 4: Model 2 + physical activity 
+ dietary pattern (n=156); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=147) 
 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-70.0mg/day); Medium Dietary 
Nitrate (71.4 – 171 mg/day) High Dietary Nitrate (172.7-1566.4 mg/day)  
 
‡P-value for difference between high and low NO3TSS groups within strata of dietary nitrate 
§P-value for interaction with ordinal Dietary Nitrate*NO3TSS interaction term
LOW DIETARY NITRATE† 
(n=56) 
MEDIUM DIETARY NITRATE 
(n=50) 





































































































Table 4.17.  Prevalence Ratios for Hypertension by High vs. Low Nitrate-reducing Taxa Summary score (NO3TSS) stratified 





















*Model 1: Crude, adjusting for total energy (kcal) (n=241); Model 2: Adjusted for total energy (kcal), age, sex, race, education, BMI, 
smoking, percent of probing sites with attachment loss ≥3mm (n=240); Model 3: Model 2 + physical activity (n=235); Model 4: 
Model 2 + physical activity + dietary pattern (n=235); Model 5: Model 2 + physical activity + dietary pattern + alcohol use (n=215) 
 
†Range of NO3TSS scores within categories of nitrate-reducing bacteria categories: Low NO3TSS (-12.0 -0.05); High NO3TSS (-0.01, 
15.57) 
Range of dietary nitrate intake within categories of dietary nitrate intake categories: Low Dietary Nitrate (8.6-119.0mg/day); High 
Dietary Nitrate (119.9-1566.3 mg/day)  
 
§P-value for interaction with multiplicative ordinal Dietary Nitrate*NO3TSS interaction term 
LOW DIETARY NITRATE† 
(n=120) 

































2. Ref 1.07 

































SUPPLEMENTARY MATERIAL  
 
Table S1. Nitrate values for the additional food items in the NCI-DHQ used in ORIGINS 
not available in the reference US dietary nitrate database 45 
 






Pasta, meatless* 2.5 
Pasta, meat* 6.6 
Pasta, salad* 15.4 
Egg rolls* 8.2 




Celery  96.7 
Radish 130 
Garlic  7 
Other Vegetables† 53.4 
 
* Values for mixed dish food items (e.g. Mexican mixtures) were calculated using standardized 
recipes from the US Department of Agriculture’s 1994-1996 Continuing Survey of Food Intakes 
by Individuals (CSFII) for relevant foods47 and weighted averages of the nitrate content of the 
foods in the recipe. When a value for a food item from mixed dishes was not available in the 
literature, we substituted a value for a similar food.   
 
†Vegetables other than those listed on the FFQ, such as cucumber, celery and radish (taken from 
the list of CSFII foods)
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Table S2.  List of food items in plant, processed and red meat, and other animal sources of 
dietary nitrate intake  
 
Plant sources  Processed and red meat sources  Other animal sources  
Tofu  Veal, venison, lamb, plain Milk, all types 
Oranges  Beef, steaks, reg Cream 
Grapefruit Beef, steaks, lean Milkshakes 
Apples/Applesauce  Beef, roast Yogurt 
Pears  Roast beef in sandwich Cheese, all types 
Peaches/nectarines/plums Beef stews/pot pies/mixtures Cottage/ricotta cheese 
Avocado, guacamole Beef, burgers, lean Sour cream 
Bananas Beef, burgers, reg Cheese sauce 
Plantains Beef, gr, meatballs/loaf/mixtures White sauce 
Cantaloupe Ham, not luncheon Cream cheese 
Other melon Pork Whipped cream 
Strawberries Pork, neck, feet,etc Ice cream 
Grapes Bacon, regular Frozen yogurt, ices, sorbet 
Dried fruit, no apricots Bacon, lean/Canadian Puddings/custards 
Apricots, dried Sausage, reg Chicken, light  
Fruit salads/other fruits Sausage, turk/lowfat Chicken, dark 
Orange/grpfrt jce, all Hot dogs, regular Chicken/turkey ground 
Other juice Hot dogs, turky/lowfat Chicken, mixtures 
Tomato/veg juice, all Shortribs/spareribs Turkey 
Beans Liver, liverwurst Tuna 
Potatoes/ potato salads Cold cuts, regular Fish fried 
Sweet potatoes Cold cuts, lowfat Fish, not fried 
Lettuce Cold cuts, poultry Fish, oysters 
Pickled vegetable and fruits Ham, cold cut/ lunch meat, reg Eggs 
Raw spinach/greens Ham, cold cut/ lunch meat, lowfat Eggs, substitutes 
Cooked spinach/greens  Eggs, salad 
Broccoli  Butter 
Carrots  Lard 
Tomatoes, raw   
Tomato salsa   
Tomato catsup   
String beans   
Cabbage/sauerkraut   
Coleslaw   
Peas   
Corn   
Cauliflower/Brussel sprouts   
Peppers   
Peppers, hot   
Onions   
Olives   
Vegetable medley   
Other vegetables    
Nuts/seeds    










A 1 standard deviation change in total dietary nitrate intake (170mg/day) was associated with a 
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The enterosalivary nitrate-nitrite-nitric oxide pathway of nitric oxide generation presents a 
mechanism for the diet and the oral microbiome to exert an influence on cardiometabolic 
outcomes. The goal of this dissertation was to advance the understanding of the association of 
nitrate-reducing oral bacteria and dietary nitrate intake with cardiometabolic outcomes in a 
population setting, and to examine the interaction of dietary nitrate intake with nitrate-reducing 
oral bacteria.  
 
Summary of results 
In Chapter 2, we assessed the literature for associations between nitrate-reducing oral bacteria 
and plasma glucose, insulin levels, insulin resistance, systolic and diastolic blood pressure, 
diabetes, and hypertension. Only 14 studies met our inclusion criteria for the review. We found 
only 3 studies that examined microbial exposure in the development of disease outcomes rather 
than the impact of the disease phenotype on microbial composition. We found no study that 
explicitly tested the hypothesis of nitrate-reducing oral bacteria exposure in the development of 
cardiometabolic outcomes. Most studies investigated a narrow spectrum of potential periodontal 
pathogens only, and there was a lack of studies examining cardiometabolic outcomes other than 
diabetes. Very few associations between nitrate-reducing oral bacteria and cardiometabolic 
outcomes were found, and all findings were cross-sectional and inconsistent across studies. This 
review highlighted the paucity of data directly addressing the hypothesis that oral nitrate-
reducing bacteria might improve cardiometabolic health. Overall, the hypothesis was 
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insufficiently tested in the literature, and there was no evidence to support the hypothesis of 
higher nitrate-reducing oral bacteria associated with better cardiometabolic outcomes.   
 
Chapter 3 using baseline data from a cohort of diabetes-free participants, tested the hypothesis 
that higher levels of nitrate-reducing oral bacteria would be associated with lower insulin 
resistance, plasma glucose, blood pressure levels, and lower prevalence of prediabetes and 
hypertension. 16S rRNA next-generation sequencing was used to identify a broader set of 
putative nitrate-reducing bacteria species than prior studies, and overall exposure to nitrate-
reducing bacteria was considered using a summary score of nitrate-reducing bacteria. We found 
higher levels of oral nitrate-reducing bacteria associated with lower insulin resistance, plasma 
glucose and mean systolic blood pressure cross-sectionally. Moreover, the results for insulin 
resistance and plasma glucose demonstrated dose-responsiveness suggesting that higher levels of 
nitrate-reducing organisms might confer health benefits across the spectrum of bacterial levels 
likely observed in human populations. We did not find an association with prediabetes and 
hypertension, and it is possible that that nitrate-reducing oral bacteria may be most relevant in 
the early preclinical stages of disease development before more advanced pathophysiological 
alterations (e.g. reduced β-cell function or increased arterial stiffness) have occurred. Our 
observation that the association between nitrate-reducing bacteria and systolic blood pressure 
was strengthened, and reached statistical significance, in sensitivity analyses including only 
participants without hypertension supports this notion. Exploratory analyses for the 20 individual 
nitrate-reducing taxa found mostly inverse statistically significant associations. Together, these 
results address the lack of evidence found in the literature review in Chapter 2, and support the 
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hypothesis that nitrate-reducing oral bacteria play a beneficial role in blood pressure regulation 
and insulin resistance.  
 
The associations between dietary nitrate intake and the cardiometabolic outcomes of interest 
were assessed in Chapter 4. No clear evidence of an association between dietary nitrate intake 
and insulin resistance, systolic and diastolic blood pressure, hypertension, plasma glucose or 
prediabetes were found. There was some indication of an association between higher dietary 
nitrate intake and insulin resistance and systolic blood pressure, though the confidence intervals 
were imprecise and these possible associations need to be replicated in larger studies. In 
sensitivity analyses, the inverse associations were most evident when focusing on nitrate from 
plant sources, while dietary nitrate intake from processed meat and red meat sources were 
generally not associated with cardiometabolic outcomes, and in some cases were associated with 
poorer cardiometabolic outcomes. These results extend previous experimental research using 
high-dose dietary nitrate supplementation, by suggesting that more modest differences in nitrate 
consumption reflective of real-world intakes may have cardiometabolic benefits as well. A 
possible plateauing of the inverse associations between higher dietary nitrate intake and insulin 
resistance and systolic blood pressure was observed in the highest tertile of dietary nitrate intake. 
The interaction between dietary nitrate intake and nitrate-reducing oral bacteria on 
cardiometabolic outcomes was assessed, but no clear evidence of interaction was found. 
 
Limitations of these findings 
There were several limitations to the findings of this dissertation. First, the analytical aims were 
cross-sectional, and we were unable to establish temporality. Second, the dissertation was 
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dependent on the previous taxonomic identification of nitrate-reducing bacteria species of 
interest, and subject to misclassification. Third, as there has been much debate over the stability 
of the oral microbiome, the use of microbial assessments from a single time point in these cross-
sectional analyses may not accurately represent the typical daily exposure to nitrate-reducing 
bacteria. Fourth, we examined subgingival bacteria when the tongue is believed to be the main 
site of bacterial nitrate reduction in the mouth and thus of greatest interest. Finally, as dietary 
nitrate intake is highly correlated to vegetable intake and we were unable to separate the effects 
of dietary nitrate intake from the many other beneficial nutrients found in a high vegetable diet, 
residual confounding was possible.  
 
Implications and Future research  
This dissertation has implications for future research studies. Most current research exploring the 
potential role of oral bacteria in extra-oral cardiometabolic outcomes has focused on the adverse 
role of oral bacteria on cardiometabolic health. However, if the oral microbiome potentially has 
both beneficial and adverse influences on health outcomes as supported by our findings, 
carefully designed studies using precise assessments of the oral microbiome are necessary for 
estimating the total effects of the bacteria and to establish clear treatment targets.  
 
Our findings provide some first steps in describing the association between demographic 
characteristics and levels of nitrate-reducing bacteria. Future research can use these findings to 
design studies that account for potential confounders. Likewise, the finding of a possible 
threshold effect between dietary nitrate intake and systolic blood pressure, highlights the 
importance of the population distribution of dietary nitrate intake when examining the 
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association between dietary nitrate intake and cardiometabolic outcomes, and can help inform 
the selection of participants in future investigations.  
Future longitudinal studies will be important for establishing the temporality of the association 
between nitrate-reducing oral bacteria and cardiometabolic outcomes. To address some of the 
limitations in operationalizing nitrate-reducing bacteria exposure highlighted by this study, 
future studies that incorporate repeated measures of both the proportion of putative nitrate-
reducing bacteria identified through taxonomic classification, and the actual functional nitrate-
reducing capacity of the oral microbiome through metagenomics or metatranscriptomics, should 
be carried out. It will also be important for future studies to directly assess nitrate-reducing 
bacteria on the tongue as this is the main site of nitrate reduction.  
 
Additional research to establish updated US-based nitrate values for all the food items of 
commonly used food frequency questionnaires will be important for more precise assessment of 
dietary nitrate intake levels, and may allow for better isolation of the effects of dietary nitrate 
intake from the effects of vegetable consumption. A biological measure of systemic NO such as 
plasma, salivary, or urine nitrite taken at the same time as the oral bacteria samples and dietary 
information would also be useful for mediation analyses. While we did not find evidence of an 
interaction between nitrate-reducing oral bacteria and dietary nitrate intake, this pattern may 
differ in populations with different distributions of nitrate-reducing bacteria or dietary nitrate 
intake, and remains to be tested.  
 
In conclusion, the overall findings of this dissertation support further exploration of the 
enterosalivary pathway for NO generation linking chronic oral microbial exposures and 
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cardiometabolic outcomes. While these findings require replication in larger, longitudinal 
studies, if this relationship is proven to be causal, interventions to manipulate nitrate-reducing 
bacteria levels may be a useful treatment modality to improve cardiometabolic health.  
 
 
 
 
 
 
